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Mesenchymal stem cells are the stem cells that replace the bone, fat and cartilage 
tissues of the human body. In addition, these cells can form muscles, ligaments and 
neurons. This wide multipotency has made mesenchymal stem cells of particular 
interest in the fields of tissue engineering and regenerative medicine. Furthermore, 
mesenchymal stem cells can modulate the immune system by reducing factors that 
increase inflammation and immune recognition. This immune recognition 
suppression has resulted in their application as part of bone marrow transplantation 
in the prevention of ‗graft versus host‘ disease. There are hundreds of on-going 
clinical trials using these cells for the treatment of autoimmune diseases such as type 
I diabetes, arthritis and multiple sclerosis. The increasing importance of these cells 
has brought in to focus the culture methods used to for their expansion and 
manipulation. Currently, animal derived components are used as surfaces for their 
growth and as components in the culture media. This exposes these cells to animal 
pathogens and antigens that can be passed to the recipients of these cells. 
In the first part of this thesis, polymer microarrays were employed to identify 
alternatives to the biological surfaces currently used for mesenchymal stem cell 
culture. This platform allowed hundreds of polyacrylates/acrylamides and 
polyurethanes to be simultaneously scrutinised to identify surfaces that could support 
their growth and maintain their stem cell characteristics. Identified polymer surfaces 
were monitored in long-term culture (10 passages) and were shown to retain the cell 
phenotype and capacity to differentiate, thus providing chemically defined substrates 
for long-term mesenchymal stem cell culture. 
In the second part of this thesis, a ‗smart‘ polymer microarray of hydrophilic cross-
linked polymers (hydrogels) were used to remove another key biological component 
of culture, trypsin. These ‗smart‘ hydrogels modulated their properties depending on 
the temperature. Hydrogels that could trigger mesenchymal stem cell release after a 
reduction in temperature were identified. A unique passaging system using a modest 




maintained and monitored for 10 passages using this novel enzyme free passaging 
method. Analysis of the mesenchymal stem cell phenotype and differentiation 
capacity revealed this method superior than conventional culturing methods. 
In the final part of this thesis, a ‗knowledge-based‘ small molecule library was 
designed, which could potentially yield small molecules to manipulate/enhance the 
mesenchymal stem cell state without the use of biological components. The key 
protein pathways that control the stem cell state were examine with the 
bioinformatics tool GeneGo was used to identify compounds that affected these 
pathways, resulting in selection of 200 small molecules. The effect of the small 
molecules on the mesenchymal phenotype was examined and 5 small molecules were 
identified that enhanced the phenotype of these cells. The anti-inflammatory 
properties associated with the hit compounds led to the investigation of their effects 
on key surface proteins associated with the immune-modulatory state of the cells. In 
this preliminary study, two of the small molecules, estriol and spermine, increased 
the expression of a key mesenchymal stem cell marker STRO-1 and down regulated 
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1.1 REGENERATIVE MEDICINE, STEM CELLS AND 
SCAFFOLDS 
1.1.1 Regenerative medicine 
Regenerative medicine has been defined as a ‗therapeutic intervention, which 
replaces or regenerates cells, tissues or organs, to restore or establish normal 
function‘ (Ducheyne & Qui 1999; Mason 2007). In recent decades, it has emerged as 
a ‗great new hope‘ for dealing with the medical issues arising from an aging 
population and because of its theoretical ability to overcome the limitations of 
conventional medicine. In the future, regenerative medicine will be increasingly 
applied to the treatment of degenerative and autoimmune diseases, and to the 
replacement/repair of organs and tissues.  
Pharmaceutical drugs often operate by blocking disease processes, such as 
cholesterol-lowering ‗statin‘ drugs used to block HMG-CoA reductase, a key enzyme 
in the production of cholesterol. They also operate by preventing other processes that 
cause injury, such as anti-inflammatory drugs that prevent inflammation, thereby 
manipulating the body‘s machinery to achieve a desired aim. Where drug treatments 
and surgical techniques fail, synthetic implants, mechanical devices and machines 
such as dialysis can be used to restore some function. 
Conventional medical techniques, such as surgery, are framed around the body‘s 
inherent regenerative capacity. When surgical treatments alone are insufficient, organ 
and tissue transplantation can be employed. Transplantation has significant 
drawbacks, such as the requirement of immune suppression and a limited supply of 
organs and tissues. Even when tissue matched organs and tissues are available, they 
have a limited lifespan and will ultimately be rejected by the host immune system.  
Regenerative medicine offers great promise, not only because it can overcome some 
of the limitations conventional medicine, but also because it offers the possibility of 




allows the development of entirely novel strategies that can open up new branches of 
medicine. 
 
1.1.2 Stem cells 
Stem cells are defined as cells with a capacity to ―self-renew‖ and in response to 
intrinsic and extrinsic determinants, differentiate into more than one cell type with 
specialised function.  The number of tissues and cell types that the cell can produce 
defines the ‗potency‘ of a stem cell (Fig. 1.1). The newly fertilised egg is ‗totipotent‘ 
because it can form all the embryonic and extra-embryonic cell types (Tarkowski 
1959). It is not a stem cell as with each cellular division that follows fertilisation the 
resulting cells differ and become more restricted in their potency than the cell from 
which they derived – there is no self-renewal.  However, early in embryo 
development, it is possible to extract and perpetuate in vitro stem cell populations. In 
mammals, embryo stem cells, with a capacity to give rise to all of the cell types and 
organs, can be isolated from the inner cell mass cells of a pre-implantation blastocyst 
conceptus. This includes the three embryonic lineages, the ectoderm layer or ‗outside 
skin‘ that forms neural tissues and skin, the mesoderm or ‗middle skin‘ that forms 
muscles and connective tissues and the endoderm or ‗inner skin‘ that forms the 
intestines and lungs. Together these layers form all the cells of the human body (Fig. 
1.1). The renewal of such ―pluripotent‖ stem cells in an unspecified state is 
dependent on core set of transcription factors. A similar form of pluripotent stem cell 
can be extracted from a sub-region of the inner cell mass known as the epiblast, 
which forms after implantation. In some species, such as the mouse, neither pre-
implantation inner cell mass or post-implantation epiblast derived stem cells can 
form extra-embryonic tissues, which constitute the embryo contribution to the 





, Cdx2+) first expressed in the outer cells of a blastocyst stage embryo 





Figure 1.1.  Hierarchy of potency. The fertilised embryo and the morula is totipotent due to 
its ability to make all the cells of the organism including the extra-embryonic tissues of the 
placenta (Gata4+/6+) and trophoblast (Cdx2+). The inner cell mass cells are pluripotent, i.e., 
they can form the three primary germ layers; mesoderm, endoderm and ectoderm and hence 
all the cells of the body, including the multipotent stem cells and the unipotent differentiated 
somatic cells (>200). Multipotent stem cells maintain tissue homeostasis after development 
and reside within specific niches. Mesenchymal stem cells (MSCs) reside next to the 
vasculature (peri-vascular), hematopoietic stem cells (HSCs) form the lineages of the blood 
and reside next to the MSCs in trabecular bone. Basil stem cells (BSCs) reside in the lung 
epithelium. Intestinal stem cells (ISCs) reside in the base of the crypts of intestinal cilia. Skin 
stem cells (SSCs) reside in the hair follicle and neural stem cells (NSCs) reside in the lateral 
ventricles (top squares) and the dentate gyrus (bottom squares). These cells go on to form 




1.1.3 Adult stem cells 
 
Once the organism is fully formed, a state of homeostasis emerges where the 
maintenance and repair of the adult tissues depends on a small subpopulation of stem 
cells (Fig. 1.1). One of the principle characteristics of stem cells is their ability to 
self-renew. When they divide they produce one stem cell and one rapidly dividing 
cell called a trans-amplifying cell that divides a finite number of times before 
differentiating into the various cell types of the tissue/organ. The low cell turnover or 
quiescence of the remaining stem cell allows the stem cell phenotype to be 
maintained over the lifetime of the adult. Stem cells in some adult tissues, which 
maintain tissue homeostasis generally differ from stem cells which are perpetuated in 
vitro, particularly pluripotent stem cells extracted from early embryos, by being 
extremely slow growing (i.e. long cell division ―cycling‖ times). It was this slow 
cycling characteristic that allowed many of the stem cell niches to be identified 
through their retention of radio labelled 5-bromo-2‘-dioxyuradine (BrdU) as so-
called label retaining cells (LRCs) (Bickenbach et al. 1981). Once localised, the 
contribution that these cells and their descendants made to the surrounding tissues 
could be scrutinised in detail to reveal their true stem cell nature.  For example, 
intestinal stem cells were verified in their location in the crypts (Fig. 1.1) by 
following inheritance patterns of changes introduced at random into gut epithelial 
cells to reveal single crypt cells that contributed to the entire crypt (Bjerknes & 
Chang 2002; Winton & Ponder 1990).  
More recently, a population of leucine-rich G protein-couple receptor-5 positive cells 
(Lgr5
+
 an orphan GPCR receptor of unknown function) were found to be responsible 
for the generation of the label retaining cell (paneth cell) and for the regeneration of 
the colon epithelium (Fig. 1.2). The Lgr5
+
 cells are able to produce mini-guts in vitro 
making them particularly promising for regenerative medicine (Buczacki et al. 
2013). In the skin a similar label-retaining experiments identified slow-cycling cells 





) do not contribute to the epidermis in the absence of injury (Cotsarelis 






Figure 1.2. Stem cell niches and associated markers for representative organs and tissues. 
A) Muscle stem cells also known as satellite stem cells due to their peripheral location on the 
myotubule are characterised by the expression of Pax7, CD34 and Myf5. B) HSCs located in 






phenotype that characterise all HSCs, 
they reside specifically near the arterioles and cell permeable vasculature (sinusoids) of the 
trabecular bone. C) Alveolar stem cells known as basal cells reside in the lung epithelium of 




 phenotype are a label retaining cell that 
reconstitutes the lung epithelium after injury. D) LGR5
+
 intestinal stem cells reside at the 
base of the intestinal crypts adjacent to paneth (yellow) cells. E) The hair follicle is the niche 
of two populations of stem cell responsible for the regeneration of hair follicle and skin, one 




) and the other lies close to the skin 
surface (LRIG1
+
). F) Neural stem cells reside in two primary locations, the dentate gyrus 











 cells, contributes to the epidermis but not the hair 
follicles.  The existence of more than one population of stem cells that contribute to 
various lineages depending on whether the tissue has been exposed to injury is 
common to both the intestinal and skin stem cell niches (Buczacki et al. 2013; Braun 




Identifying stem cells in organs with slow cell turnover, i.e., stem cell niches in 
‗terminally differentiated‘ organs such as the heart and brain required the opposite 
approach (identification of cells undergoing renewal). In the brain, early studies to 
identify renewal involved the application of tritiated thymidine, which incorporates 
into the DNA of dividing cells and is detected by autoradiography (Smart & Leblond 
1961). This work identified the sub ventricular zone (SVZ) (Fig. 1.2F) as one of the 
main reservoirs of neural stem cells. Later work identified the dentate gurus (DG) 
and olfactory bulb as a second location for these cells (Kaplan & Hinds 1977). 
Neural stem cells primarily differentiate into astrocytes, oligodendrocytes and 
neurons. The niche contains activated neural stem cell identified by the markers 
GFAP
+
 (glial fibrillary acidic protein), CD133
+
 (prominin, a transmembrane 
glycoprotein expressed on the cilia), EGFR
+
 (epidermal growth factor receptor), as 





(Codega et al. 2014) (Fig. 1.2F). Resident stem cell populations that repair the 
peripheral nervous system have yet to be isolated. However, Swann cells have 
demonstrated extensive plasticity and even dedifferentiation in response to injury 
through the activation of Sox2 (Le et al. 2005) and cJun (Arthur-Farrage et al. 2012). 
Injury causes the Swann cells to take on an undifferentiated ‗Büngner‘ cell 
phenotype (where Sox2 and cJun are up-regulated) to proliferate allowing 
regenerating axons to create a nerve bridge and restore function (Kim et al. 2013). 
Where skin and intestinal stem cells reside in high turnover organs and neural stem 
cells reside in ‗terminally differentiated‘ organs, other stem cell niches reside in 
organs that have relatively low cell turnover but retain impressive regenerative 
capability, such as the liver, muscle and lungs. This is highlighted by the fact that 
two thirds of the liver can be removed and it will regenerate. In skeletal muscles, 
injury results in very efficient regeneration through the activation of normally 
quiescent cells known as satellite cells, which are located on the outer part of the 
muscle fibres (Fig. 1.2A). These cells were first implicated through the distribution 
of thymidine in the muscle fibres (Moss & Leblond 1971) with later experiments 
using isolated myofibrils showing their definitive contribution (Bischoff 1975; 
Bischoff 1986) and their ability to self-renew (Collins et al. 2005). Injury of the 




a daughter satellite cell and a trans-amplifying cell that become myoblasts and 
eventually the myofibre. This process is characterised by the concerted up regulation 
and down regulation of a number of different genes at different stages. Genes CD34, 
PAX7 and Myf5 characterise the quiescent phase of the satellite cells (Fig.2). Pax7 is 
a transcription factor that is essential for the formation and maintenance of functional 
satellite cells (Kuang et al. 2006). Pax7 has been shown to associate with the Wdr5–
Ash2L–MLL2 histone methyltransfease (HMT) complex that directs methylation of 
histone H3 lysine 4 (H3K4). Pax7 associates with the Myf5 (among other myogenic 
development genes) gene resulting in H3K4 trimethylation of the surrounding 
chromatin and transcriptional activation (McKinnell et al. 2008). Myf5 is expressed 
in quiescent satellite cells (Kuang et al. 2007), however, they are prevented from 
entering the myogenic program through the sequestration of Myf5 mRNA in 
messenger ribonucleoprotein (mRNP) granules. In activated cells the mRNP granules 
dissociate and the satellite cells enter the myogenic program (Crist et al. 2012).  
During activation of satellite stem cells the myogenic transcription factor MyoD is 
also up regulated through Six1 (Sine oculis homeobox gene 1) (Liu et al. 2013). 
MyoD targets a large number of myogenic differentiation genes, 1.4k in myoblasts 
and 9.3k in myotubes. Initial expression of MyoD does not initiate differentiation as 
the targets of MyoD are blocked through the transcriptional repressor Snail by the 
recruitment of histone deacetylases HDAC1 and HDAC2. This results in continued 
myoblast proliferation until expression of two miRNAs, miR30a and miR206 that 
target snail1 and snail2 respectively resulting in their removal and activation by 
MyoD target genes (Soleimani et al. 2012). Terminal differentiation ensues with the 
up-regulation of myogenin and the formation of the myotube. At this point the 
quiescent stem cell markers CD34 and PAX7 are down regulated signifying 
commitment to differentiation and fusion of the cells into the myotubule. The final 
maturation phase is signified by the expression of MLC3F and the down regulation 
of Myf5, MyoD and Myogenin (Zammit et al. 2006). The age associated 
degeneration of muscle fibres resulting in sarcopenia (muscle loss) has recently been 
demonstrated to be the result of alterations of fibroblast growth factor receptor 1, 
p38α and p38β mitogen-activated protein kinase signalling in satellite cells. This 




renew. Remarkably, pharmacological manipulation of the pathways was able to 
ameliorate the age associated muscle loss and restore the satellite stem cells capacity 
for self-renewal (Bernet et al. 2014).  
In the lung, turnover is relatively low, but again the lung has the capacity to 
regenerate after removal of large sections of tissue (unilateral pneumectomy) 
(Esenhauer et al. 2013). The lungs harbour label retaining cells known as basal stem 
cells. These cells are signified by the markers, transformation related protein 63 
(Trp63) and cytokeratin 5 and/or 14 (Krt5/14) (Hong et al. 2004). Basal stem cells 
repopulate the lung epithelium after injury. Regaining the precise dimensions of the 
damaged tissue is important to restore lung function. Patterning of the lung tissue 
during development occurs primarily through secretion of FGF10 by progenitor cells 
in the developing bud (Nyeng et al. 2008), and the distance of the cells from the 
FGF10 determines the ability of the cells to differentiate with cells furthest away able 
to fully differentiate. Likewise, in the adult lung basal cells produce FGF10 after 
injury allowing progenitor cells to expand in the surrounding areas (Volckaert et al. 
2013) until a state of homeostasis is re-established (Hsu et al. 2012). 
Finally, the most well-known and applied stem cells are hematopoietic stem cells in 
the bone marrow, the critical cells in bone marrow transplantation. The ability to 
isolate these cells using surface markers dates back to 1988 (Spangrude et al. 1988). 









 immunophenotype (Kiel et al. 2005). In vivo the 
hematopoietic stem cell niche is composed of mesenchymal stem cells (Méndez-
Ferrer et al. 2010) and endothelial cells in the perivascular niche adjacent to the 
blood vessels in the trabecular bone (Fig. 1.2B). The maintenance of the niche 
operates through the production of CXCL12 and stem cell factor (SCF) by 
mesenchymal stem cells and endothelial cells (Ding et al. 2012).  
The structure of the niche is composed of the interface of the trabecular bone with 
the bone marrow called the endosteum. HSCs are mainly located near the sinusoidal 
endothelial cells and arterioles peripheral to the central vein. Sinusoids are structures 
in the bone marrow composed of endothelial cells that are a discontinuous reticulum 




system.  Located on the surface of endothelial sinusoidal cells are a number of other 
phenotypes that have been shown to be critical to maintaining the hematopoietic 
stem cell niche, including CXCL12-abundant reticular (CAR) cells (Sugiyama et al. 
2006) and lepr
+
 perivascular cells. CXCL12 (also known as SDF-1) and its receptor 
CXCR-4 have been shown to be critical in HSC engraftment. Disruption of this axis 
through chronic G-CSF followed by acute treatment with plerixafor (AMD3100) 
results in rapid HSC mobilisation (Pitchford et al. 2009).  
Secretion of stem cell factor (scf) has also been shown to be important in this niche 
with the lepr+ cells expressing the highest levels and the endothelial cells expressing 





cells in the sinusoidal niche results in the elimination of 85% of the HSC population 
(Oguro et al. 2013). Other locations in the bone marrow have also been shown to 
effect the HSC niche. Arterioles are small arteries located peripherally to the central 
vein and supply the bone marrow with nutrients and oxygen. Quiescent HSCs are 




 perivascular cells 
distinct from the lepr
+
 cells located on the sinusoids (Kunisaki et al. 2013). 
Isolation of the location of adult stem cells, identification of unique markers for 
resident stem cell populations, and understanding of the niche within which the stem 
cell resides, has advanced considerably in the last decade. In terms of regenerative 
medicine, where an autologous source of stem cells is intended for use in a particular 
application, knowing the location and the identity of the stem cell population, and the 
factors affecting its maintenance, is critical. This was clearly demonstrated by the 
pharmaceutical manipulation of the signalling pathways for the satellite stem cell to 
restore function (Bernet et al. 2014). When the identifying markers of the stem cell 
population are on the cell surface, as with LGR5
+
 intestinal stem cells, the cells can 
be isolated using flow cytometry, and manipulated and differentiated in vitro under 
the appropriate conditions (in the case of LGR5
+
 cells to produce ‗mini colons‘). The 
use of autologous stem cells for the recapitulation of organs and tissues has the 
advantage of avoiding immune rejection and use of immunosuppressant medication. 
A biopsy followed by the isolation of the stem cell population and subsequent 




sources of the stem cells can be limited or inaccessible (e.g. neural stem cells and 
cardiac stem cells). In addition, the ‗autologous route‘ does not offer ‗off the shelf‘ 
treatments, which is one of the goals of regenerative medicine. 
 
1.1.4 In vitro pluripotent stem cells 
One of the most important achievements in regenerative medicine has been the 
isolation of the human cells of the inner cell mass in pluripotent state, and their 
maintenance for extended passage in vitro (Thomson et al. 1998). This has provided 
an in vitro model for mammalian and human development and disease processes. 
Importantly, it provided a potentially unlimited source of cells for regenerative 
medicine as these human embryonic stem cells (hESCs) had seemingly unlimited in 
vitro expansion capacity. Consequently, the ability of human embryonic stem cells to 
differentiate into the various cells of the human body such as cardiomyocytes, 
osteoblasts, neurons, and hepatocytes has been demonstrated (Kehat et al. 2001; 
Sottile et al. 2003; Zeng et al. 2004; Duan et al. 2010). It has also been possible to 
differentiate hESCs into cells that display the stem cell phenotype, providing a 
potentially unlimited source of multipotent stem cells (Ardehali et al. 2013; Karlsson 
et al. 2009).  
A significant advance in pluripotent stem cell research involved the reprogramming 
of fully differentiated human fibroblasts using retrovirus transfection containing the 
genes that encode for the four reprogramming factors Oct4, Sox2, Klf4 and cMyc 
(Takahashi et al. 2007). This work followed on from the identification of these 4 
factors in the reprogramming of MEFs into cells indistinguishable from mouse 
embryonic stem cells (Takahashi & Yamanaka 2006). The ability to reprogram 
differentiated adult cells into pluripotent stem cells (called induced pluripotent stem 
cells or iPS) avoided the ethical issues surrounding hESC derivation (from fertilised 
human embryos) and provided a source of stem cells that have the potential to reduce 
immune rejection. iPS also offer a means for deriving pluripotent stem cells from 
patients with genetic diseases providing more accurate in vitro models for diseases 




the study of human neural disorders due to the inability to access the tissues at 
various stages of disease progression. iPS generated from genetic neural disorders 
gives the further advantages that the observed response/behaviour of cells can be 
directly attributed to identified mutations. Neural diseases that can be non-hereditary 
or hereditary are particularly active areas of research, for example familial 
Parkinson‘s disease (PD) arises due to mutations in the LRRK2, PINK1, SNCA, 
PARKIN, DJ-1, ATP1A3, UCHL1 and GBA genes (Imiazumi & Okano 2014). 
These genes are also implicated in the pathogenesis of sporadic PD. Motor symptoms 
do not appear until 70% of dopaminergic neurons in the substantia nigra have been 
lost, iPS has allowed for the generation of cell models of familial PD associated with 
mutations such as PARKIN (Imiazumi et al. 2012) to provide better models of this 
disease and of PD in general. The increased understanding of resident stem cells, the 
ability to derive pluripotent stem cells from fertilised embryos, and through the 
reprogramming of differentiated fibroblasts, gives the field of regenerative medicine 
a number of different tools to be applied to the myriad of human diseases and 
degenerative disorders 
 
1.2 MESENCHYMAL STEM CELLS 
 
Mesenchymal stem cells (MSCs) were first isolated from a bone marrow aspirate by 
Friedenstein as a rare population of fibroblastic cells termed ‗colony forming units‘ 
(Friedenstein et al. 1974). These cells were later identified as a multipotent stem cell 
population that can give rise to bone, fat and cartilage tissues (Pittinger et al. 1999). 
The identification of the in vivo niche as well as in vivo phenotype was much later 
identified as PDGFR-b, CD146 and NG2 positive cells located next to the 
vasculature (Crisan et al. 2008) (Fig. 1.2). Within the bone marrow, MSCs act as a 
supportive stromal layer for hematopoietic stem cells (section 1.1.2). The importance 
of this cell type for regenerative medicine and tissue engineering arises from their 
wide multilineage potential, immune-modulation properties, ease of isolation, and 




response to material properties is also making MSCs a particularly useful model 
system for cell/substrate interactions (Engler et al. 2006). 
 
1.2.1 Embryonic origins from mesenchyme and neural crest lineages  
Although MSCs have been extensively researched for their regenerative potential, 
the embryonic origin of this stem cell in vivo is not fully understood. What is known 
is that these cells come from both the ectoderm (Takashima et al. 2007) and 
mesoderm lineages (Dennis & Charbord 2002b). The mesoderm is seen as the 
primary source of MSCs that form the bone and connective tissues (Dennis & 
Charbord 2002b). Pericytes that develop around the trunk vessels in the axial and 
lateral plate are thought to come from the mesoderm (Hungerford & Little 1999). 
Evidence for their mesodermal origins stems from the fact that they show the same 
markers during development as other cells of mesodermal origins (e.g. vascular 
smooth muscle) (Remy-Martin et al. 1999; Owens 1995). MSCs also localise with 
other stem cells of mesodermal origin such as hematopoietic stem cells (Mendes et 
al. 2005; Mendes-Ferrer et al. 2010). MSCs from ectodermal origin are derived from 
neural crest cells (Le Douarin et al. 2004). After the formation of the three primary 
germ layers, the ectoderm splits into two, forming the surface ectoderm and the 
neural ectoderm. The neural ectoderm goes on to form the neural tube (precursor to 
the brain and spinal cord). The dorsal part of the tube that is in contact with the 
surface ectoderm is where the neural crest cells reside. These migratory cells have 
wide multilineage potential and form neurons, glial cells of the peripheral nervous 
system, smooth muscle cells of the heart and bone, cartilage cells of the face and 
mesenchymal stem cells (Morikawa et al. 2009). MSCs derived from neural crest 
cells retain some of their neural lineage capacity (Shi et al. 2013). The mixed 
embryonic origins may explain the wide range of cell types that MSCs are capable of 






1.2.2 Applications of MSCs 
The potential of MSCs in stem cell therapy has grown with increasing numbers of 
accessible and more readily obtainable sources of these cells including adipose tissue 
(Zuk et al. 2001), umbilical cord blood (Lee et al. 2004), and Wharton‘s Jelly (Wang 
et al. 2004). In addition, the range of cell types that MSCs can generate has expanded 
from the originally characterised adipocytes, chondrocytes and osteocytes (Pittenger 
et al. 1999) to smooth muscle cells (Wakitani et al. 1995) and neurons (Tropel et al. 
2006). Furthermore, MSCs have also been shown to be capable of modulating the 
immune response, attenuating inflammation and graft versus host responses (Lazarus 
et al. 2005). Hundreds of clinical trials (http://clinicaltrails.gov, accessed 2nd June 
2014) are underway investigating MSCs ability to modulate the immune system in a 
number of diseases as well as for tissue repair (Uccelli & Prockop 2010; Singer & 
Caplan 2011). The discovery that MSCs prevented T cell proliferation in vitro and in 
vivo to promote skin graft survival (Bartholomew et al. 2002) has resulted in these 
cells being applied to many other autoimmune diseases including type 1 diabetes  
(Fiorina et al. 2009), arthritis (Augello et al. 2007), Crohn‘s disease (Dala et al. 
2012) and multiple sclerosis (Cohen 2013). 
 In tissue engineering, MSCs have long been used for bone repair in conditions such 
as critical bone defect repair (Long et al. 2014) and cartilage repair (Gopal et al. 
2014). Their use has also expanded into periodontal applications (Tobita & Mizuno 
2013), myocardial infarction (Yannarelli et al. 2014) and wound healing (Maxson et 
al. 2012). Surgical stitches have been filled with adipose derived MSCs to accelerate 
healing (Reckhenrich et al. 2014; Casado et al. 2014). MSCs have been successfully 
applied in the clinical transplantation of a tissue engineered trachea (Macchiarini et 
al. 2008). In this ground breaking study, a donor trachea was first decellularised and 
subsequently reseeded with MSCs and endothelial cells that were extracted from the 
patient‘s bone marrow and brachial mucosa respectively. The cells were expanded in 
vitro and in the case of MSCs, differentiated toward chondrocytes, and then injected 
onto the decellularised trachea where they were further cultured in a bioreactor. 
Transplantation resulted in the restoration of normal function in what was once a 




developed in the native trachea which required repeat stinting. However, the tissue 
engineered trachea had completely recellularised and vascularised with normal 
respiratory function and no anti-donor antibodies had developed (in the absence of 
any immune-suppression treatment). To date this procedure provides the best 
treatment option with patients with a long segmental airway disorder (Gonfiotti et al. 
2014).   
The growing number of applications, and therefore increasing importance of MSCs 
in stem cell biology, has made it crucial to develop fully defined culture systems to 
allow the expansion of these cells for research and therapeutic purposes. The 
maintenance of MSCs in their ‗stem cell‘ state in the absence of undefined 
components remains a challenge and represents a major limitation for their long-term 
clinical potential. 
 
1.2.3 MSC sources 
MSCs populations are heterogeneous populations containing undifferentiated MSCs 
as well as various progenitor cell types with varying degrees of multipotency 
(Pevsner-Fischer et al. 2011). Although the criteria for identifying cells as MSCs 
include the ability of cells to differentiate towards the adipogenic, osteogenic and 
chondrogenic lineages, the proportion of cells that are multipotent within a 
population remains unknown. Without functional MSCs markers, the criteria for 
defining and isolating MSCs are based solely on consensus which lack meaningful 
correlation to the multipotent state (Dominici et al. 2006). Currently, the phenotype 
of MSCs is defined as the ability to adhere to tissue culture plastic, being positive for 
CD90, CD105, CD73, negative for CD45, CD34, CD14, CD19 and HLA-DR, and 
the ability to differentiate down the osteogenic, adipogenic and chondrogenic 
lineages (Dominici et al. 2006). In the development of more selective defined 
systems, which specifically selects for a homogenous multipotent sub-population, the 
readout in terms of positive markers for the MSC phenotype and markers for 
progenitor and differentiated cell types will be critical. Markers that reflect 




Some strategies have attempted to sidestep MSC in vitro culture all together by using 
freshly isolated MSCs from adipose tissue, an abundant source of MSCs. This is 
possible due to the fact that in vivo pericyte markers (a perivascular cell type with the 
MSC phenotype) are known (PDGF-Rβ, NG and CD146). Direct isolation of these 
pericytes using flow cytometry can theoretically provide the cell numbers required 
for MSC therapies (James et al. 2012). However, the quantity of the antibodies 
required makes this approach impractical. 
The heterogeneity of MSC culture is further complicated by the large variety of 
tissues that MSCs have been isolated from. This in itself is not an issue, but 
considerable marker variation occurs depending on the source of the MSCs (Table 
1.1) (Nery et al. 2013; Murray et al. 2014). 
 
Table 1.1 MSC marker expression of MSCs derived from a variety of sources. 
MSC 
MARKER 






CD14 X  X    
CD34   X    
CD58 X X X X   
CD73   X  X X 
CD90 X  X X X X 
CD105 X  X   X 
CD146 X     X 
CD271       
STRO-1       
HLA-DR     X  

















In addition, the source of the MSCs can result in differences in differentiation 
capacity. Adipose derived MSCs (ADMSCs) and bone marrow derived MSCs 
(BDMSCs) differentiation capacity reflect the source of the tissue. ADMSCs and 
BDMSCs differentiate significantly better into adipocytes and osteocytes, 
respectively (Peng et al. 2008). Some of these differences are due differences in 
receptor signalling, such as the requirement for BMP-2 and TGF-β signalling for 
chondrogenic differentiation. Weak chondrogenic differentiation with ADMSCs can 
be compensated for by addition of both factors in the chondrogenic diffentiation 
media (Mehlhorn et al. 2007). 
 
1.2.4 Development of hES-MPs from human ESCs 
An alternative and potentially unlimited source of MSC has emerged with the 
development of protocols for obtaining mesenchymal progenitors (MPs) from 
hESCs. This can potentially produce cells of consistent phenotype and multipotency 
(Karlsson et al. 2009; Kopher et al. 2010). The three principle methods for obtaining 
mesenchymal stem cells (MSCs) from hESCs are via embriod body (EB) formation 
(Brown et al. 2009), via substrate outgrowth culture (Karlsson et al. 2009), or by co-
culture with more differentiated cell types (Barberi et al. 2005). Very often EB 
formation is followed by plating and differentiation, similar to outgrowth culture 
(Sottile et al. 2003). In terms of clinical applicability and simplicity, the outgrowth 
culture method has an advantage due to the lack of an EB step. For example, 
Karlsson et al. plated hESCs on 0.1% gelatin feeding the cells with MSC medium 
consisting of DMEM with 10% fetal calf serum (FCS) supplemented with 10ng/mL 
of human recombinant basic fibroblast growth factor (hrbFGF). Serial passaging 
produced a homogeneous fibroblast morphology of hES-MPs with the characteristic 
markers of MSCs (Dominici et al. 2006) and chondrogenic, adipogenic and 
osteogenic differentiation potential. The hES-MPs can passaged for > 20 passages 
without sinesence (Karlsson et al. 2009). hESC derived MSCs can supply ‗off the 




autologous MSCs means that present research is primarily focused on autologous 
sources of MSCs. hESCs do present a consistent and unlimited supply of MSCs for 
research purposes without the need for primary sources. 
 
1.2.5 MSC markers 
A review of the literature would indicate that some markers are better indicators of 
MSC potency. It has been suggested that CD146 could be used as a single marker for 
MSC potency; however, this is also a marker of endothelial cells. Furthermore, 
MSCs from the tunica (adventitial cells) are negative for CD146 and positive for 
CD34 (Corselli et al. 2012). CD271 (low affinity nerve growth factor receptor) has 
become commercially popular marker due to its high expression and ability to isolate 
the entire CFU-F fraction of cells from bone marrow aspirate (Buhring et al. 2007). 
The ability of MSCs to form colonies is critical component for expansion and 
multipotency (Castro-Malaspina et al. 1980). When over expressed, CD271 inhibits 
the differentiation of MSCS into osteogenic, adipogenic, chondrogenic, and 
myogenic lineages indicating an important role in maintaining the MSC state 
(Mikami et al. 2011).  
STRO-1 was the first MSC marker used to isolate MSCs from bone marrow aspirate 
as opposed to tissue culture plastic adherence. The STRO-1 antibody was generated 
by raising antibodies against the stromal fraction of bone marrow aspirate (Simmons 
& Torok-Storb 1991) and has also been used to isolate the CFU-F fraction of freshly 
sorted MSCs (Gronthos et al. 1994). This has made it one of the most widely used 
Markers. Cells isolated purely on STRO-1 intensity have increased expression of the 
cytokine stromal derived factor 1 (SDF-1) and PDGF-ββ. The addition of PDGF-ββ 
and SDF-1 to media results in a significant increase in CFU-F frequency and reduced 
IL-4 induced apoptosis (Kortesidis et al. 2005). The STRO-1 fraction has also been 
shown to be the one responsible for the immune modulation capability of MSCs 
(Nasef et al. 2009). This, combined with the extensive characterisation of the STRO-




Jian et al. demonstrated that the marker CD105 correlates to increased chondrogenic 
potential of freshly isolated MSCs. The adherent fraction of adipose derived MSCs 





 fractions of the adherent populations. The CD105
+
 
fraction was differentiated down the adipogenic, osteogenic and chondrogenic 




 groups with 
the CD105
+
 fraction showing significantly higher levels of the chondrogenic markers 
collagen II and aggrecan. The most important observation was that the CD105 cells 
where able to form homogenous cartilage tissue when seeded onto PGLA scaffolds 
compared to the CD105- fraction. This indicated that the CD105 marker is an 
important indicator of cartilage differentiation in freshly isolated ADMSCs (Jiang et 
al. 2010).  





, selects specifically for pericytes, which have been proposed as the in vivo 
source of MSCs. In addition, these cells go down the myo, chondro, adipo and osteo 
lineages after being clonally derived, a key distinction between these cells and many 
other studies (Crisan et al. 2008). A high-throughput assay showed that sorting of 
MCSs based on this marker resulted in enrichment in the trilineage differentiation 
potential when compared with CD73 and CD271 indicating greater multi-lineage 
capacity with MSCs that have this marker (Russel et al. 2010).  In addition, FACS 
isolation of cells with the CD146 marker from adipose tissue also showed enhanced 
CFU-F capacity (Zannettino et al. 2008). Isolation of MSCs from the umbilical cord 
using the CD146 marker gave a stable phenotype over 10 passages (Schugar et al. 
2009). 
For characterisation studies, particularly those involving long-term culture, a 
selection of well-characterised markers, i.e., markers consistently associated with the 







1.3 POLYMERS AS BIOMATERIALS  
1.3.1 Biomaterials 
Biomaterials are materials intended to interface with biological systems. 
Biomaterials include ceramics, metals, glass, polymers or any material that is applied 
in a biological context without adverse effects. The required properties of a 
biomaterial depend on its intended purpose, for example, synthetic hips are widely 
used biocompatible devices that are tailored for manoeuvrability and load bearing 
functions while heart valves are chosen for their mechanical reliability and neutrality 
to blood factors over the lifetime of the patient. The ability to fine tune a material to 
its end use and therefore improve its compatibility gives synthetic polymers an 
enormous advantage over other materials. Stiffness, elasticity, load bearing capacity, 
biodegradability, surface structure and chemistry, and biomolecule incorporation can 
all be considered and tuned to match the desired function.  
 
1.3.2 Polymers  
Polymers are molecules composed of repeating units. There are many commonly 
found in nature (e.g. DNA, proteins, polysaccharides) and in synthetic chemistry 
(e.g. polystyrene, polyurethane, polyethene). The most widely used synthetic 
polymers for tissue engineering are aliphatic polyesters such as poly(glycolic acid) 
(PGA), poly(lactic acid) (PLA) and poly(caprolactone) (PCL), which are 
biodegradable through hydrolysis of the ester linkages. PGA was first applied in 
biomedicine as resorbable stitches (Katz & Tumer 1970). Lactic acid is a chiral 
molecule and poly(L-lactic acid) and poly(DL-lactic acid) have been extensively 
applied in tissue engineering. Poly(L-lactic acid) forms a semi crystalline structure 
with a high Young‘s modulus and has been applied as a bone substitute. Poly(DL-
lactic acid) is amorphous and is less resistant to hydrolysis (by H2O) than Poly(L-
lactic acid) causing it to biodegrade faster. PCL degrades much more slowly than the 
other polymers. The differences in the rates of degradation (PGA fast, PLA 
intermediate and PCL slow) and the ability to adjust the physical properties e.g. by 




poly(lactic-co-glycolic acid) (PLGA). PLGA (which has FDA approval for clinical 
use in medical devices) has been used extensively in tissue engineering and drug 
delivery (Kasuya & Tanishita 2012, Fioretta et al. 2012; Liu et al. 2012; Romagnoli 
et al. 2013). To some extent the wide current application of these polymers arises 
from the fact that they are known to be biocompatible. As the demands of the field of 
regenerative medicine increases what is expected of polymers, this necessarily 
requires the expansion in the number, type and diversity biocompatible polymers. 
 
1.3.3 Hydrogels 
Hydrogels are a group of polymeric materials in which hydrophilic structure allows 
them to retain amounts of water in their three-dimensional networks. Hydrogels have 
been used for a wide variety of tissue engineering applications because they resemble 
soft tissues and can have good biocompatibility (Van Vlierberghe et al. 2011). The 
hydrophilicity of the cross-linked polymer network arises from hydrophilic groups 
such as -OH, -COOH, -CONH, -CONH2, -SO3H (Baroli et al. 2007). Interaction with 
water causes the hydrogel to swell to many times its un-hydrated size. 
The most commonly used synthetic hydrogels are formed from acrylate and 
acrylamide monomers. They are usually cross-linked through the addition of a cross 
linker such as N,N-methylenebisacrylamide (MBA), gluteraldehyde or ethylene 
glycol dimethacrylate (EGDMA). Another method of hydrogel formation is through 
ionic interactions. Hydrogels of this type (e.g. alginate, chitosan and hyaluronin) are 
composed of linear saccharides that ‗cross-link‘ through ions such as Ca
2+
. There has 
been increasing interest on these hydrogels as they are formed without harsh 
conditions making them amenable to protein and cell encapsulation (Burdick & 
Prestwich 2011). Ionic and covalent double-networked hydrogels have been 
successfully combined to give hydrogels that are highly stretchable and strong (Sun 
et al. 2012).  
Other types of hydrogel networks are also possible. Of particular importance is 
gelatin, which forms through heat-mediated denaturation of the triple helix of 




hydrogen bonded interwoven strands (gelation). The overlapping nodules ‗cross-link‘ 
these gels (Joly-Duhamel et al. 2002). These denatured and renatured extracellular 
matrix proteins make excellent substrates for cell growth as they retain the features 
(e.g. RGD binding sequences) that cells normally interact with in vivo (see Section 
1.3.1).  
The ability of a hydrogel to interact with the solvent though hydrogen bonds and 
ionic interactions means that changes in the surrounding environment can alter the 
hydrogel. Changes in pH, temperature and light have all been used to alter the 
properties of hydrogels (Yin et al. 2006; Hu et al. 1995; Wells et al. 2011). In this 
thesis the alteration of the properties of hydrogels through changes in temperature is 
employed to identify thermo responsive hydrogels that trigger cellular release (see 
Chapter 4). 
 
1.3.4 Thermo-responsive hydrogels 
The transition between a solution and a gel is called the ‗sol-gel transition‘. For 
hydrogels that form upon cooling, such as gelatin and agarose, the point at which the 
polymer transitions from solution to a gel is called the upper critical solution 
temperature (UCST). Polymers that separate from a solution to form a ‗solid‘ above 
a certain temperature exhibit ‗a lower critical solution temperature‘ (LCST). These 
transitions result from a change in solubility resulting from an overall change in the 
hydrophilicity of the hydrogel, thus the polymer becomes ‗insoluble‘ above a certain 
temperature and forms a gel. If the temperature is reduced below the LCST the 
polymer will become soluble and re-liquefy. Hydrogen bonding and hydrophobic 
effects are temperature dependent. At the transition to gel, hydrogen bonding 
between the polymer and water becomes unfavourable compared to the 
corresponding polymer–polymer and water–water interactions. This results in a rapid 
change as the hydrated polymer quickly dehydrates becoming ‗insoluble‘ and 
forming a solid network (Wischerhoff et al. 2000).  
The most investigated thermo-responsive hydrogels are based on poly(N-




pNiPAAm homo polymer is 32 °C, making it particularly amenable to the formation 
of in situ hydrogels at physiological temperature (Ruel-Gariepy et al. 2004). NiPAA-
based nanoparticles have also been employed for encapsulation and release of 
proteins and small molecules (Fan et al. 2011). Other poly(N-alkylacrylamide) 
hydrogels, such as poly(N,N-diethylacrylamides) (DEAA), have been investigated 
for drug delivery and as thermally adjustable sieves for DNA separation (Ngadaonye 
et al. 2012). 
 
1.3.5 Scaffolds in tissue engineering 
Scaffolds are biocompatible materials that support 3-dimentional tissue formation 
through cell recruitment, physical and/or biological cues. Scaffolds are either 
composed of, or mimic, the components of the extracellular matrix such as collagen, 
fibronectin, chitan, or hydroxyapitite allowing the cells within them to behave as 
they do in native tissue. Scaffolds have been fabricated by a variety of methods such 
as electrospinning (Lao et al. 2011), freeze drying (Budyanto et al. 2009), solvent 
separation (Heijkants et al. 2006), self-assembly (Nagahama et al. 2008) and 3D 
printing (Serra et al. 2013). Typically, scaffolds can either consist of a scaffold 
template alone, or be preloaded with cells.  
In one study (Quarto et al. 2001), autologous MSCs were expanded and seeded onto 
a scaffold of macroporus hydroxyapitite. This was then used to fill sections of bone 
in three patients with a critical bone defect. Critical bone defect occurs when a 
patient loses a substantial section of bone (> 3.5 cm). The size is critical because 
beyond this body‘s native bone repair mechanism is impaired, leaving a substantial 
gap in the bone. Traditional treatment often uses autologous bone, but on site tissue 
morbidity and complications from the additional surgery make this a less than ideal 
option (Younger & Chapman 1989). Furthermore, in cases where the missing bone 
section is large, the bone graft approach is impractical. Over the period of 
observation the patients showed significant bone repair.  
Much of the subsequent bone repair scaffold work from other groups followed this 




vascularisation, such as vascular endothelial growth factor (VEGF) have also been 
incorporated in the scaffolds. This was possible due to use of supercritical CO2 and 
the biodegradable polymer poly(DL-lactic acid) in the scaffold formation, allowing 
the incorporation of temperature and solvent sensitive growth factors as no solvents 
are required and the temperature of the process never exceeds 35°C. These scaffolds 
were pre-loaded with MSCs to facilitate bone formation. The ability to incorporate 
sensitive proteins added a new level of sophistication into the scaffold and showed 
significantly improved levels of bone formation (Kanczler et al. 2007).   
A protein or small molecule can be physically trapped, adsorbed or covalently 
bonded (degradable linkers) within hydrogel scaffolds (Censi et al. 2012). The 
release mechanisms are diffusion, degradation, swelling or use of a trigger (e.g. 
temperature). For most applications diffusion offers the most practical and efficient 
option (Boerckel et al. 2011). The ability of hydrogels to encapsulate small 
molecules and growth factors in a temporal manner gives them an advantage over 
other scaffolds. This approach has been taken further with the additional 
incorporation of micro carriers (hydrogel microspheres) with varying degrees of 
release to allow multiple factors to be released at different times (Chen et al. 2009). 
The controlled release of factors from scaffolds have used polyethylene glycol (PEG) 
hydrogel scaffolds that encapsulated VEGF to promote vascular growth for the 
treatment of hind limb ischemia in mice (Phelps et al. 2010).  
Scaffolds for tissue engineering have been fabricated from nanofibres made from 
polymers such as PLA, PLGA and PCL, with the nanofibres closely resembling the 
nanostructure of ECM proteins such as collagen and chitosan. Combining these 
synthetic polymers with ECM proteins in 3D scaffolds allows for the mechanical 
properties to be better designed as well as allowing the controlled release of growth 
factors and small molecules (Carbone et al. 2014). 
One of the most important developments in tissue engineering has been the 
application of decellularised tissues as scaffolds (Uygun et al. 2010; Elder et al. 
2009; Song et al. 2013). Decellularised tissues have had their cell components 
removed through detergent and enzymatic treatments.  The subsequent 




and organs. In the first study of transplantation of a recellularised trachea, 
considerable effort was put into completely decellularise the tissue to remove any 
potential antigens that could result in immune rejection (Macchiarini et al. 2008). 
Recellularisation of whole organs, such as the liver and kidney, resulted in the 
formation of microstructure and the partial restoration of function (Song et al. 2013). 
Although this technology has generated considerable excitement, a donor organ is 
still required and the strategy does not represent a solution for replacement organs. 
However, for some tissues, such as skin where large amounts of tissue is available, 
this does offer an alternative non-immunogenic source of tissue.  
Advances have been made with scaffolds for regenerative medicine, however, these 
have been applied only to the ‗simple targets‘, such as bone, skin and cartilage 
(Falanga & Sabolinski 1999). The current applications usually consist of tissues with 
limited complexity, i.e., they require a limited number of cell types that are readily 
identifiable and expandable in vitro. This has allowed the partial restoration of 
function in these tissues but falls far short of clinical need.  
In order for scaffolds to make a real impact in tissue engineering and regenerative 
medicine, new generic platforms are required that can incorporate a wide range of 
synthetic and natural biomaterials in high resolution architectures, allowing 
controlled release/incorporation of small molecules and proteins. If the intention is 
for these scaffolds to be fully absorbed, the biodegradability of the biomaterial must 
match the rate it is being replaced by native extracellular matrix. In addition, the 
increased understanding of the in vivo stem cell niche needs to be transferred to in 
vitro culture. For in vitro tissues, scaffolds should effectively specify cell growth 
only at their intended location as well as provide the required nutrients in the form of 
a functional vasculature. As with in vivo development, scaffolds should facilitate 
temporal changes, i.e., facilitate growth of a stem cell progenitor and subsequently 
stimulate differentiation. Finally, these constructs should ultimately restore function 






1.4 DEFINED ENVIRONMENTS FOR STEM CELL CULTURE  
 
The culture conditions used in in vitro expansion of stem cells should be ideally in 
the absence of animal derived products. With cells aimed for clinical use, all 
elements of culture need to be defined for both consistency and traceability (EU 
directives 2003/94/EC and 2004/24/EC). The need to remove animal products arises 
from the underlying risk that these products contain pathogens or antigens that could 
be transferred to humans. The biological nature of these components, and methods 
involving co-culture cells, means that they cannot be sterilised and require time-
consuming procedures to verify their disease free status. Animal derived products in 
stem cell culture have also resulted in immunogenic reactions due to the 
incorporation of xeno epitopes such as siliciac acid (Martin et al. 2005). Verification 
of substrates, such as lactate-dehydrogenase-elevating virus (LDV) free Matrigel
TM
 
(derived from mouse sarcomas), are acceptable for research purposes but clearly 
insufficient in a clinical setting. In addition, batch-to-batch variation of biological 
substrates and serum make quality control difficult as well as confounding the 
outcomes of research.  Due to their clinical potential, hESCs and MSCs have been 
the focus of defining stem cell culture.  
 
1.4.1 Defined media for hESC culture 
hESCs were originally derived on a feeder layer of mouse embryonic fibroblasts 
(MEFs) in serum containing media (Thomson et al. 1998). The initial advances 
towards a more defined system involved the removal of the feeder layers with the 
basal lamina substitute MatrigelTM in combination with MEF conditioned media 
allowing the separation of human and animal cells (Zuk et al. 2001). This was 
quickly followed by the use of the conditioned media from human sources (Richards 
et al. 2002; Amit et al. 2003). The critical components in this media required by hES 
cells were subsequently identified and used to formulate the first xeno-free fully 
defined media, mTESR (Ludwig et al. 2006). This has been further refined to eight 




TGFβ in DMEM/F12 with pH adjusted with NaHCO3) known as E8 media (Chen et 
al. 2011).  
 
1.4.2 Defined media for MSC culture 
The standard culture conditions for the expansion of MSCs rely on supplementation 
of the media with 10% FCS. As described previously, the removal of animal 
products is a requirement for MSC clinical applications. The ability to isolate the 
colony forming unit fraction of bone marrow using the surface marker STRO-1 
(Simmons & Torok-Storb 1991) allowed the freshly isolated STRO-1 positive 
population to be investigated under low serum conditions. Expansion using 2% FCS 
identified key factors that are critical for the colony formation, namely TGF-B, bFGF 
and EGF (Gronthos et al. 1994). Examination of these factors in long-term culture 
under low serum conditions resulted in the cells differentiating towards the 
osteogenic lineage (Apel et al. 2009) and in a failure to differentiate down the 
chondrogenic lineage (Girdlestone et al. 2009).  However, long-term studies also 
showed that serum-containing medium, supplemented with bFGF, enhances long-
term growth (Walsh et al. 2000). Eventually, it was shown that the presence of TGF-
β, bFGF and PDGF-ββ under serum free conditions could maintain MSCs for up to 8 
passages (after an initial 5 passages in 10% FBS containing media) and retain their 
potency (Ng et al. 2008; Chase et al. 2010). Jung (2010) fully described a defined 
formulation for the maintenance and isolation of MSCs. This study indicated that 
PDGF-ββ had a significant effect on growth, but reduced both the size and efficiency 
of colony formation indicating that PDGF-ββ may up-regulate the proliferation of the 
non-MSC fraction. TGFb and bFGF, but not PDGF-ββ, was included in their final 
media formulation. The study by Chase (2010) in contrast indicated a synergistic 
relationship between the different growth factors and showed that the presence of 
PDGF-ββ, BFGF and TGF-β, insulin and ‗other factors‘ resulted in colony forming 
unit efficiencies similar to that of serum containing medium. Commercial media 





 (Stem cell technologies) and MSCGM-CD
TM 




has also been demonstrated to maintain hMSCs. This media contains a high level of 
both bFGF and TGFb and many of the other factors of the Jung (Lonza) media 
formulation (Hudson et al. 2011). 
 
1.4.3 MSC surface interactions 
Although standard tissue culture plastic (composed of plasma treated polystyrene) is 
sufficient to support attachment and isolation of MSC from a heterogeneous primary 
tissue isolate, it is insufficient to maintain the growth and properties of these cells for 
long-term culture (Mauney et al. 2004 & 2005). The complex factors controlling cell 
fate in MSCs have been shown to be due to the rigidity of the matrix it occupies 
(Engler et al. 2006), cell–material interactions (Khalil et al. 2014), nanostructure 
interactions (Dalby et al. 2007), cytoskeletal tension (McBeath et al. 2004), and the 
components in the media (Discher et al. 2009). The effect of matrix rigidity was 
demonstrated using collagen coated polyacrylamide gels with varying degree of 
stiffness (obtained through varying the proportion of cross linkers). After one week 
of culture, the softer matrix, similar to brain tissue (with a tensile strength of 0.1-1 
kilopascals (kPa)) resulted in MSCs with a morphology similar to primary neurons 
grown on MatrigelTM. Stiffer substrates (8-17kPa) resulted in myoblast morphology, 
whereas the stiffest matrices (25-40kPa) produced cells with an osteoblast 
morphology (Engler et al. 2006). It was also demonstrated using a NMMII ATPase 
inhibitor blebbistatin that matrix-mediated differentiation occurred through the 
cytoskeletal filament non-muscle myosin 2 (NMMII). Mechanotransduction 
(communication of the extracellular matrix properties to the cells) is mediated 
through focal adhesion tension by myosin filaments acting on actin filaments. 
Alteration of the cytoskeleton occurs through focal adhesion kinase (FAK) and Rho-
associated kinases (ROCKs) (Schaller 2010).  
Surface chemistry also directly influences the differentiation potential of cultured 
cells. Curran et al. examined the effect of methyl (-CH3), amino (-NH2), thiol (-SH), 
hydroxyl (-OH) and carboxy (-COOH) modified glass surfaces (Curran et al. 2006). 




The cells grown on the amino and -SH modified surfaces showed promotion of 
osteogenisis with and in the absence of osteogenic stimulus. Conversely, these 
surfaces did not promote chondrogenisis with or without chondrogenic stimuli. The 
cell viability of hMSCs on the amino modified substrates with chondrogenic stimulus 
was significantly reduced. The hydroxy and carboxy modified surfaces promoted 
chondrogenisis under both basal and chondrogenic stimulus, but did not support 
osteogenisis. Only the methyl and unmodified surfaces seemed to maintain the MSC 
phenotype (Curran et al. 2006). A follow up study of the methyl modified silane 
surfaces showed that the chain length had a significant effect on the ability of the 
surface to support hMSC growth directly related to induced FGF release, with the 
best performing having a CH3(CH2)6- motif  (Curran et al. 2011).  
A study by Benoit and Anseth (2008) used PEG hydrogels in which MSCs were 
encapsulated to quantify the effect of various small functional groups. In addition to 
the PEG monomer, 5 other acrylate monomers containing different functional groups 
were added at 3 different concentrations. The five functional groups where amino, t-
butyl, phosphate, fluoro andcarbolylic acid, all of which having a common 
methacrylate group. The concentrations of the functional group monomers where 
chosen so as not to effect the material properties such as stiffness and swelling. UV 
treatment (~4mW cm
-2
) encapsulated the MSCs in a rounded morphology. The 
results showed that the phosphate groups significantly elevated levels of osteopontin 
and CBFA1 (markers of osteogenisis) and the t-butyl groups resulting in elevated 
levels PPAR-γ (a regulator of adipogenisis). The chondrogenic markers collagen II 
and aggrecan were significantly elevated with the carboxyl monomer correlating to 
the increased chondrogenic differentiation observed by Curran (2006) described 
above. 
 
1.4.4 Integrins and extracellular matrix proteins 
Polymer surfaces vary in their ability to bind extracellular matrix proteins such as 
fibronectin, vitronectin and collagen, which facilitate MSC binding (Danmark et al. 




interaction with the integrins (Fig. 1.3). Integrins are surface receptors composed of 
two non-covalently bound subunits (αand β). These transmembrane receptors have a 
large extracellular domain and a short cytoplasmic tail. Mammals have 18 different 
α-units and 8 β-units that combine to produce 24 heterodimers that can bind to cell 
surface, extracellular matrix or protein ligand domains (Table 1.2). The various 
subunit combinations determine which ligand the receptor will bind to. The 
extracellular matrix contains a host of binding motifs including the arginine-glycine-
aspartic acid (RGD) binding motif. The intracellular domain is connected to the 
cytoskeleton through actin filaments (Fig 1.3).  
 
Figure 1.3. Basic structure of the integrin heterodimers with the α and β subunits, an 
extracellular domain that interacts with the extracellular matrix (ECM) proteins and the 
cytoplasmic tail with actin filaments and focal adhesion kinase (FAK) that transduce the 
mechanical tension and alter the cytoskeleton according though the action of Rho-
associated kinase (ROCK). 
 
Recently, it has been demonstrated that MSCs don‘t interact with a polymer surface 
directly but through the proteins that are bound to it (Li et al. 2013). The mechanical 
tension between the integrins and the proteins bound to the polymer indirectly 
determined the polymer stiffness. MSCs proactively pull on the extracellular matrix 
fibres, which are more stretched on rigid structures than on softer materials (Li et al. 
2013).  Furthermore, the density of the integrin contacts points with the extracellular 




Table 1.2. List of the 24 known integrin combinations expressed in mammals, the 








EXPRESSION IN  MSCs 
   
β1   α1 Collagens, laminins  Gronthos et al. 2001 (α&β) 
       α2 Collagens, laminins Majumdar et al. 2000 (α) 
       α3 Collagens, laminins, fibronectin, entactin Heckmann et al. 2006 (α) 
       α4 Fibronectin, VCAM-1 Walsh et al. 2001 (α) 
       α5  Fibronectin Gronthos et al. 2001 (α) 
       α6 Laminins Gronthos et al. 2001 (α) 
       α7 Laminins  
       α8 Vitronectin, fibronectin, tenascin  
       α9 Vitronectin, fibronectin, tenascin  
       α10 Collagens ‡ Goessler et al. 2006 (α) 
       α11 Collagens ‡ Foster et al. 2005 (α) 
       αV Fibronectin, vitronectin Klees et al. 2005 (α) 
β2   αL ICAM-1, ICAM-2, ICAM-3 Majumdar et al. 2000 (α&β) 
       αM iC3b, fibrinogen, ICAM-1, coagulation factor 
X 
Dominici et al. 2006 (α) 
       αX Fibrinogen, iC3b  
       αD ICAM-3  
β3   αIIβ Fibrinogen, fibronectin, von Willebrand factor 
vitronectin, thrombospondin, tenascin 
Gronthos et al. 2001 (β) 
       αV Fibrinogen, fibronectin, von Willebrand 
factor, 
vitronectin, thrombospondin, osteopontin, 
collagens 
Gronthos et al. 2001 (α&β) 
β4   α6 Laminins Klees et al. 2005 (α) 
β5   αV Vitronectin, fibronectin Reyes et al. 2001 (α&β) 
β6   αV Fibronectin, tenascin Chastain et al. 2006 (β) 
β7   α4 Fibronectin, VCAM-1, MAdCAM-1  
       αE E-Cadherin  
β8   αV Vitronectin  
   
 
When extracellular matrix contact points are varied under constant stiffness in a 
polyacrylamide matrix coated with collagen (as described in the Engler paper above), 
the stem cell fate altered with higher densities giving bone morphology and lower 
densities the neural morphology (Trappmann et al. 2012). Synthetic substrates with 




density and cell fate where high-density GRGDSP surfaces (2.5%) resulted in higher 
levels of osteogenic differentiation compared to low-density surfaces (0.27%) 
(Koepsel et al. 2012).  
MSC bind to the extracellular matrix through focal adhesions. The integrins at focal 
adhesions are clustered. One study varied both the density of the RGD containing 
sequence (YRGD) and the number of sequences per cluster (1, 5, and 9). This 
showed that the most efficient binding occurred with clusters of nine sequences at 
distances of 190 nm (Maheshwari et al. 2000). Both surface chemistry and contact of 
the extracellular matrix play a critical role in binding and determining MSC stem cell 
fate. 
 
1.4.5 Polymer substrates for long-term MSC culture 
It has been shown that continued culture of MSCs on tissue culture plastic results in 
loss of osteogenic (Mauney et al. 2004) and adipogenic (Mauney et al. 2005) 
differentiation potential. To overcome these limitations, hMSCs are typically 
cultured on biological substrates such as gelatin (Mauney et al. 2004) and fibronectin 
(Kisiday et al. 2011), and little work has been reported regarding defined synthetic 
substrates for long-term culture. One of the few studies to do this built on previous 
work that showed that 150 nm pits in a square at distances of 300 nm from centre to 
centre showed osteogenic differentiation when the squares were offset by 50 nm 
(Dalby et al. 2007). Using electron beam lithography and a PCL substrate, 150 nm 
pits in an asymmetrical arrangement (300 nm centre to centre) were able to maintain 
the MSCs for 8 weeks, however, the markers used to characterise the cells were 
limited (STRO-1, CD166 and CD63) passaging experiments however did examine 
STRO-1 expression at each passage with the offset of 50 maintaining the phenotype 
where the symmetrical square had lost it (McMurray et al. 2011).  
Curran et al. used dip pen nanolithography (DPN) to interrogate the effect of both 
nano-topography and functional group presentation. This technology used thiolated 
molecules on gold (nano-structured self-assembled monolayers (SAMs)) presenting 




corroborated previous studies showing the –CH3 functional group maintained the 
MSC phenotype. In addition, the study also revealed that the distance between 
presentation of the functional group was critical to this property. The DPN dots were 
70nm in diameter to allow for the formation of a single focal adhesion known to be 
between 60-67nm (Poole et al. 2005), and only a distance of 280 nM between spot 
centres could maintain the phenotype (Curran et al. 2010). 
Currently, all ‗defined‘ culture systems require the use of biological substrates (Frith 
et al. 2012) as tissue culture plastic cannot support MSC growth with defined media. 
To date, a polymer substrate able to maintain MSCs in serum free media is not 
known. Recently, a peptide–acrylate substrate has been reported for defined hMSC 
culture, however, the details of the substrate were not disclosed, whether the 
substrate was a polymerised version of extracellular matrix protein sequences or de 
novo sequences remains unknown (Dolley-Sonneville et al. 2013). Given what is 
now known about MSC–substrate interactions, it is not surprising that media 
containing no serum components, and therefore no extracellular matrix components 
containing the RGD binding sequence, cannot support MSCs in completely synthetic 
substrates. The requirements for purely synthetic substrate are considerably higher in 
the absence of serum components as the polymer will have to directly interact with 
the cell surface integrins in a way that can maintain the hMSCs in their stem cell 
state.  
 
1.5 POLYMER MICROARRAYS  
 
As described in section 1.3, stem cells represent a particularly difficult problem when 
designing/identifying substrates that maintain them in their stem cell state. The 
problem arises from the many factors that influence their stem cell state including 
surface chemistry, protein adsorption, material stiffness, nano-topography, and 
integrin contact point density. Characterisation of all the biomaterials that support 




strategy. As more stem cells types become isolable, a strategy for the identification 
biomaterials for a diverse range of stem cells with different sets of environmental 
cues becomes necessary. Indeed, with the added criteria of the next generation of 
scaffolds (see section 1.3) any strategy for identifying these materials will require a 
high-throughput component to cover the combinatorial chemical space needed to 
identify advanced materials that fit all the necessary criteria.  
Polymer science has produced a wide range of potential biocompatible materials for 
regenerative medicine. In particular, methods incorporation combinatorial chemistry 
have advanced the field. Using combinatorial approach, Brocchini created polymer 
libraries by combining different monomers. Here, the first monomer group (A) 
containing 14 monomers (tyrosine derived diphenols) was polymerised with to the 
second monomer group (B) containing 8 monomers (aliphatic diacids) to give a 
library of 112 structurally related polyarylates (Brocchini 1997). Turning these 
libraries into a usable platform (polymer microarrays) that could interrogate cell 
material interactions was achieved by applying the printing technology developed in 
the microelectronics and graphic design industries (Roth et al. 2004).  
Polymer microarrays were originally developed by Bradley and Langer (Mizomoto 
2004; Anderson et al. 2004; Tourniare et al. 2006). Two primary methods are used 
for the production of polymer microarrays, contact printing and inkjet printing. Both 
these methods involve the printing of the polymer libraries onto glass slides. Polymer 
microarrays typically consist of printed circular polymer features of ~350 μm in 
diameter printed in a predefined grid with approximately 800 μm between features to 
represent each polymer in the library. For cell studies, the incubation of cells on the 
polymer microarray allows the simultaneous scrutiny of cell interactions with 
polymer libraries using nL volumes of polymers.  
 
1.5.1 Applications of polymer microarrays 
Langer applied a polymer microarray composed of 576 polymers made up from 25 
different acrylate monomers to hESCs. Glass slides were coated with poly(HEMA) 




(embryonic stem cells grouped into rounded spheres), harvested, plated onto the 
arrays, and incubated for 6 days in the presence of the differentiation factor retinoic 
acid. The cells that attached to the polymer features were subsequently stained for 
cytokeratin 7 (epithelial marker) and vimentin (a mesoderm marker). This work 
identified some substrates that showed enhanced cytokeretin 7 in the presence of 
retinoic acid (Anderson et al. 2004). These studies demonstrated the potential power 
of the polymer microarray method; however, the lack of follow up meant that, 
although polymer microarrays could bind diverse cell types, whether these particular 
polymers could maintain growth and phenotype at a large scale remained unknown. 
A different approached by Bradley used a polyurethane-based polymer microarray. 
The 120-member polymer library was constructed using a polymerisation of a polyol 
and a diisocyanate monomers with a chain extender (Appendix 1.1C). This polymer 
microarray format was tested with human tubular renal epithelial cells with a culture 
period of 5 days. ‗Hit‘ candidates were identified but no large-scale follow up studies 
were performed (Tourniaire et al. 2006). The same 120-polymer microarray was used 
to identify polymer candidates that promoted the adhesion of bone derived dendritic 
cells. Scale-up studies were performed by spin coating glass coverslips with ‗hit‘ 
polymer solutions. Importantly, functional studies showed the cells had retained their 
phagocytosis capability on the synthetic polymer substrates. This was the first 
example that demonstrated the technology beyond ‗proof of principle‘ experiments 
(Mant et al. 2006). 
Zhang (2008) expanded the polymer microarrays to include hydrogel microarrays. 
The use of inkjet printing in array fabrication allowed for in situ photo-initiated 
polymerisation. In contrast to previous inkjet methods, the monomers were mixed in 
situ with the cross linker and UV photo initiator. Exposure of the arrays to UV for 30 
minutes after printing polymerised the mixture to produced hydrogel features. The 
power and versatility of the new hydrogel array was demonstrated using an array 
containing 2280 different hydrogels. This hydrogel array included N-alkyl 
substituted acrylamides monomers, such as N,N-diethylacrylamide (DEAA) and N-
isopropylacrylamide (NIPAA), with known thermo-responsive abilities (Hirokawa & 
Tanaka 1984). Incubation of the hydrogel array with HeLa cells followed by a 




cellular release of up to 90% of cells in 30 min. The top three hydrogels were 
subsequently scaled up and cultured with different cell types (Zhang et al. 2008), one 
of which, a mouse embryonic cell line (E14tg2a), did not grow. These were 
rescreened to identify a thermo-responsive hydrogel capable of supporting these 
cells. This demonstrated the power of the array to identify cell specific substrates that 
could trigger cellular release.  
Up to this point much of the research into polymer microarrays concentrated on 
development of the technology (Liberski et al. 2009), or expanding the chemical 
‗space‘ that these arrays covered. Since then, the emphasis has shifted to the practical 
application of this technology. These applications have included identification of 
polymers for the isolation of osteoblasts for bone tissue engineering (Tare et al. 
2008), polymers that capture protozoan pathogens (Wu et al. 2012), anti-bacterial 
polymers (Pernagallo et al. 2011; Hook et al. 2012), platelet activating polymers 
(Hansen et al. 2011) and polymers for the isolation and growth of functional 
hepatocytes (Hay et al. 2011). 
Polymer microarrays have also been applied to stem cells, particularly for those of 
clinical importance. Anderson applied the polymer microarrays to primary pancreatic 
islet cells (Mei et al. 2010b). Hit polymers were identified and scale-up experiments 
performed. However, it should be noted that the arrays and subsequent scale up 
experiments were coated with fibronectin, an extracellular matrix protein known to 
support many cell types. Furthermore, comparisons of various extracellular matrix 
proteins were made, demonstrating that these cells could be maintained on Matrigel, 
Laminin (sigma), polylysine and G408 supernatant (the standard coating for 
maintaining primary pancreatic cells). Fibronectin was not compared, it is therefore 
difficult to ascertain whether the ‗hit‘ polymers act as ‗true‘ surfaces or if the 
fibronectin coating is the primary source of cell binding and maintenance (Mei et al. 
2010).  
The identification of the defined components of hESC media had now shifted the 
focus towards defining the substrate (Baker 2011). The most successful strategies 
involved the use of recombinant extracellular components such as laminin 511 




Although successful at maintaining hESC in defined conditions, these substrates 
would be economically prohibitive for clinical application.  Mei et al. used polymer 
microarrays to identify a ‗defined‘ substrate for hESCs long term culture, however, 
the substrates were coated with FCS, which is the primary undefined component that 
defined media such as mTESR (the media that the cells were cultured in) was 
designed to replace. Indeed, almost all of the publications that have applied the 
polymer library originally described by Langer et al. for cell studies have required 
some form of augmentation with extracellular matrix proteins or FCS. This would 
suggest that the chemical diversity of this array is too limited for cell studies. Perhaps 
in recognition of this, the authors of these papers have published a new array format 
(Celiz et al. 2014). By contrast Bradley et al. have developed and applied arrays 
containing over 7000 polymers (Hansen et al. 2014).  
Brafman (2010) applied polymer microarrays to identify a poly(methyl vinyl ether-
alt-maleic anhydride) PMVE-alt-MA that could maintain hESCs and iPS for 5 
passages. To avoid extracellular matrix protein interference, the polymer microarray 
screening was performed with hESCs cultured in the defined media StemPro, 
Subsequent long-term culture and characterisation was performed in serum 
containing media. The first fully defined hESCs culture system using a polymer 
substrate used the hydrogel polymer microarray described above (Zhang et al. 2013). 
hESCs were screened using a 609 hydrogel polymer microarray cultured in defined 
mTESR media. 25 ‗Hit‘ hydrogel candidates were examined for their ability to 
support hESCs in scale-up culture. The top 10 candidates were then further tested to 
reveal hydrogels that support hESC and trigger cellular released based upon 
temperature reduction (15 °C for 30 min). One hydrogel based on 2-
(diethylamino)ethyl acrylate termed (HG21) supported hESC growth in defined 
conditions for over 20 passages while retaining pluripotentcy. In addition, this was 
achieved in the absence of chemical and enzymatic passaging.  In a subsequent 
study, a polymer substrate that could support hESCs in defined mTESR media was 




In this thesis, the application of the microarray platform is applied to the clinically 
important MSCs to achieve culture in the absence of biological substrates and 
enzymatic passaging. 
 
1.6 THESIS AIMS  
 
The aim of this thesis is to develop new chemically defined culture systems for 
mesenchymal stem cells and to identify small molecule factors that could 
enhance/manipulate the stem cell phenotype. High-throughput methods were 
employed which 
 Could identify synthetic polymer alternatives to the use of animal 
derived biological substrates for the long-term culture and 
maintenance of MSCs. 
 Could identify ‗smart‘ hydrogels that allowed MSCs to be passaged in 
the absence of harsh enzyme treatment. 
 Could identify small molecules that could substitute for growth or 
enhance/alter the MSC marker phenotype of MSCs. 
 
Taken together these achievements would represent a definite advance in the 

















MATERIALS AND METHODS 
 
2.1. POLYMER MICROARRAYS 
2.1.1 Polymer and Hydrogel Libraries 
The polyacrylate/acrylamide library was synthesised by Dr. Mizomoto (Appendix 
1A and B) and the polyurethane library was synthesised by Dr. Thaburat (Appendix 
1C) under the supervision of Professor Mark Bradley. 
 
2.1.2 Polymer microarray fabrication 
2.1.2.1 Slide preparation 
Glass microscope slides (76 × 26 mm) were cleaned with oxygen plasma 
(Europlasma, Belgium) at 20 °C for 5 min, treated with 2% (3-
aminopropyl)trimethoxysilane in acetonitrile (w/v) for 1 h, washed with acetonitrile 
and acetone, and oven dried at 100 °C for 2h. For agarose coating, slides were dipped 
into a 2% agarose solution (w/v) at 65
 
°C. The slides were air dried and stored at 
room temperature.  
 
2.1.2.2 Contact printing  
Polymers were contact printed onto agarose coated slides by using a Qarrayer
mini
 
(Genetix, UK) with aQu solid pins (K2785, Genetix) inked from 384-well plates 
filled with 1% (w/v) polymer solutions in N-methylpyrrolidone (NMP). Each spot 
was stamped 5 times with 200 ms inking time and 100 ms stamping time, resulting in 
~ 310 µm spots in diameter. For the initial screen the arrays of the polymers (n = 4) 




overnight.  The ‗hit arrays‘ were fabricated in a similar way as described above 
(polymer n = 6).   
 
2.1.3 Hydrogel microarray fabrication 
2.1.3.1 Slide preparation 
Glass microscope slides (76 × 26 mm) were cleaned with oxygen plasma 
(Europlasma, Belgium) with 1.5 bar oxygen pressure. Slides were washed with water 
and acetone. Sucrose solution (30% w/v) was printed onto the glass slide as 2 nL 
spots in a 28 × 38 array with a pitch of 800 µm between spots. The sucrose printed 
slides were coated with 15 µL of tridecafluoro-1,1,2,2-tetrahydrooctyl-
dimethylchlorosilane (FDS) for 12 hours in a sealed container. Slides were washed in 
acetone before printing. 
 
2.1.3.1 Preparation of polymer hydrogel microarrays 
A MicroDrop MD-E-401 printer with an autodrop pipette in conjunction with a MD-
O-538-85 CCD camera was used. The humidity of the printing chamber was 
carefully controlled using a v5100N vicks ultrasonic humidifier with a TH-810 
humidity controller. Arrays were fabricated by printing aqueous solutions of 18 
acrylate/acrylamide monomers (Table 4.1) in drops on a masked glass slide using a 
MicroDrop inkjet printer and polymerised in situ in the presence of a cross-linker 
N,N‘-methylenebisacrylamide (MBA 5% v/v) and photo-initiator 1-
hydroxyclyclohexyl phenyl ketone  (9% v/v). Each array had 28 × 87 features giving 
609 different polymers each printed in quadruplicate with 7 different ratios of 2 







2.1.4 Microarray screening 
2.1.4.1 Cell culture 
Cell culture reagents were purchased from Invitrogen unless otherwise stated. hES-
MPs were grown 0.1% gelatin coated 75 cm tissue culture flasks (Corning) in 
DMEM supplemented with 10% FCS, bFGF (4 ng/mL), L-glut (100 units/mL) and 
pen/strep (100 units/mL), and incubated at 37 °C with 5% CO2. 
 
2.1.4.2 Binding assay 
A suspension of hES-MPs (4 mL) was added to the microarray slides (initial screen n 




, placed in 
a 4-well rectangular chamber. After 24h incubation, the slides were washed with 
PBS and the cells fixed with 4% formaldehyde in PBS for 10 min, stained with DAPI 
(0.1 µg/mL in PBS) for 10 min, and washed 3 times with PBS. Image capture was 
carried out using a Nikon Eclipse 50i microscope with the Pathfinder software 
(IMSTAR, France). Cell counts were determined by Pathfinder image analysis 
software. 
 
2.1.4.3 Hydrogel binders 
The combined results of the 3 arrays were used to select the best binding hydrogels. 
Hydrogel binding and cell morphology were analysed to select candidates for the 88 
‗hit‘ array. 
 
2.1.4.4 Polymer binders 
Polymers with ≥ 5 cells per feature were selected (Fig.3.2) resulting in 171 





2.1.5 Second focused screen 
The top candidates from the binding array were used to construct hydrogels and 
polymer arrays containing only the identified ‗hits‘. Each time point was represented 
by 3 microarrays giving a total of 9 slides for the polymer array and 9 slides for the 
hydrogel array. For the analysis each hydrogel/polymer feature was imaged 4 times 
to give a bright field, DAPI (λEx/λEm 358/461 nm), FITC (λEx/λEm 495/519 nm) and 
RHOD? (λEx/λEm 555/565 nm) image. A circle was drawn around the spot to define 
the size of the feature. Image analysis was performed by IMSTAR Pathfinder 
software. The ‗focused arrays‘ were also assessed for cell viability 
(CellTracker
TM
Green) at the day 7 time point. 
 
2.1.5.1 Immunocytochemistry 
Cells on the arrays were stained using standard immunocytochemistry protocols. 
hES-MPs were blocked for 1h with 10% FCS in PBS. They were then incubated 
overnight at 4 °C with primary antibodies against STRO-1 (mouse anti-human, 
Millipore), CD105 (goat anti-human, R&D systems) both at 1:100 dilution, and for 
the scale-up experiment also with CD271 (rabbit anti-human, Millipore) at 1:50 
dilution. The cells were incubated for 4 h with the appropriate AlexaFluor®-
conjugated secondary antibodies; STRO-1 (donkey anti-mouse 488) at 1:200, CD105 
(donkey anti-goat 555) at 1:400 and CD271 (chicken anti-rabbit) at 1:100 dilution. 
Excess antibody was removed by washing 3 times with PBS. Finally, cells were 
stained with DAPI (0.1µg/mL in PBS) and washed 3 times with PBS.  
 
2.2 SCALE-UP STUDIES 
2.2.1 Coating of polymers on coverslips 
Glass coverslips (Menzel-Gläser, Germany), 10 mm (scale-up experiments) and 32 
mm diameter (long-term culture), were washed with tetrahydrofuran (THF) and spin-




coverslips were dried overnight in a vacuum oven (200 mbar) at 40 °C. The coated 
coverslips were sterilised with UV light for 20 min prior to cell culture. 
 
2.2.2 Preparation of polymer treated coverslips 
Glass coverslips were placed in 1M NaOH solution overnight on a shaker. The 
NaOH solution was removed and the coverslips were washed with water and acetone 
after which the coverslips were air-dried. Next, the coverslips were placed in a 
container with 97.5 mL of acetonitrile, 2 mL of trimethoxysilylmetacrylate and 0.5 
mL of triethylamine, covered and placed on a shaker overnight. The solvent was 
removed and the coverslips were rinsed with acetone and air dried and stored at 
−20 °C until required. 
 
2.2.3 Preparation of hydrogel coated cover slips 
Monomer, photo-initiator and cross-linker solutions were prepared in NMP and 
placed on acrylate treated coverslips (10, 19 and 32 mm in diameter with 1, 1.6 and 
10 µL of solution used, respectively). The coverslips were exposed to UV irradiation 
(Model B 100AP, Black-Ray) for 30 min before incubation overnight at 40 °C. The 
coated coverslips were then washed with ethanol and acetone before air drying. The 
coated coverslips were sterilised with UV for 20 min and washed with PBS two 
times (5 min per wash) prior to cellular studies. 
 
2.2.4 Preparation of agarose coated well plates 
A 0.5% Agarose (type B) solution was prepared in 200 mL of deionised water. The 
solution was heated in a microwave to dissolve the agarose. Agarose was heated 
prior to coating of well plates (100µL/48-well). Once coated, the plates were put in 





2.2.5 Scale-up culture and cell analysis on polymer/hydrogel coated 
coverslips  
For both the polymer and hydrogel screens, 30 candidates were identified for further 
analysis in scale-up cell culture. 48-Well plates were coated with 0.5% agarose 
solution (100 µL/well) and dried overnight at 50 °C. The polymer or hydrogel coated 
coverslips (n = 4) were placed into the wells and sterilised by UV irradiation for 20 
min and washed twice with PBS. The tissue culture plastic controls consisted of 3 
wells of a 48-well plate, and the gelatin controls consisted of 3 well of a 48-well 
plate coated with a 500 µL 0.1% gelatin solution (in PBS). This was followed by 
seeding with hES-MPs at 1 × 10
4
 cells per well. Media was changed every 2 days. At 
day 7, cells were washed with PBS, fixed with 4% formaldehyde, stained with DAPI 
(1 µg/mL in PBS) and triple immunostained for STRO-1, CD105 and CD271. Each 
well was imaged 9 times on four channels: λEx 360 nm (DAPI), λEx 488 nm (STRO-
1), λEx 555 nm (CD105) and λEx 649 nm (CD271). Stained nuclei were counted and 





 (the intensity was normalised to the cell number). The background 
fluorescence for each candidate was calculated using a replicate stained only with the 
secondary antibody and deducted from the sample fluorescence to give a corrected 
fluorescence intensity value for each surface.  
 
2.2.6 Identification of thermo-modulatable hydrogels  
Based on the results of the scale up study, 10 hydrogels were tested for their capacity 
to trigger cellular release. hES-MPs were seeded onto 10 mm hydrogel coated 
coverslips placed into agarose coated 48-well plates, and cultured for 7 days. To 
trigger release, the hES-MPs on hydrogels were removed from the incubator and left 
at 21 °C for 1h, after which detached cells were collected by gentle pipetting and 
transfer to Eppendorf tubes. The remaining cells were detached by trypsinisation. 
Both, thermo-detached and trypsinised cells were centrifuged (1000 rpm for 5 min), 
the cells re-suspended in 50 µL of media, and the cells counted with a Neubauer cell 




according to the volume. Comparison between trypsin detached cells and thermo-
detached cells determined the % detachment. The average and standard deviation for 
each hydrogel was obtained. 
 
2.3 LONG-TERM CULTURE 
2.3.1 Source of hES-MPs and ADMSCs 
For long-term culture studies hES-MPs and ADMSCs were used. Ethical approval 
for the collection of adipose tissue and subsequent research was granted by the South 
East Scotland Research Ethics Committee (Ref 10/S1103/45h) and hES-MPs were 
purchased (hES-MP™002.5, Cellectis bioresearch). The ADMSCs were derived 
from the stromal vascular fraction of lipoasperate from adipose tissue (Zuk et al. 
2001). 
 
2.3.2 Long-term passaging  
hES-MPs and ADMSCs were seeded at 3 × 10
4
 cells/well onto 32 mm diameter 
polymer and hydrogel coated coverslips (n = 3), which were placed into agarose 
coated 6-well plates (0.5% agarose, 500 µL/well). For gelatin controls, 6-well tissue 
culture plates were treated with 0.1% gelatin in PBS (3 mL/well) for 5 min, and the 
excess solution removed prior to the application of cells and media. Media was 
changed every 2–3 days and cells were passaged every 5–6 days at a 1:6 splitting 
ratio.  
 
2.3.3 Long-term enzyme free passage (Hydrogels) 
hES-MPs and ADMSCs were cultured on hydrogel-coated coverslips in 6-well plates 
where removed from the incubator and plated in a tissue culture hood for 1h. Using a 
p1000 pipette, the media within the well was gently pipetted 10 times over the 




centrifuged for 5 min at 1000rpm. Cells were re-suspended in DMEM supplemented 
with 10% FCS, bFGF (4 ng/mL), L-glut (100 units/mL) and pen/strep (100 units/mL) 
and split in a 1:6 ratio and replated onto fresh coverslips. 
 
2.4 CHARACTERISATION 
2.4.1 Flow cytometry 
At passage 5 (hES-MPs and ADMSCs) and passage 10 (ADMSCs) cells were 
stained for CD105, STRO-1, CD271, CD90, CD73, CD34, CD14, CD146, CD140b, 
and HLA-DR, and analysed by flow cytometry.  
For flow cytometry analysis, cells from each replicate (n = 3) were trypsinised. After 
removing media and washing with PBS, TrypLE™ Express (500 µL) was added to 
each well for 5 min and subsequently neutralised with media (2 mL). The cells were 
spun down (5 min, 1000 rpm) and resuspended in 600 µL of FACS-PBS (PBS with 
0.1% of BSA and NaN3). To 100 µL of cell suspension 2 µL of the designated 
fluorescent-conjugated antibody was added; CD105–FITC (Biolegend), STRO-1–
APC (Biolegend), CD73–PE (BD Bioscience), HLA-DR–FITC (BD bioscience), 
CD14–PE (BD Biosciences), CD34–PE (Biolegend) CD140b–APC (BD 
Biosciences), CD271–PE (BD Bioscience), CD146–FITC (eBiosciences) and CD90–
FITC (Biolegend). After incubation for 20 min at 4 °C, 2 mL of FACS-PBS was 
added to each tube and the tubes centrifuged for 7 min (475 rpm). The PBS was 
gently decanted ensuring the pellet was not dislodged and the cells resuspended in 
250 µL of FACS-PBS and analysed on a FACSCalibur flow cytometer. Flow 
cytometry histograms were generated using FlowJo. 
 
2.4.2 Osteogenic and adipogenic differentiation 
After 5 passages on HGL1, PU157, PU108, PA338, tissue culture plastic and 
gelatin, ADMSCs were plated at 1.9 × 10
4
 cells per well (n = 3) in standard tissue 
culture 12-well plates for osteogenic differentiation, and 3.8 × 10
4




3) for adipogenic differentiation. After 24 h the media was changed to StemPro 
osteogenic or adipogenic differentiation media and the cells were cultured for 28 
days with media changes every 3–4 days. After washing with PBS, the cells were 
fixed in 4% formaldehyde and stained with DAPI (1 μg/mL). Osteo-induced cells 
were stained with 2% Alizarin red S solution (pH 4.2) and adipo-induced cells with 
Oil Red O solution (3 parts of 0.5% Oil Red O in isopropanol to 2 parts of water). 
Adipocyte differentiation was quantified by comparing the number of DAPI stained 
nuclei with the number of differentiated cells.  
 
2.4.3 Image capture 
ADMSCs and HE-SMPs grown before and after long-term passaging on 32mm 
diameter coverslips (for 6-well plates) were imaged with a Zeiss Observer 
microscope. 
HGL1, P338, PU157 and PA108 adipogenic quantification was evaluated by 
comparing total cells with differentiated cells. For the two channels (bright field and 
DAPI) 12 images were taken for each of the replicate wells (n=3). Firstly, cell counts 
where made of the DAPI stained nuclei for each of the images in image J. Secondly, 
merged images of the DAPI stained and bright field images where produced. 
Differentiated cells were marked and counted. Comparison with the DAPI channels 
gave a percentage of differentiation for each image. The data for the 12 images of 
each well where combined. The data for the 3 wells were averaged and the standard 
deviation determined. 
PA338, PU157 and PU108 osteogenic differentiation was evaluated by amount of 
Alizarin red S positive pixels in osteogenic differentiation images. This was 
quantified using ImageJ by setting the image/adjust/colour threshold option. The 
‗analyse option‘ (analyse particles) calculated the percentage of pixels above 
threshold. The best and poorest Alizarin red S stained wells were used as reference 





2.4.4 Protein extraction from polymer surfaces 
Polymer coated coverslips (n = 3) were placed into a 12-well tissue culture plate and 
sterilised with UV for 10 min. The coverslips were washed twice (10 min) with PBS 
and 3 mL of culture media (DMEM supplemented with  10% FCS, 4 ng/mL bFGF, 
100 units/mL of L-glutamine, and 1% pen/strep) was added to each well. Plates were 
placed in an incubator at 37 °C with 5% CO2 for 24 h. The media was removed and 
the coverslips washed twice with PBS. Each coverslip was placed into 1.5 mL 
Eppendorf tube and broken up into small pieces using tweezers. For the gelatin and 
tissue culture plastic controls, surfaces were removed using curved scalpels. For the 
culture media control, 40 µL of media was added to a tube. The tubes were 
centrifuged at 11000 rpm for 5 min. To each tube, 40 µL of sample buffer (0.5 M 
Tris-HCl (pH 8.8), 4% SDS (w/v), 20% glycerol (v/v), 2% 2-mercaptoethanol (v/v), 
and 0.0025% bromophenol blue in distilled water) was added and the tubes heated at 
100 °C for 10 min. The proteins were separated on a Novex Mini Cell in TGS buffer 
(Tris 0.025 M, Glycine 0.192 M, 0.1% SDS (w/v)) using a NuPAGE 4–12% Bis-Tris 
Gel (1mm × 12 well). Gels were run for 40 min at 200 V, 120 mA. For silver 
staining, gels were placed in deionised water and stained with Sigma ProteoSilver 
Silver Stain Kit (PROTSIL1-1KT) following the manufacturer‘s instructions. For 
Oriole fluorescent staining, gels were placed directly into 100 mL of premixed 
fluorescent gel stain (Biorad 161-0496) for 90 min and transferred to deionised water 
and stored in the dark. Gels were imaged using a BIORAD image analyser and 
analysed with the Biorad image lab 3.0 software. 
 
2.4.5 Polymer and monomer structures 








2.5 SMALL MOLECULE HIGH-THROUPUT SCREENING 
2.5.1 Identification of the small molecule library 
The GeneGo bioinformatics software allowed searches of the key pathways and 
markers identified with MSC ‗stemness‘ (Table 5.1, Appendix 3). Pathways in 
GeneGo highlight (with a blue hexagon) the points of the pathways that are known to 
be affected by small molecules. By right clicking the blue hexagons, the small 
molecule(s) are listed with their properties. These can then be compared with the 
selection criteria (FDA/EU approved, toxicity and solubility). Candidates that 
fulfilled these criteria were selected for the library. 
 
2.5.2 Preparation of the small molecule library 
The members of the small molecule library were mainly ordered from sigma (see 
appendix 4.1). The majority of the small molecules were dissolved in DMSO with 
some compounds requiring the addition of 1M HCl or 1M NaOH. The compounds 
were weighed and dissolved in 2 mL glass vials to make 1.5 mL of 100 mM stock 
solution of each small molecule. To organise the library small molecule location 
maps where produced. The maps corresponded to fluidX 1.1 mL Data Matrix Screw-
top, robot rack-96 barcoded tubes (v-bottom). 3 maps covered the 200 small 
molecule library. 1mL of a small molecule solution was transferred to its 
corresponding vile in the rack. The 1mM solution library was stored at -80 °C. 
 
2.5.3 Preparation of media for small molecule screen and optimisation 
plate 
Master feeder plates (Axygen deep well plates, 96-well, clear) were constructed 
corresponding to the 3 small molecule maps. 2 mL of hES-MP media was added to 
each well and to each well 20 µL of stock solution (thawed and well mixed) was 
added to give a 1 mM concentration. This master plate was used to make the 96-well 




added to each well. Using a multi-channel pipette, media with small molecule 
solution were mixed well (pipetting up and down 8 times) and 200  L of solution 
was transferred to the corresponding well containing 1800 µL of media in the 100 
µM feeder plate. Once complete the 100 µM solution of this feeder plate was then 
used to construct the 10 µM plate using the same procedure. In total 3 feeder plates 
were made for each concentration (9 plates). Note that the preparation for the small 
molecule screen in defined media is the same as stated above with the exception of 
using the define media formulation. 
 
2.5.4 Defined cell culture 
hES-MPs and ADMSCs, on gelatin substrate, were transitioned onto the defined 
media formulation over ~10 days by increasing the proportion of defined media to 
undefined (serum containing) media. The media was changed every 2–3 days by 
raising the defined media component in increments (25:75, 50:50, 75:25, 100%).  
 
2.5.5 Plating, fixing and staining 384 well plates 
384-Well black clear bottomed plates (PerkinElmer Cell Carrier, 6007430) were 
coated with 0.1% gelatin solution. 100 µL of hES-MP cell suspension (1 × 10
4
 
cells/mL) was added to each well using a 12 tip multi-channel pipette. Making sure 
cells are in suspension at this point requires continuous mixing of the cell 
suspension. Cells were incubated for 24h, media removed, and 200 µL of the small 
molecule containing media was added to the wells. Note the media has to be well 
mixed before adding it to the cells (pipetting 8 times). Cells were incubated for 7 
days with media changes every 2 days after which they were washed with PBS and 
fixed with 4% formaldehyde. Cells were stained with DAPI nuclear stain, STRO-1, 






2.5.6 Scanning and analysis with Opera and ACAPELLA 
384-well plates were scanned using the Opera high-throughput microscope. Each 
was imaged 9 times from different representative areas of the well in the DAPI 
channel (λEx/λEm 340/488 nm), FITC (STRO-1 antibody λEx/λEm 495/519 nm), 
RHOD (CD105 antibody λEx/λEm 555/565 nm) and far red (CD271 antibody λEm/λEm 
650/668 nm) channels. The parameters of the analysis script used by ACAPELLA to 
produce the data are given below. Each florescent channel required separate analysis. 
For each screen the parameters were checked and adjusted if necessary for nuclear 
















                             General  
 0 
Image Field 3 
Number Of Channels 3 
Channel number of neclear channel 1 
Channel number for cytoplasm channel 3 
Show Illustrations 0 
Nuclear Detection 
Nuclei Detection Algorithm F 
Theshold Adjustment 6 
Minimum Nuclei Distance 8 
Nuclear Splitting Adjustment 6 
Individual Threshold Adjustment 0.4 
Minimum Nuclear Area 60 
Minimum Nuclear Contrast 0.03 
Parameter SCAN None 
Cytoplasm Detection 
Cytoplams Threshold Adjustment 0.5 
Cytoplasm Individual Threshold Adjustment 0.1 
Cytoplam Region 
CytoplasmOuterBorderShift 0 
CytoplasminnerBorder Shift 0 
NucleusBorderShift  
Filters 
Intesity Threshold 500 
Upper Area Threshold 15000 
Lower Area Threshold 500 
Lower Roundness Threshold 0.9 




2.5.7 Preparation of defined media  
The defined serum free media was prepared as outlined by Jung (see table 2.1) (Jung 
et al. 2010). DMEM/F-12 (1:1) (Gibco 31331) was used a base media. Media (1 L) 
was placed in the upper cup of a filter unit. To this was added 50 µL of progesterone 
stock solution (1mg/8.83mL, in chloroform), 10 mL L-glutamine (200 mM), 1 mL of 
chemically defined lipoconcentrate (Gibco STEMPRO-LipoMax, A10850), 20 mL 
sodium bicarbonate (17.22 g/100mL), 10 mL of HEPES (4.12g/100mL, Sigma 
H4034), 20 mL insulin (69.3g/60mL) form a bovine pancreas (Sigma I1882), 0.5g of 
human apo-transferrin (Sigma T2252), 1 mL of putrescine dihydrochloride 
(0.09g/10mL) (Sigma P6024), and 40 g of human serum albumin (Sigma A1653), 
consecutively.  
 
Table 2.1. Defined media components in the serum free media (Jung et al. 2010).  
COMPONENT SOLVENT CONCENTRATION 
   
DMEM/Ham‘s F12 medium (1:1)   
Progesterone Chloroform 0.018µM 
L-Glutamine Media 4 mM 
Chemically defined lipoconcentrate  100µl/100ml 
Sodium bicarbonate Media 20.5 mM 
HEPES Media 4.9 mM 
Bovine insulin H2O at pH 2 4.9 mM 
Human apo-transferrin Media 0.5g/L 
Putrescrine dihydrochloride Media 55.9 µM 
Human serum albumin Media 40g/L 
Ascorbic acid Media 284 µM 
Hydrocortisone DMSO 100 nM 
Fetuin Media 20.7 µM 
bFGF H20 2ng/mL 
TGF-β H20 1ng/mL 
   
 
Note, the human serum albumin was difficult to dissolve and required repeated 
mixing by pipetting. To this solution, 10 mL of ascorbic acid (500mg/100mL) 
(A4403), 18 µL (10mg/mL) hydrocortisone (Sigma H0888), 200 µL of bFGF 
(10ng/µL)  (R&D systems), and 3.3 mL of TGF-β (300ng/mL) (R&D systems) were 
added. Finally, the solution was mixed using a 50 mL pipette and sterilised by 




2.6 SMALL MOLECULE SCALE-UP STUDIES 
2.6.1 IFN-γ, TNF-α and small molecules treatment of ADMSCs in serum 
containing and serum free media 
ADMSCs were seeded onto 6-well plates coated with 0.1% Gelatin, at a density of 3 
× 10
4
 cells per well. To determine whether the ADMSCs would respond to IFN-γ and 
TNF-α treatment would be effective at the published concentrations (English et al. 
2007; Chan et al. 2008) and optimisation experiment was performed. In this 
experiment the treatments were tested in serum containing (hESMP media) and 
serum free media (Table 2.1). The concentrations chosen for this experiment were 
20ng/mL IFN-γ and 10ng/mL TNF-α. Treatment was initiated after 24 hours 
incubation at 37 °C. Defined media and undefined (Serum containing) media were 
prepared with the stated concentrations of each protein. The six conditions testes 
were, INF-γ defined, TNF-γ defined, untreated defined, INF-γ undefined, TNF-γ 
undefined, untreated undefined. ADMSCs where incubated with these conditions for 
4 days. Media was changed after 2 days and on the fourth day cells were trypsinised 
and stained for ICAM-1, HLA-DR, HLA-ABC, B7-1 and B7-2 (Appendix 4.3).   For 
each of the 5 drugs, 2 drug concentrations were selected based on the most effective 
concentrations from the third screen. In undefined media small molecules estriol 
(50µM, 100µM), telmisartan (50 µM, 100 µM), spermine (1µM, 3 µM), IFNγ 
(20ng/mL), TNF-α (10ng/mL) were prepared. In defined media, niacin (1 µM, 3 
µM), atenolol (50 µM, 100 µM), IFN-γ (20ng/mL) and TNF-α (10ng/mL) were 
prepared. Defined and undefined media were used as untreated controls. ADMSCs 
were seeded for 24h in defined and undefined media, after these cells were washed 
twice in PBS and drug and cytokine containing media was added. This media was 
changed after 2 days and on the 4
th
 day cells were prepared and stained with flow 
cytometry antibodies for ICAM-1–PE (BD Biosciences), HLA-DR–FITC 
(Biolegend), HLA-ABC–PE (BD Bioscience), B7-1–FITC (BD Bioscience), B7-2–
PE (BD Bioscience) and STRO-1–FITC (Biolegend). Analysis of the optimisation 
experiment and small molecule treatment experiments was done using flowJo (see 





2.7 STATISTICAL ANALYSIS 
2.7.1 Statistical analysis for small molecule screens 
For each drug concentration 4 wells used to determine the average and standard 
deviation for cell counts and for florescent measurements. Using the Instat software 
package (Graphpad), the data was compiled to give the average, sample number and 
standard deviation. Small molecules where compared to control wells using the 
Dunnett‘s test (one way ANOVA). This allows large data sets to be compared to a 
control. Unpaired t tests where performed between drug treatment groups at a given 
concentration (e.g. 100µM) with the controls at that same concentration for the 3
rd
 
screen of the small molecule assessment (chapter 5). 
 
2.7.2 Statistical analysis for polymer and hydrogel screens 
For the adipogenic quantification data a one way ANOVA was performed between 
the differentiated hydrogels and polymers and the gelatin controls (n= 3). 
For the thermo detachment experiment using different monomer proportions, cells 
from the replicates were detached using the thermo-detachment procedure (see 
enzyme free passaging). The remaining cells where detached by trypsinisation. 
Detached and trypsinised cells where centrifuged (1000 rpm for 5 min) and cell 
counts were made by re-suspending cells in 50µL of media. Comparison between 
trypsin detached cells and thermo-detached cells determined the % detachment. The 
average for each hydrogel was obtained with the standard deviation and where 
compared with the untreated gelatin control. A one way ANOVA was performed 
using Instat software and the p values determined. 
Unpaired t tests where performed between to compare the flow cytometry data 







A Polymer Microarray Approach for Identifying 
Defined Substrates for Mesenchymal Stem Cells 
Parts of this chapter were previously published in: 
Duffy, C.R.E., Zhang, R., How, S.E., Lilienkampf, A., Tourniaire, G., Hu, W., West, 
C.C., de Sousa, P. & Bradley, M,. (2014) A high-throughput polymer microarray 
approach for identifying defined substrates for mesenchymal stem cells. Biomaterials 
Science, 2, p1683–1692. doi: 10.1039/c4bm00112e. 
ADMSCs were supplied by Dr Chris West Ethical and approval for the collection of 
adipose tissue and subsequent research was granted by the South East Scotland 
Research Ethics Committee (Ref 10/S1103/45h). 
 
3.1 INTRODUCTION 
Given the clinical importance of MSCs, their culture is crucial for any downstream 
application. MSCs grown on tissue culture plastic have been shown to lose both 
osteogenic and adipogenic potential compared to those grown on gelatin (Mauney et 
al. 2004; Mauney et al. 2005). However, the use of animal derived substrates such as 
gelatin, collagen or fibronectin is problematic due to the presence of a multitude of 
undefined factors, batch variation and the potential for pathogen transfer. In order to 
realise the full clinical potential of MSCs there is a pressing need for defined 
synthetic substrates for long-term culture. Since MSC populations contain cells of 
varying degrees of multipotency (Pevsner-Fischer et al. 2011), the ideal substrates 
should not only maintain the cells, but enrich also the most multipotent cell type.  
Polymer microarrays allow the high-throughput interrogation of hundreds to 
thousands of defined surfaces for various biomedical applications. They have been 




undefined (Brafman et al. 2010) and defined media (Zhang et al. 2013; Hansen et al. 
2013). The ability to isolate and expand stem cells in vitro of clinically relevant 
numbers requires the identification of substrates that not only bind cells and facilitate 
growth but also maintain stem cell phenotype over multiple passages. The polymer 
microarray platform offers an approach whereby substrates that promote adhesion 
and growth can be rapidly identified, and enables the identification of substrates that 
can maintain or enhance the stem cell phenotype, i.e., cells can be evaluated for 
multiple markers and characteristics in a high-throughput manner.  
The use of a high-throughput system to some extent allows multiple components to 
be taken into consideration simultaneously. Surface chemistry in terms of functional 
group presentation can be represented to a much greater extent than the -CH3 
(methyl), -NH2 (amino), -OH (hydroxyl), -COOH (carboxyl), -SH (thiol), -F 
(fluoro), and –PO4 (phosphate) functional groups presented in other studies (See 
appendix 2.1A-C for a full list of monomers) (Curran et al. 2006; Benoit et al. 2008). 
In the Curran study, ‗bulk‘ presentation resulted in heterogeneous cell growth due to 
a lack of control with the polymerisation process, i.e. there was an inherent 
variability and a lack of control over how little or how much ‗functional‘ group was 
presented on the surface.  
This was considerably improved in a latter study in which the distance between 
functional groups was controlled using dip pen nanolithography (Curran et al. 2010). 
These chemical functionalities were deposited at the nanometer scale with thiolated 
molecules of gold that formed self-assembling monolayers (SAMs). This added the 
dimension of control between functional group presentation that allowed nano-scale 
modification of the distance between the deposited spots. This confirmed the 
previous works finding that the –CH3 functionality was able to maintain the MSC 
phenotype but in addition it was shown that a ‗minimal‘ spot diameter of 70nm was 
required for cell adhesion. A pitch between spots of 280nm was also necessary to 
maintain the cell phenotype. The 70nm diameter is similar to the periodicity of type 1 
collagen (Das et al. 2013) and close to the minimal area for focal adhesion formation 
of 60-67nm (Poole et al. 2005). This ‗pitch‘ between centres is also remarkably close 




maintain MSCs in there stem cell fate over multiple passages (McMurray et al. 
2011). It has been shown that nano-topographical features less than 10nm in diameter 
can be sensed by the cells though so called ‗nanopodia‘ (Dalby et al. 2004).  
The important role that nano-topography plays in maintaining and controlling stem 
cell fate is highlighted in these and many other studies (Dalby et al. 2014). The 
control provided by such nano-surfaces over topography and functional group 
presentation is restricted to surfaces with a uniform stiffness. ECM varies in both 
nano-topography and stiffness/elasticity. The effect of variation of stiffness on MSC 
fate has been dramatically demonstrated (Engler et al. 2006), this makes comparisons 
of different studies looking at the same surface chemistries on surfaces of different 
stiffness/elasticity difficult to interpret. The disadvantage with complete control of 
the nano-topography means that the structures have to be hypothesised and tested on 
surfaces with uniform stiffness.  
The advantage with the microarray format is that no presuppositions are required 
prior to the experiment about surface chemistry, nano-topography or surface 
stiffness. The polymer microarray format allows a large variety of surface 
chemistries to be concurrently scrutinized by cells. The ability to vary the proportion 
of different monomers allows variation of functional group presentation. The wide 
variety of monomer combinations will necessary result in surfaces with a wide range 
of topographies and stiffness‘s. The readout of the screening process can then be 
used to make connections between the cell behaviour and the surface which is 
causing the cell to exhibit a particular phenotype.  
The aim of this study was to apply the polymer microarray platform to MSCs to 
identify substrates that can maintain/promote MSC phenotype in long-term culture 
while retaining their multipotency. By combining the high-throughput screening 
methodology with scale-up studies examining the MSC phenotype with ever greater 
scrutiny this study aims to identify polymers with superior maintenance properties 
that can also reveal cell surface interaction relationships. An overview of the strategy 





Figure 3.1. An outline of the polymer microarray platform to identify and verify lead polymers 
for long-term MSC cultured in 10% FCS containing media. A) In an initial screen hES-MPs 
were incubated for 24 h on polymer microarrays and the polymers evaluated for cell binding. 
B) A focused screen with microarrays containing 171 polymers from the initial screen were 
evaluated. Each polymer feature was evaluated for cell number (DAPI), viability, and STRO-
1 and CD105 marker intensity. The top 30 polymers were coated on cover slips (∅ 10 mm) 
and after 7 days of culture, cells were stained with DAPI and CellTracker
TM
Green and for 
STRO-1, CD105 and CD271. C) 3 ‘lead’ polymers were validated in long-term cultures with 
hES-MPs (5 passages) and ADMSCs (10 passages) on polymer coated coverslips. 
Extensive MSC marker analysis (CD73, CD90, CD105, STRO-1, HLA-DR, CD146, CD271, 
CD140b, CD34 and CD14) was carried out using flow cytometry. ADMSCs were 
differentiated down the adipogenic and osteogenic lineages at passage 5. 
 
For the screening and scale-up experiments hES-MPs were used as a stable and 
robust surrogate for adult derived MSCs (Karlsson et al. 2009). The analysis of both 
hES-MPs and ADMSCs with multiple MSC markers during screening, scale-up and 
long-term passaging, combined with the high-throughput polymer microarray 
platform, provided an effective strategy for the identification of two synthetic 
substrates that could act as effective defined alternative to biological substrates, a 







3.1.1 Chapter aims 
The aim of this chapter is to widen the current surfaces that are used for the 
maintenance of MSCs. Using the high-throughput polymer microarray platform it is 
hoped that polyacrylates and polyurethanes can be identified that can bind and 
facilitate the growth of MSCs in long-term culture while maintaining the MSC 
phenotype multipotency. This would identify synthetic surfaces could act as 
synthetic alternatives to biologically derived surfaces to make MSCs more amenable 
to therapeutic applications. The polymer microarray platform also has the potential to 
reveal components of how MSCs interact with the surface and the important factors 
for maintaining their ‗stemness‘. 
 
3.2 RESULTS AND DISCUSSION 
3.2.1 Screening on polymer microarrays 
Two polymer libraries, a ‗PA-library‘ (consisting of 453 co-polymers synthesised 
from acrylate, acrylamide and vinyl monomers) and a ‗PU-library‘ (204 
polyurethanes), were investigated using polymer microarray technology. These 
polymers were constructed to include a diverse range of monomers (appendix 1.1A–
C) with a range of physico–chemical properties, such as variation in charge, 
lipophilicity, and wettability. The polymer libraries used in this study had been 
developed in two previous studies (Hitoshi et al. 2004; Tourniaire et al. 2006). The 
two libraries were printed onto agarose coated glass slides with each polymer printed 
in quadruplicate (Figure. 3.1A) (Pernagallo et al. 2008). In the initial screen, hES-
MPs were incubated for 24 h on the microarrays to enable the identification of 
polymers that facilitated cell binding, as assessed by counting DAPI stained nuclei 
on each polymer feature. Slides were imaged with a Nikon 50i microscope using the 
software Pathfinder (IMSTAR). Each feature was imaged via bright field and the 
DAPI channel (λEx/λEm 358/461 nm). From this initial screen, 171 polymer 
candidates were identified (Figure 3.2). Based on cell binding from the initial screen, 





Figure 3.2 A) Results of the initial 24 h binding screen (hES-MPs) on the 204 member PU-
library and the 453 member PA-library. 69 polymers form the PU-library and 102 polymers 
from the PA-library were selected for the ‘focused’ screen. B) An example of a DAPI stained 
nuclei and bright field images of a polymer binding cells (24 h binding screen). Scale bar 
100µM. 
The new arrays were incubated with hES-MPs for 2, 4 or 7 days, and analysed for 
cell binding on each polymer. In order to compensate for any variation in feature size 





Figure 3.3. A) Top 30 polymer candidates for hES-MP binding and growth (cells/mm
2
) after 
2, 4 and 7 days of culture on the ‘focused’ 171-member polymer microarray. B) Staining and 
imaging of the polymer PA338 with DAPI (nuclei stain) and the markers STRO-1 and CD105 





Figure 3.4. The top 30 polymers in terms of cell viability measured by fluorescence 
intensity/mm
2
 (λEx/ λEm 495/519 nm) from staining of cells on the ‘focused’ polymer 
microarray with CellTracker Green at day 7. Note that polymer PA306 is auto-fluorescent. 
 
Figure 3.5. The top 30 polymers in terms of STRO-1 staining (λEx/λEm 495/519 nm) from the 
‘focused’ polymer microarray measured as fluorescence intensity/mm
2
.  
 Figure 3.6. The top 30 polymers in terms of CD105 staining (λEx/λEm 555/565 nm) from the 







To select substrates that would potentially favour the multipotent stem cells over less 
potent progenitors, criteria for selecting candidates for larger scale studies took into 
consideration marker intensities as well as cell count and viability.  
Table 3.1. The top 30 performing polymers from the 171 member ‘focused’ polymer 
microarray were ranked for each criterion, i.e., cell count (cells/mm
2
), STRO-1 intensity, 





The best polymers in terms of number of cells/mm
2
, cell viability, STRO-1 intensity 
and CD105 intensity were ranked with the 30 highest-ranking polymers selected for 
more detailed studies (Table 3.1). 
 
3.2.2 Lead identification 
The top 30 polymer candidates were coated onto glass coverslips and incubated with 
hES-MPs for 7 days using gelatin and tissue culture plastic as controls, followed by 
staining with DAPI, CD105, STRO-1, and an additional marker CD271 (CD271 was 
included to provide additional criteria for lead polymer selection). 
 
 
Figure 3.7. A) The number of hES-MPs/mm
2
 for each of the polymer candidates after 7 days 
incubation on polymer coated coverslips (n = 3, error bars represent SEM). The blue bars 
represent polymers selected as ‘leads’ and the black bars represent the controls. B) Relative 
marker intensity for STRO-1, CD105 and CD271 for hES-MPs grown on the 3 ‘lead’ 
polymers PU157, PU108 and PA338, and gelatin (GEL) and tissue culture plastic (TCP) (n = 
3). Statistical significance compared with the GEL and TCP controls is denoted with black 
and red star respectively. C) Examples of images of cells grown on the ‘lead’ polymer PU157 
stained for DAPI, STRO-1, CD105 and CD271. Scale bar 100µM. 
 
After 7 days of culture, 5 polymers showed better or similar levels of cell growth 
compared to gelatin or tissue culture plastic (Fig. 3.7), however, statistical 
comparison shows that only the bottom three candidates had significantly lower 
growth when compared with the gelatin control. The two top polymers, PA338 and 




‗lead‘ substrates (Fig. 3.7 and Fig. 3.8). On larger surfaces, PU157 showed relatively 
modest cell growth but significantly enhanced STRO-1, CD105, and CD271 
intensities (Fig. 3.7B and C), and was therefore taken forward as the third ‗lead‘ 
polymer for long-term culture and characterisation with hES-MPs and ADMCSs. 
 
3.2.3 Long-term culture and characterisation of hES-MPs on lead 
polymers 
For extended culture on the lead polymers PU157, PU108 and PA338 (Fig. 3.8), a 
variety of MSC markers were used to fully probe the suitability of the substrates for 
long-term MSC culture. In addition to CD105, STRO-1 and CD271, seven additional 
markers were used. This included positive markers CD90 and CD73, and negative 
markers CD14 and CD34, chosen because they are used as part of the minimal 
criteria for defining MSCs (Dominici et al. 2006). 
 
 
Figure 3.8. Structures of the copolymers PU157, PU108 and PA338. PU157 was 
synthesised from poly(butyleneglycol) (mw 250) and 4,4'-methylenediphenyldiisocyanate 
with 3-(dimethylamino)-1,2-propanediol as an extender, PU108 from poly(butyleneglycol) 
(mw 1000) and hexamethylenediisocyanate with 3-(diethylamino)-1,2-propanediol as an 
extender. PA338 is a poly(methylmethacrylate-co-glycidylmethacrylate) (synthesised in 1:1 
monomer ratio) modified with N-methylaniline. The lead structures where drawn using 





CD34 positive populations are present in MSCs obtained from adipose tissue 
(Corselli et al. 2012) and MSC marker expression in general has been shown to 
depend on the source (Nery et al. 2013). CD146 and CD140b were selected as these 
are considered as in vivo MSC markers (Crisan et al. 2008), while HLA-DR is a 
standard negative marker for MSCs as well as an indicator of the immune 
modulatory state of MSCs (HLA-DR is up regulated when MSCs are primed into 
their immune modulatory state) (Singer et al. 2011). Prior to the long-term culture on 
the ‗lead‘ polymers, hES-MPs were characterised at ‗passage 0‘, i.e., the point of 
removal from gelatin, for the expression of CD105, STRO-1, CD271, CD90, CD73, 
CD34, CD14, CD146, CD140b, and HLA-DR (Fig. 10A). Here, cells were positive 
for CD73 and STRO-1 (100% and 99%, respectively), positive for CD105 and CD90 
(91% and 83%, respectively), and moderately positive for CD34, CD146 and CD14 
but had been significantly down-regulated by passage 5. hES-MPs grown on the 
‗lead‘ polymers were assessed with these 10 markers at passage 5 to monitor the 
marker conservation or changes in the marker expression levels. 
Flow cytometry analysis at passage 5 showed that hES-MPs cultured on PU108, 
PU157 and PA338 expressed similar levels of the markers to cells grown on gelatin 
(Fig. 3.9A, Appendix 2.1). However CD105, which is considered one of the essential 
markers for MSCs, expression was reduced on cells grown on all ‗lead‘ polymers, 
but levels were comparable with gelatin. Interestingly, hES-MPs are currently 
derived through serial passaging of hESCs on gelatin (Karlsson et al. 2009) Notably, 
CD105 was significantly reduced and almost completely lost at passage 5 on tissue 
culture plastic (Fig. 3.9A). 
The marker CD90, which is bimodal in hES-MPs (Karlsson et al. 2009; Li et al. 
2013), showed a substantial increase in the negative fraction with culture on PA108 
when compared to other substrates (Fig. 3.9A and Fig. 3.10). Comparison with the 
‗p0‘showed a significant fall in CD90 on this polymer (55%). However, hES-MPs 
cultured on PU157 and PA338 maintained CD90 at levels similar to tissue culture 
plastic and gelatin (73%, 74% 70% and 82% of positive cells, respectively), although 
PA338 did show a significant fall in expression (Fig. 3.9A). Decreasing levels of 




MSCs (Campioni et al. 2009). The ability of PU157 and PA338 to maintain marker 
expression (including CD105 and CD90) similar to gelatin indicates that they may 
act as chemically defined alternatives to gelatin for serial passaging of hESCs to 
produce hES-MPs.  
 
3.2.4 Long-term culture and characterisation of ADMSCs on the lead 
polymers 
ADMSCs grown on PU157, PU108 and PA338, closely resembled the gelatin 
control with most of the MSC markers at passage 5 (Fig. 3.9B, Appendix 2.2). At 
passage 5, ADMSCs grown on tissue culture plastic, gelatin, PU157, PU108 and 
PA338 were positive for CD105, although a significant loss in marker intensity was 
observed with all substrates when compared with ‗passage 0‘ (Fig. 3.9B and Fig. 
3.11). 
A further reduction in the CD105 marker intensity was observed by passage 10 with 
PU157 and PA338 (49% and 49% of positive cells, respectively), although with cells 
grown on gelatin and tissue culture plastic the levels were maintained (85% and 
81%, respectively) (Fig. 3.9B and 3.11, Appendix 2.3). 
At the start (‗passage 0‘), ADMSCs showed a 44% positive population for STRO-1. 
By passage 5 there was a significant positive shift in STRO-1 intensity with tissue 
culture plastic, which became even more pronounced by passage 10  with 70% of 
cells being positive (Fig. 3.5 and 3.11). High expression of STRO-1 has been 
associated with an increase in adipogenic and osteogenic markers PPAR-G and 
RUNX2, respectively, and up-regulation of either of these markers could reduce the 





Figure 3.9. Flow cytometry analysis of 10 MSC markers for hES-MPs (A) and ADMSCs (B) 
prior to the culture on PU157, PU108 and PA338, termed ‘passage 0’ (p0), and at passage 5 
(p5) and 10 (p10) (ADMSCs only) on PU157, PU108, PA338, gelatin (GEL), and tissue 





Figure 3.10. Representative flow cytometry traces of the markers CD105 and CD90 with 
hES-MPs at ‘p0’ and p5 on gelatin (GEL), tissue culture plastic (TCP), PU157, PU108 and 
PA338 (red trace for stained cells, black for unstained cells).  
PPAR-G is a nuclear receptor and master regulator (along with C/EBPα) of terminal 
adipogenisis involving the coordinating the expression of many hundreds of genes 
(Farmer 2005). RUNX2 is an early transcription factor in osteoblast differentiation, it 
binds to the promoter region OSE2 found in the promoter region of all major 
osteoblast marker genes (Bruderer et al. 2013). 
Figure 3.11. Representative flow cytometry traces of the markers CD105, HLA-DR and 
STRO-1 with ADMSCs at ‘p0’ , p5 and p10 on gelatin (GEL), tissue culture plastic (TCP), 




3.2.5 Differentiation of ADMSCs 
At passage 5, ADMSCs grown on PU157, PU108, PA338, gelatin, and tissue culture 
plastic were differentiated down the adipogenic and osteogenic lineages to evaluate if 
they retained their differentiation potential.  
 
Figure 3.12 A) Histological staining of ADMSCs differentiated down the osteogenic lineage 
with red staining indicating calcium deposits (Alizarin Red) and ADMSCs differentiated down 
the adipogenic lineage with red spots indicating fat droplets (Oil red O) Scale bar 100µM. B) 
The percentage of ADMSCs that differentiated down the adipogenic lineage after 5 
passages on gelatin (GEL), tissue culture plastic (TCP), PU157, PU108 and PA338  (n = 3 
with error bars representing SD, for each replicate 12 images were taken and analysed). 
ADMSCs were also stained for DAPI, the number of differentiated cells/total cell number 




Histological staining of the cells with Alizarin Red and Oil red O showed that the 
ADMSCs had differentiated down the osteogenic and adipogenic lineages, 
respectively, proving that the cells had clearly maintained their multi-lineage 
potential (Fig. 3.12A). The ADMSCs grown on PU157 (53%), PU108 (57%), 
PA338 (47%), gelatin (54%), and tissue culture plastic (61%) showed no significant 
difference in the percentage of cells capable of differentiating down the adipogenic 
lineage (Fig. 3.12B).  
Image analysis of the Alizarin Red S stained cells showed that PA338 (71%), PU157 
(38%), PU108 (30%), gelatin (58%) and tissue culture plastic (83%) had different 
levels of staining, however, the high variability meant there was no significant 
difference in the level of Alizarin Red S staining (Fig. 3.13).  
Figure 3.13. Comparison of the amount of Alizarin red S positive pixels from osteogenic 
differentiation images of ADMSCs after 5 passages on gelatin (GEL), tissue culture plastic 
(TCP), PU157, PU108 and PA338. Osteogenic comparison was carried-out using ImageJ by 
setting the image/adjust/colour threshold option. The ‘analyse particles’ option quantified the 
percentage of pixels above threshold. The values correspond to the percentage of positive 
pixels on an image that are above a defined minimum threshold (n = 3, error bars given as 





A similar ability of ADMSCs to differentiate at passage 5, regardless of which 
substrate they were grown on, suggests that the differences seen in marker expression 
at this passage has no significant effect on their differentiation capacity. 
 
3.2.6 Polymer analysis 
To investigate if the chemical composition of the polymer surface can be correlated 
to cell binding/growth and stem cell maintenance, the monomers present in the top 
candidates from the scale up studies were analysed. The top ten performing polymers 
from the PA-library showed some monomers to be highly preferred over others, with 
only 10 monomers making up the 10 copolymers (Fig. 3.14).  
Figure 3.14. The monomers found in the top 10 polymers in the PA library in the scale up 
experiment. The GMA
*
 containing polymers were subsequently functionalised with a variety 
of amines (signified by *). The figure legend shows the likely properties of the monomers at 
physiological pH (MAn is an aniline derivative and mostly uncharged). 
Methyl methacrylate (MMA) was present in 8 out of 10 polymers. This would 
correspond to the work of Curran (2006 & 2010) and Benoit (2008) that showed the 
methyl (–CH3) functional group to be critical in maintaining the mesenchymal stem 
cell state. A second monomer GMA (modified) was present in 7 of the top 10 
polymers, the modified monomers; MnHA, DnBA, MAn and DEMEDA all 




addition, the presence of an aryl ring seemed beneficial for the top PA candidate 
(PA338 is a copolymer of MMA and N-methylaniline functionalised glycidyl 
methacrylate (GMA) designated MAn) (Fig. 3.14, Appendix 1A-B for chemical 
structures). The presence of 3 groups (-CH3, -OH, -N) instead of one adds to the 
previous studies. 
Analysis of the top 10 polyurethanes from the scale up experiments showed 4,4‘-
methylenebis(phenylisocyanate) (MDI) and poly(butyleneglycol) (PTMG) were 
present in 8 and 5 polymers, respectively, both of which were present in the lead 
PU157 along with 3-dimethylamino-1,2-propanediol (DMAPD) (Fig. 3.15 and 3.16, 
for chemical structures of the monomers see appendix 1.1C). The MDI monomer 
contains two aryl groups and the DMAPD monomer contains a tertiary amine (-N). 
Interestingly, the lead PU candidate PU157 does not contain a methyl group (-CH3) 
(or hydroxyl group (-OH)). Taken together with the PA monomers and the lead 
candidate PA338 this could indicate that the critical components may be the aryl 
group and tertiary amine.  
 




Certain monomers, e.g. poly(ethylene glycol) (PEG), seemed disadvantageous in 
terms of binding and promotion of growth. PEG was a well-represented monomer in 
the polymer library (Fig. 3.15) but did not appear in the top polymers (Fig. 3.16) or 
in the top 30 performing polymers (Table 3.1). Whether this is due to its hydrophilic 
nature, stiffness or surface topography requires additional analysis but this is 
surprising due to its use in many cell studies.  
Adhesion of cell on the surface is a complex process depending on a combination of 
cell–protein and polymer–protein interactions, and the physico–chemical properties 
of the surface as well as the topography and nano-topography of the surface. In stem 
cell culture, the ability of the substrate to maintain the cells in their stem cell state 
adds another level of complexity to the material–cell interactions. Therefore, 
although some common features could be found on the chemical composition of non-
binding versus lead polymers, drawing direct ‗structure–function relationships‘ for 
polymer surfaces and stem cell maintenance remains a challenge, further highlighting 
the advantages of a high-throughput approach for the discovery of new substrates. 
 





3.2.7 Surface characterisation 
Water contact angle (the angle a drop of water makes on the polymer surface) has 
previously been reported to be one of the most important determinants for cellular 
binding and growth for hESCs (Mei et al. 2010). Of the lead polymers, PA338 and 
PU157 had a water contact angle of 81° and 70°, respectively (representative control 
polymers, which showed no or poor cell binding or growth, had contact angles of 
27–67°) (Table 3.2). However, PU108 had a relatively small water contact angle of 
46°, suggesting that water contact angle or the surface energy is a poor indicator of 
stem cell adhesion/growth with MSCs and the polymer libraries investigated. 
Table 3.2. Molecular weight, polydispersity index (PDI), water and formamide contact 
angles, and surface energy calculations of the 3 lead polymers PU157, PU108 and PA338, 
and representative non-binding polymers PA554 and PU6, and ‘mid-range polymers’ PA63 
and PU212.*
 









      
PU6 59000 2.0 26.5 ± 1.6 27.1 ± 2.0 66.0 ± 0.9 
PA554 110000 2.2 65.7 ± 0.5 32.3 ± 0.6 51.2 ± 0.7 
PU212 66000 2.2 61.8 ± 1.2 32.3 ± 0.0 49.8 ± 0.2 
PA63 52100 4.2  66.7 ± 1.9 46.3 ± 5.1 41.5 ± 3.1 
PU108 233000 2.5 46.1 ± 3.6 27.6 ± 2.2 54.0 ± 1.9 
PU157 41000 1.9 69.8 ± 1.2 51.8 ± 1.5 38.0 ± 0.9 
PA338 > 2,000,000 N.D 81.1 ± 0.7 62.1 ± 0.6 31.8 ± 0.6 
      
* PA63 is a copolymer of HBMA and PAA, and PA554 of AH and HEMA. PU212 was 
synthesised from PHNAD and HDI with PG as a chain extender, PU6 from PEG and BICH. 
For the monomer structures see appendix 2.1A-C. The contact angle and surface energy 
measurements were performed by W Hu and R Zhang. 
 
To investigate global protein binding on the polymer surfaces, polymer coated cover 
slips were treated with culture media (supplemented with 10% FCS) for 24 h, and 
adhered proteins analysed by gel electrophoresis (Fig. 3.17).  With the exception of 
PU108, which showed slightly different protein binding pattern, PU157, PA338, 
PA554, PU6, PA63 and PU212, including poor cell binding controls, showed protein 
binding similar to gelatin and tissue culture plastic, thus suggesting that the surface 
chemistry plays an important role in the cell adhesion and growth, although subtle 







Figure 3.17. Protein analysis on 4-12% gradient polyacrylamide gels (silver or fluorescent staining) after protein extraction from polymer-coated 
coverslips, gelatin and tissue culture plastic (TCP), incubated for 24 h with culture media (DMEM containing 10% FCS, 4 ng/mL bFGF, 200u/mL of L-






Using hES-MPs in a ‗three-step‘ screening strategy, which consisted of two iterative 
rounds of polymer microarray screens followed by a large scale 30 polymer study, a 
number of polymers were identified that could potentially support long-term MSC 
culture. Based on cell growth and the intensity of markers CD105, STRO-1 and 
CD271, two polyurethanes (PU157 and PU108) and one polyacrylate (PA338), were 
identified as ‗lead‘ substrates.  
hES-MPs and ADMSCs were cultured on PU157, PU108 and PA338 for 5 and 10 
passages, respectively, and analysed for 10 MSC markers. All substrates showed 
similar growth rates for both cell types. After 5 passages on the polymer substrates, 
both cell types expressed similar marker levels as control cells grown on gelatin, 
whereas on tissue culture plastic the marker CD105 was lost (hES-MPs). hES-MPs 
cultured on PU108 showed an increase in the negative fraction for CD90 and 
ADMSCs cultured on PU108 continued to express HLA-DR at passage 10. 
Irrespective of some variation in the marker expression between ADMSCs grown on 
different substrates, the cells were successfully differentiated into osteoblasts and 
adipocytes at passage 5. Overall, PU157 and PA338 showed the most similarity to 
gelatin and efficiently maintained growth and conserved phenotype over multiple 
passages for both hES-MPs and ADMSCs. Both these polymers contained an aryl 
group and a tertiary amine but only one PA338 contained a methyl group identified 
in previous studies as being able to maintain the MSC state. The application of the 
polymer microarray platform in conjunction with marker analysis proved an effective 
strategy for identifying two defined substrates PU157 and PA338, as a potential 
alternative to gelatin which offers chemically defined synthetic polymer substrates 
for efficient long term MSC culture. This strategy can be applied to other cell types 










Long-Term Mesenchymal Stem Cell Culture on a 
Defined Synthetic Hydrogel with Enzyme Free 
Passaging 
Parts of this chapter have been previously were published in: 
Duffy, C.R.E., Zhang, R., How, S.E., Lilienkampf, A., de Sousa, P.A. & Bradley, 
M., (2014) Long term mesenchymal stem cell culture on a defined synthetic substrate 
with enzyme free passaging. Biomaterials, 35(23), p5998–6005. 
ADMSCs were supplied by Dr Chris West Ethical and approval for the collection of 
adipose tissue and subsequent research was granted by the South East Scotland 
Research Ethics Committee (Ref 10/S1103/45h). 
 
4.1 INTRODUCTION  
 
In chapter 3, polymer microarrays where applied to the identification of defined 
polymers that could retain the MSC phenotype and multilineage capacity in long-
term culture. The benefit of the polymer microarray approach was clearly 
demonstrated with two polymers identified PA338 and PU157 that could maintain 
the phenotype of the MSCs in long-term culture. The application of hydrogels to 
stem cell culture has become and an increasingly active area in stem cell applications 
because of their similarity to native tissues and because of the wide range of 
applications due to their ability to encapsulate proteins/small molecules (Censi et al. 
2012), alter stiffness/elasticity (Engler et al. 2006), change properties with various 
environmental cues such as pH (Yin et al. 2006), light (Hu et al. 1995), temperature 




Moreover, hydrogels have been used to investigate mechanical dosing using 
hydrogels with photo-cleavable cross linkers. These experiments showed that the 
hardness of the growth substrate directly influenced the expression of differentiation 
markers (PPARγ and RUNX2) in MSCs and that the length of time MSCs where 
exposed to such mechanical factors influenced their ability to differentiate down the 
adipo or osteogenic lineages (Yang et al. 2014). Studies where the mechanical 
properties remain constant and the functional group presented to the MSCs varies has 
revealed that small molecule functional groups alone can induce cells towards 
differentiation depending on the functional group, with charged phosphate groups 
inducing osteogenisis and hydrophobic t-butyl groups inducing adipogenesis (Benoit 
et al. 2008).  
The opportunity to apply the polymer microarray platform to MSCs would allow the 
identification of hydrogels that could maintain the MSC phenotype in long term 
culture. This platform would allow the presentation of functional groups at different 
concentrations on surfaces with different mechanical properties. In the previous 
chapter the application of a polymer microarray identified a number of candidates 
that could have been taken forward in long term culture, three of which were 
selected.  However, MSCs grown on these substrates still required trypsinisation at 
passage, a process that will ‗shave off‘ a multitude of vital cellular surface proteins 
(Khalil et al. 2014) and is also animal derived. This is clearly an undesirable process 
if the stem cell ‗state‘ is to be maintained, and which must also lead to variation and 
uncertainty in apparent surface marker expression.  
As discussed in section 1.4.4, maintaining the stem cell state is a fine tuned 
interaction with the extracellular matrix. Treatment with trypsin destroys the 
extracellular matrix components that the cells are attached to and have secreted. The 
destruction of the niche at each passage will require a reassessment of the new 
substrate through integrin interactions with the extracellular matrix (Li et al. 2013). 
So-called ‗smart‘ hydrogels add an additional dimension as they can respond to 
environmental cues. A relatively large hydrogel microarray containing over 2000 
hydrogels had been previously developed by Zhang et al. incorporating monomers 




hydrogels identified in this work could be applied to MSCs to identify substrates that 
can maintain the MSC phenotype and remove the need for enzymatic treatment at 
passage. This aim of this chapter was to focus on removal of the additional 
component of enzymatic/chemical passaging to eliminating yet another component 
of MSC culture while maintaining the growth and phenotype of the MSCs.  
 
4.2 RESULTS AND DISCUSSION 
 
 
Figure 4.1.Overview of the polymer microarray system for the identification of thermo-
modulatable hydrogels. A) An inkjet synthesised 609-member hydrogel library (each 
hydrogel in quadruplicate) was fabricated. hES-MPs were incubated on the arrays for 24 
hours to assess binding. The top binding hydrogel ‘hits’ were identified. B) A second ‘hit 
array’ was inkjet synthesised and incubated with HES-MPs cells for 2, 4 and 7 days and 
assessed for growth and the two MSC markers CD105 and STRO-1. C) The top 30 hits 
identified in step 2 were scaled-up and coated onto coverslips and incubated for 7 days with 
hES-MPs and assessed for growth with the markers CD105, STRO-1 and CD271. The top 
10 leads were further assessed for their thermo-modulatable abilities. The top candidates 
were examined for long-term cell growth and maintenance of phenotype using marker 




A 609-member hydrogel microarray was applied to MSC cell culture. Iterative 
screens and scale-up experiments identified a family of thermo-modulatable 
hydrogels for long-term culture of MSCs (Fig. 4.1). hES-MPs were incubated with a 
609 member inkjet synthesised hydrogel array with each hydrogel in situ synthesised 
in quadruplicate (20nL per hydrogel spot). Hydrogels that showed good cell binding 
and good morphology were selected for a new ‗hit array‘. The best candidates from 
the ‗hit‘ array were tested for their ability to trigger cellular release upon temperature 
reduction. The best candidates in terms of growth and thermo-modulation and 
phenotype where taken forward as lead candidates for long-term passage and 
characterisation. 
 
4.2.1 Screening – Hit hydrogel identification 
609 hydrogels were initially assessed for cell binding by looking at the number of 
cells attached to each feature (determined using nuclear stain DAPI) and morphology 
of cells that bound after 24 hours incubation (Fig. 4.2). This was achieved by 
imaging each of the features on the array with a Nikon Eclipse 50i microscope using 
the IMSTAR software and the obtained images were analysed with the software 
PathFinder. This hydrogel library was printed onto 2 microscope slides and the 
screen was repeated 3 times with hES-MPs. This high-throughput system allowed 
each individual feature to be imaged and subsequently analysed in up to 4 separate 
channels allowing multiple MSC markers to be quantified in terms of fluorescence 
intensity. On polymer features identified as ‗hits‘, the cells were ideally spread with a 
fibroblast-like morphology as opposed to being ‗clumped‘ or having proportions of 
cells with very bright (DAPI) small nuclei indicating apoptosis.  
This initial screen identified 88 hydrogels as ‗hits‘ (Fig. 4.2), which were synthesised 
by inkjet printing onto glass slides to fabricate a ‗hit array‘ for further evaluation. In 
the ‗hit array‘ the number of replicate features was increased from 4 to 9. Figure 4.2 
shows the printing pattern of the ‗hit‘ array with the ratio of each monomer. The 
structure of the monomers and the cross linker used to construct the hydrogel library 






Figure 4.2. The results of the primary screen assessing cell binding. The table (left) is an example of one of the three screens performed (form monomer 
abbreviations see table 3.1). Red boxes indicate selected hydrogels used to construct the ‘hit array’ (right) containing replicates of the 88 ‘hit hydrogels’. For 
the selection of candidates, a number of criteria were considered, i.e. cell count (C), morphology (M) and also chemical composition of the hydrogel (D). 
Candidates with good cell morphology and good binding were selected for further evaluation (C, M). Candidates with high cell numbers but poor morphology 




Table 4.1.Monomers used in the inkjet microarray fabrication. 15% of methylene 
bisacrylamide (MBA) was used as a cross-linker. 
 
 
For a hydrogel to act as an effective substrate it must not only bind cells but also 
promote cell growth while maintaining the cellular phenotype. The ‗hit arrays‘ (n = 
3) were incubated with hES-MPs, and subsequently fixed and assessed at day 2, 4 
and 7 for cell number (Fig. 4.3A), and immunostained for two well established 
markers of MSC phenotype, STRO-1 and CD105 (Fig. 4.3B). As the hydrogel 
features vary in size, a simple cell count per spot would be inaccurate. In order to 
compensate for variations in the feature size, the area of each feature was measured 
and used to quantify the cells/mm
2
. Fig. 4.3A shows the top 10 hydrogels from the 
second screen. For all hydrogels, the cell count on day 7 was higher than day 2, 
clearly showing the top candidates promoted growth as well as binding. The immune 
staining of hES-MPs on the hydrogel feature (Fig. 4.3B) shows that some hydrogels 
maintained the expression of CD105 and STRO-1. Comparison of the distribution of 
monomers used to construct the polymer library (Fig. 4.4 top) and the monomer 
representation of the top 30 candidates (Fig. 4.4 bottom) shows some monomers 





Figure 4.3 A) Analysis of the top 10 candidates from the ‘hit array’ after for 2, 4 and 7 day 
incubation. The vertical axis indicates the monomer combinations and ratio used to formulate 
the hydrogel with (15% MBA as the cross-linker). The data are ordered according to the day 
7 results. Analysis shows a general trend of cell growth between days 2 and day 7 indicating 
that the substrates support binding and growth of hES-MPs. Error bars represent the 
standard deviation from four separate slides. Scale bar 100µM B) An example of the output 
from the IMSTAR imaging system showing clear STRO-1 and CD105 staining. The DAPI 
stained nuclei can be seen in the merged image. 
 
Examination of the structure of AEtMA-Cl (Table 4.1) indicates that a quaternary 
amine group might be favoured for cell binding and growth on these hydrogels. This 
amine containing monomer is positively charged, similar to coatings used to promote 
cell binding. Cell binding on plasma treated polystyrene (tissue culture plastic) is 
thought to be the result of increasing the density of carboxyl groups on the surface 
(Ramsey et al. 1984).  However, the large amounts of serum in the media means that 
direct structure–attachment relationships can be difficult to interpret as the surfaces 






Figure 4.4.Top, Representation of the different monomers A and B used in combination to 
construct the hydrogel library. Lower, monomers A and B occurring in top 30 hydrogels 
based on cell count after 7 day incubation with hES-MPs.  The pie chart shows that some 
monomers are clearly favoured (e.g. DMAEMA and AEtMA-Cl). 
 
4.2.2 Screening – Lead optimisation  
The top 30 hydrogels identified in the focused screen were re-assessed with hES-
MPs after 7 days for growth (cell number) and then for their ability to trigger cellular 
release following temperature reduction (Fig. 4.1C, Table 4.2).  
Cells were grown on hydrogel coated coverslips (10 mm diameter), fixed and 
immune-stained after 7 days for the expression of CD105, STRO-1 and CD271. The 
lead hydrogels all facilitated binding and promoted growth with the markers STRO-1 





Table 4.2. The top 30 candidates identified from the screens. The top 10 hydrogels in terms 
of growth and thermo-detachment after re-assessment are shown in red with their 
corresponding monomers and monomer ratios. The cross linker ratio is 15%. 
 
 
The hydrogel candidates triggered cellular release after being subjected to room 
temperature (21 °C) for 1 hour (red diamonds) with the exception of hydrogel 
HGL4. Based on the cell count, high levels of thermo-detachment at 21 °C, and 
MSC marker intensities (Fig. 4.5A), hydrogel HGL1 was taken forward for long-
term culture and characterisation. Interestingly, analysis of the marker intensities of 
STRO-1, CD105 and CD271 for the top 30 candidates showed that one of the 
hydrogels HGL6 had significantly higher intensities of STRO-1, CD105 and CD271 




potentially promote the MSC stem cell phenotype over other less potent cells in the 
mixed MSC population (MSCs are composed of a heterogeneous population of cells 
with varying degrees of potency (Pevsner-Fischer et al. 2011)). A substrate that 
could promote the ‗true‘ MSC phenotype over other cell types would result in more 
clinically relevant homogeneous MSC population. HGL6 also showed good thermo-
detachment and reasonable cell growth (Fig. 4.5A). HGL6 was therefore also chosen 
for long-term passage and characterisation. The structures of HGL1 poly(AEtMA-
Cl-co-DEAA) and HGL6 poly(DMAEMA-co-DMOBAA) are shown in Fig. 4.5C. 
 
 
Figure 4.5. Thermo-detachment of the top hydrogel candidates identified from the ‘hit array’ 
and marker intensity and structures of the lead candidates. A) Comparison of the thermo-
detachment of the top 10 candidates compared to the gelatin control. The blue columns 
represent the total cell counts after 7 days at 21 °C incubation on hydrogel coated coverslips. 
Red diamonds represent the % thermo-detachment after 1h (n = 3, error bars given as SD). 
B) Normalised fluorescence intensity of the top candidates compared to controls for the MSC 





Note the amine groups present in HGL1 and HGL6 as they were present in the lead 
candidates PA388 and PU157 discussed in chapter 3.  
Prior to initiation of long-term culture and characterisation, the conditions for 
thermo-detachment passaging were optimised. Fig. 4.6A shows the results of four 
different test conditions. Applying the passaging protocol immediately after removal 
from the incubator showed no significant difference to controls. A 30 minute 
exposure to 12 °C resulted in a significant difference (p<*) from the gelatin control. 
A 30 minute at exposure at 21 °C resulted in an additional improvement (p<**). 60 
minutes at 21 °C proved optimal, with a significant difference between HGL1 and 
the gelatin control (p<***).  Fig. 4.6B shows cells on HGL1 before and after 
thermo-detachment under the optimal conditions. Treatment of cells at 21 °C for 60 
minutes was chosen as the passaging method for long-term characterisation of HGL1 
and HGL6. 
To further assess the thermo-detachment properties, the proportions of each 
monomer in HGL1 were varied, and the effects on thermo-detachment evaluated. 
Having lower amounts of the monomer DEAA present in the hydrogel polymer 
resulted in a significant reduction in the percentage of cell that thermo-detached 
during the 21°C, 1h treatment regime (Fig. 4.6B). The lower critical solution 
temperature (LCST) of DEAA homopolymer is 32 °C. Temperatures below the 
LCST results in a rapid transition from the solid gel phase into a liquid solution 
phase.  
 
4.2.3 Long-term culture and characterisation of hES-MPs and ADMSCs 
on HGL1 and HGL6 
hES-MPs were grown in DMEM containing 10%FCS for 5 passages on HGL1 and 
HGL6, utilising the thermo-detachment regime, and characterised at p5 by flow 
cytometry, and compared to cells grown on gelatin and tissue culture plastic. After 5 
passages of growth using the thermo-detachment method, the cells were stained for 
STRO-1, CD73, CD105, CD90 and CD34, CD14 and HLA-DR. These markers were 




phenotype varies considerably according to the source of the tissue from which they 
are derived (Nery et al. 2013). 
 
 
Figure 4.6.Optimisation of thermo-detachment conditions and the effect of alteration of the 
monomer ratios on the thermo-detachment. A) Percentage of thermo-detached cells at 
different temperatures and times. n=3, Error bars denote SD. Scale bar 100µM B) Effect of 
alteration of the monomers composing HGL1, (HGL1 has a 1:1 ratio). Significance denotes 
comparison with the gelatin control C) HGL1 with cells before and after thermo-detachment. 
(n=3). 
 
Comparison with the gelatin control (p0) showed a small reduction in STRO-1 
positive cells after 5 passages. Interestingly, one of the key markers used to define 
MSCs, CD105, showed a dramatic reduction both on gelatin and HGL6, and was 
completely lost when the cells were grown on tissue culture plastic (Fig. 3.7A and 
B). Remarkably, HGL1 maintained this marker at original levels. Thus, passaging 
cells on HGL1 using thermo-detachment confers advantages over other synthetic 




marker. This may also implicate trypsin passaging in the loss of this marker. The 
absence of enzymatic or chemical passaging methods could therefore potentially play 
a role in maintaining the multipotency of these cells. CD105 (also known as 
endoglin) forms part of the TGFβ receptor complex and is a Type I homo-dimeric 
transmembrane glycoprotein. CD105 has been shown to be absent in freshly isolated 
MSCs but is quickly up-regulated, which is associated with increased proliferation 
after isolation (Braun et al. 2013).  
 
Figure 4.7.Flow cytometry analysis of 6 MSC markers after 5 passages using the thermo-
detachment protocol with hES-MPs. A) Table showing the percentage of positive cells for 
each of the markers before passaging (p0) on the four substrates; gelatin (GEL), HGL1, 
HGL6 and tissue culture plastic (TCP) and after 5 passages. Values constitute mean +/- 
standard deviation of n=3 treatment groups.  B) Histograms of two markers, CD105 and 
CD90 prior to passaging (p0) and after passaging (p5) on the four substrates. M1 represents 
the negative staining gate and M2 represents the positive staining gate. The black histogram 
signifies unstained cells and the red histogram signifies stained cells.  
 
Another critical marker CD90 (also known as Thy-1), had a bimodal distribution in 
hES-MPs (Fig. 4.8) (Karlsson et al. 2009; Li et al. 2013), remained unchanged on 




4.7A and B). This cell surface protein, with an immunoglobulin domain, is a minimal 
marker for MSCs (Dominici et al. 2006), however, it is weakly expressed in hES-
MPs when compared to ADMSCs (Fig. 4.8).  
It has also been reported that decreased intensity of CD90 is associated with the loss 
of the immune-modulatory properties of MSCs (Campioni et al. 2009). The 
comparatively low expression of this marker in hES-MPs in general, compared to 
adult derived MSCs, may explain the fact why hES-MPs do not possess the property 




Figure 4.8. Flow cytometry traces for marker CD90 with hES-MPs and ADMSCs grown on 
gelatin control (GEL) for 5 passages.  
 
To test the ability of these substrates to maintain adult MSCs and demonstrate their 
clinical potential, ADMSCs were cultured on the HGL1 and HGL6 for 10 passages, 
with differentiation potential assessed at passage 5 (Fig. 4.10) and MSC markers 
assessed by flow cytometry at p5 and p10 (Fig. 4.9). With ADMSCs the overall 
marker expression for cells grown on gelatin and HGL1 were comparable, although 
HGL6 showed a complete loss of STRO-1 at p5 (Fig. 4.9A) with other markers 
being maintained. However, cells grown on HGL6 could not be effectively expanded 
beyond this point, although this cannot be linked directly with the loss of STRO-1 
this marker has been associated with proliferation (Walsh et al. 2000). These cells 
were generally positive for CD34 and negative for CD146, however, recent studies 























































 (known as adventitial cells) have 
the characteristic MSC phenotype (Corselli et al. 2013). These ADMSCs display the 
MSC phenotype and differentiation analysis showed them to be multipotent (Fig. 
4.10).  
 
Figure 4.9.Flow cytometry data for MSC markers on ADMSCs grown on gelatin (GEL), 
HGL1, HGL6 and tissue culture plastic (TCP) for 5 and 10 passages. A) Table showing the 
percentage positive cells for the MSC markers before multiple passing (p0) and after cells 
were grown on GEL, HGL1, HGL6 and TCP for p5 and p10. Values constitute mean +/- 
standard deviation of n=3 treatment groups. B) Flow traces for the HLA-DR marker at p0, p5 
and p10 for GEL, HGL1 and TCP. M1 (black) shows the trace for unstained ADMSCs and 
M2 (red) shows the trace for cells stained for this marker  
 
The immune-privileged state of MSCs is associated with the low expression of 
Human Leucocyte Antigen-DR (HLA-DR) (Chan et al. 2008). Interestingly, HLA-
DR was down regulated on cells grown on gelatin and HGL1 at p5 but not HGL6 or 
tissue culture plastic (Fig. 4.9B). If applied in therapy, cells expressing HLA-DR 
would be recognised by the immune system as foreign, when donors are HLA 




matched patients (Imanishi et al. 2008). Therefore, the dramatic down regulation of 
this marker on cells grown on both gelatin and HGL1, reinforces the ability of 
HGL1 to act as a synthetic alternative to gelatin. By contrast the inability of tissue 
culture plastic to down regulate this marker reinforces it as an inappropriate substrate 
for maintenance of this cell type. The absence of STRO-1, the continued expression 
of HLA-DR at p5, and the substantial loss of the MSC defining marker CD90, also 
suggests that HGL6 is not an ideal substrate for long-term MSC culture (Fig. 4.9B). 
The flow cytometry analysis shows a loss of CD105 with the hES-MPs grown on 
tissue culture plastic (Fig. 4.7) and also shows very consistent correlation between 
the positive control, gelatin, and HGL1 for both hES-MPs and ADMSCs (Fig. 4.7 
and Fig. 4.9). In terms of marker expression, HGL1 is superior to gelatin.  
 
 
Figure 4.10.Osteocyte and adipocyte differentiation of ADMSCs maintained for 5 passages 
on HGL1 and HGL6 using thermo-detachment passaging compared with the gelatin control 
passaged using enzymatic (trypsin) passaging. Scale bar 100µM A) Percentage of cells that 
differentiated into adipocytes on the 3 substrates (n = 3, 12 images/replicate). B) Alizarin red 
and Oil red O staining of cells differentiated for 28 days in osteogenic and adipogenic 





Differentiation analysis of ADMSC after 5 passages on HGL1, HGL6 and gelatin 
down the adipo and osteo lineages is shown in Fig. 4.10. Fig. 4.10B shows clear oil 
red O staining of the fat droplets and alizarin red staining of the calcium deposits, 
demonstrating that they have retained lineage potency characteristic of these cells. 
Fig. 4.10A shows the proportion of cells that differentiated and clearly indicates that 
cells passaged on both hydrogels showed a significantly higher proportion of cells 
capable of differentiating down this lineage than when passaged on the control 
substrate gelatin. It is not possible from this data to determine whether the difference 
in differentiation potential is as a result of the non-enzymatic passaging methodology 
or is a consequence of the hydrogel substrate.  
 
4.3 CONCLUSIONS 
Using a microarray platform, defined synthetic hydrogels have been rapidly 
identified that allow for enzyme free passaging of ADMSCs while maintaining their 
potency and phenotype. One hydrogel substrate, poly(AEtMA-Cl-co-DEAA) cross-
linked with 15% MBA, allowed long-term culture of hES-MPs and ADMSCs. This 
new substrate provides a significant improvement over current methods of long-term 
passaging for MSCs, improving their potential for future clinical applications. The 
ability of hydrogel HGL1 to maintain and allow gentle passaging without destruction 
of extracellular matrix in the absence of chemical or enzymatic treatment makes it an 
attractive alternative to animal derived gelatin. In addition, the HGL1 substrate and 
the thermo-detachment regime maintains critical MSC markers, in some cases better 
than gelatin, suggesting a potential role for the isolation of these cells in the complete 












Knowledge-based small molecule screen to identify 
growth factor replacements in MSC culture 
5.1 INTRODUCTION 
The identification of the critical components within growth media that allows the 
long-term culture of stem cells has been pivotal in attempts to progress such cells 
clinical application. However, the critical growth factors necessary in defined media, 
such as TGF-β, bFGF, insulin, PDGR-ββ, are typically from recombinant bacterial 
origin and are hugely expensive. Similarly, the key components required to 
differentiate cells down their desired lineages (e.g. TGF-β3, Insulin and BMP-4) or 
activating cells into an immune-modulatory state (e.g. IFN-γ and TNF-α) are of 
recombinant origin. This imposes burdens on generating clinically relevant cell 
numbers for biomedical/tissue engineering applications due to the enormous expense 
of such growth factors, variability and their origins. An attractive alternative is to 
replace these vital growth factor components with robust, readily obtainable, 
synthetic small molecules. 
 
5.1.1 Substitution of growth factors in stem cell reprogramming with 
small molecules  
Screening of small molecules has been successfully applied to allow the replacement 
of some or all of the biological factors used to reprogram differentiated cells into 
induced pluripotent stem cells (iPS) (see section 1.1.4.) (Takahashi et al. 2007). 
Initially, screens of large numbers of small molecules identified two small molecules, 
CHIR99021 (CHIR) and PD0325901 (structures in Fig. 5.1), which could replace 
cMyc and Sox 2 in the reprogramming process (Silva et al. 2008). Interestingly, this 
study revealed a pre-pluripotent state that morphologically resembled pluripotent 
stem cells and resulted in the loss of somatic markers. However, Nanog was 




This study hypothesised that stem cells would be more amenable to reprogramming 
due to less stringent epigenetic restrictions than somatic cells. Neural stem cells 
(NSCs) where retrovirally transfected with the four factors, Oct4, Sox2, Klf4 and 
cMyc. Within 3 days cells took on the pre-pluripotent state, subsequently cells were 
cultured in media containing mitogen activated protein kinase signalling (Mek/Erk) 
and glycogen synthase kinase-3 (GSK3) inhibitors (PD0325901 and CHIR 
respectively) and leukaemia inhibitory factor (LIF). This resulted in the rapid 
conversion into the true pluripotent or ‗ground state‘. It was subsequently found that 
Sox2 and cMyc were dispensable, however, Sox2 is normally expressed in NSCs and 
the removal of cMyc reduced the efficiencies of iPS formation to levels similar to 
MEF reprogramming. This did however reveal the importance of Mek/Erk and 
GSK3 in the maintenance of the pluripotent state.   
Other screening studies have identified small molecule combinations that included 
previously identified factors CHIR, valproic acid (VPA), and 616452, in combination 
with a random library to identify the small molecule tranylcypromine (tranyl) that 
allowed, in combination with the other factors, only Oct4 for reprogramming (Fig. 
5.1). These small molecule screens used improvement in reprogramming efficiency 
of MEFs transfected with Oct4/Sox2/Klf4 as the readout for the compound 
identification (Li Y et al. 2011). It is now possible to reprogram fibroblasts into iPS 
in the absence of genetic manipulation using a combination of 7 small molecules 
(CHIR, VPA, 616452, tranyl, forskolin, 3-deazaneplanocin A and Arotinoid acid) 
(Hou et al. 2013) (Fig. 5.1). These studies demonstrated that substitution of protein 
factors is achievable even in processes that previously required multiple protein 
factors.  
 
5.1.2 Substitution of factors in stem cell culture with small molecules 
Maintaining the stem cell state using small molecules in the absence of growth 
factors was first achieved with mESCs. Using expression of Oct4 as a readout, a 
high-throughput small molecule screen was performed which identified the small 




al. 2006). This was achieved though the inhibition of two differentiation inducing 
proteins, Ras GTPase-activating protein (RasGAP) and mitogen activate protein 
kinase 3 (MAPK3). Importantly, the identification of such small molecules helped 
reveal part of the underlying network involved in the signalling that maintains the 
pluripotent state. In hESCs culture, it was found that the two of the compounds used 
to replace cMyc and Sox2 during cell reprogramming, CHIR (glycogen synthase 
kinase-3 inhibitor (GSK3)) and PD0325901 (a MEK inhibitor) in combination with 
the ROCK inhibitor (Y27632) and bFGF, were able to maintain hESCs on a 
fibronectin substrate for 20 passages (Tsutsui et al. 2011) (Fig. 5.1). However, the 
culture conditions were not defined.  
In a study designed to identify compounds that showed promoted Oct4 expression in 
H9 hESCs, Genzalez et al. used a defined serum free system that lacked the bFGF 
and TGF-β growth factors to screen 50,000 compounds. Here, hESCs were plated 
onto 384-well plates on an undefined matrigel surface, and compounds were added. 
High content microscopy identified 11 candidates, one of which dorsomorphin (Fig. 
5.1), an inhibitor of bone morphogenic protein type I (BMP1) receptors and showed 
the highest levels of Oct4 staining in a dose dependent manner. Dorsomorphin was 
able to maintain hESCs for 5 passages in this minimal media formulation. 
Pluripotency was verified by differentiating EB into mesoderm, endoderm and 
ectoderm. Teratoma studies also confirmed the formation of all three germ layers 
(Fig.1.1). Dorsomorphin was found to inhibit the up-regulation of BMP2 and BMP4 
mRNA, which spontaneously occurs in the absence of bFGF (Gonzalez et al. 2011). 
To date, no defined single formulation using only small molecules in the absence of 
growth factors for long-term culture (>5 passages) of stem cells has been published, 
however, a combination of the work by Tsutsui and Gonzales would seem a 







Figure 5.1. Structures of small molecules that can substitute for protein factors, differentiate 
or enhance stem cell phenotype. SC1, CHIR99021, PDO325901, valproic acid, 616452, 
artinoid acid, tranylcypromine, 3-deazaneplanocin A and forskolin enhance or directly 
reprogram diffentiated cells into induced pluripotent stem cells (iPS). Dorsomorphin acts as a 
small molecule substitute for bFGF, SR1 enhances the HSC phenotype in vitro and ROCK 
inhibitor promotes clonal growth and can be used with other factors to maintain stem cell 
growth. 
 
5.1.3 Small molecule mediated enhancement/differentiation of stem 
cells 
Haematopoietic stem cells (HSCs) have been the most widely used cells in stem cell 
therapy. One of the major limitations of the application of these cells has been the 
rapid loss of phenotype during in vitro culture, signified by the loss of CD34 and 
CD166. A small molecule screen of 100,000 heterocyclic compounds identified a 
small molecule, Stem Regenin 1 (SR1) (Fig. 5.1) that resulted in a rapidly 




a 17-fold improvement in engraftment when treated HSCs were transplanted into 
SCID mice when compared to untreated cells (Boitano et al. 2010). SR1 acted by the 
inhibition of the aryl hydrocarbon receptor (AhR), which acts as a quiescence 
regulator of haematopoiesis requiring down regulation for HSCs to escape from 
quiescence (Singh et al. 2009). Therefore, SR1 provides an escape route allowing 
considerable expansion and engraftment of the HSC population. AhR has also been 
implicated in other stem cell populations such as skin stem cells (SSCs) and NSCs 
(Panteleyev & Bickers 2006; Singh et al. 2009). This clearly demonstrated that a 
small molecule could enhance the stem cell phenotype and create a homogenous 
stem cell population from a heterogeneous starting population. 
Small molecules have also been applied to the derivation, maintenance and 
differentiation of multipotent stem cells. NSCs can be derived from ESCs in a two-
step process using low serum conditions with LIF, followed by treatment with bFGF 
(Tropepe et al. 2001). This results in cells with the NSC phenotype and 
differentiation potential.  A novel approach using LIF and a combination of small 
molecules CHIR, SB431542 (SB) (Fig. 5.1) (a TGF-β and activin receptor inhibitor) 
and a γ-secretase inhibitor (presenilin) was also able to produce cells with the NSC 
phenotype. In addition, this method resulted in a rapid and homogenous NSC 
population that could be maintained thereafter with LIF, CHIR and SB (Li et al. 
2011b).   
In MSC culture, small molecules have been used as differentiation factors for 
osteogenic differentiation (ascorbic acid, β-glycerophosphate, and dexamethasone) or 
adipogenic differentiation (dexamethasone, isobutyl methyl xanthine, and 
indomethacin) in combination with FCS (Jaiswal et al. 1997; Augello et al. 2010). 
Small molecules have also been identified that can differentiate MSCs into 
hepatocytes (Ouyang et al. 2012) and cardiomyocytes (Song et al. 2011). 
 
5.1.4. Chapter aims 
The power of small molecules to control and manipulate cells is enormous as they 




can differentiate cells into progenitor stem cell types or terminally differentiated 
cells. Small molecule modulators also enable pathway analysis allowing the role of 
that pathway to be better understood, thus revealing of the role of important 
pathways.  
Many of the pathways that control the stem cell state of hESCs and hMSCs are the 
same (e.g. Insulin signalling, TGF-β and bFGF). Although work has been done to 
identify small molecules that differentiate MSCs, little has been done in terms of 
finding small molecules that can maintain the MSC state in the absence of serum and 
growth factors, or enhance their phenotype.  
In this chapter, a ‗knowledge-based‘ small molecule screen was performed on MSCs 
to identify small molecules that could: 
1) Enhance growth and substitute for the protein growth factors in culture 
media. 
2) Enhance phenotype with the aim of producing a more stable homogenous 
stem cell population. 












5.2 RESULTS AND DISCUSSION  
5.2.1 Screening strategy for the identification of small molecules 
Rather than performing a ‗blind screen‘ some of the key pathways/proteins 
associated with hESCs and the MSC phenotype were identified (Table 5.1, Appendix 
3) and using pathway analysis software (GeneGo), drug molecules that acted as 
agonists or antagonists of these pathways were identified and scrutinised.  
To focus the screen, and to aid future regulatory approval, only small molecules that 
had FDA/EU regulatory approval were considered. Other factors, such as their ability 
to affect multiple pathways, and solubility, were also considered in the compound 
selection. In all, 200 compounds were identified for the MSC screens (Fig. 5.2, 
Appendix 4.1). The screening strategy and overall results are shown in figure 5.3 and 
5.4. The knowledge-based small molecule library was tested using hES-MPs at 3 
concentrations (1 µM, 10 µM and 100 µM) in 384-well plates (n = 4). After 7 day 
treatment, the cells were fixed and stained for the MSC marker STRO-1 (this was 
extended to STRO-1 and CD105 in the validation screen and STRO-1, CD105 and 
CD271 in the third screen). 
 









MSC Stemness Marker Pathway 
  
Protein tyrosine receptor type F PDGF-ββ 
Endolase 2 Bfgf 
RAB3B TGF-β 
THY-1 Integrin 
Frizzled 7 IGF-1 
Dickkopf 3 GPCR 
Biglycan IL-1 receptor type II 
Decorin IL-6 
Thrombospondin Insulin Receptor signalling 
Steroid sensitive gene 1 Pyrimidine metabolism 
CD73 NFKB 






    
Figure 5.2. Selection criteria of the small molecules used in the first hES-MP screen.  
 
Plates were scanned with the Opera high-throughput high-content imaging system 
(Perkin Elmer) and analysed using the ACAPELLA analysis software. This provided 
9 images per well and nuclear counts, and measured fluorescence from each image. 
A number of criteria were used to a potential candidates, 1) statistically significant 
growth or STRO-1 expression (evaluated by a fluorescent antibody) above the 
vehicle controls, 2) images from each well were visually examined for changes in 
cell morphology, to potentially identify small molecules that promote differentiation 
or alter potency. These criteria identified 73 potential candidates for the validation 
stage of screening (Fig. 5.3). Cell growth was analysed to validate candidates 
identified in the first screen. This also acted as a validation of the screening process 
itself. 
The candidates identified in this ‗primary‘ screened were validated in a second round 
of screening which analysed the additional marker CD105. This round of screening 
identified 22 candidates to take forward for a third screen. This screen was 
performed at 6 concentrations (as opposed to 3) and the additional phenotypic 




enhance some of the phenotypic markers of MSCs. Literature research was 
performed on the function of these candidates and further validation was performed 
with flow cytometry (Fig. 5.4). 
 
 
Figure 5.3. Overview of the knowledge-based screening strategy to identify candidates that 
can substitute for growth factors, enhance phenotypic marker expression or induce 
differentiation. First screen showing incubation of hES-MPs in 384-well plates treated for 7 
days with small molecules at 1µM, 10µM and 100µM concentrations in the serum containing 
media. Scanning with the Opera high throughput microscope and analysis with ACAPELLA 






Figure 5.4. The 73 identified candidates were to identify 22 lead candidates. These were 
subsequently rescreened at 6 concentrations in defined and undefined media and 5 
candidates where selected. Candidates were further scrutinise with flow cytometry and 2 
candidates that could potentially alter MSC phenotype were identified.  
 
Small molecules that significantly enhanced STRO-1 and/or CD105 were selected 
for further analysis. A screen was performed in serum free and serum containing 
media to identify if any of the small molecules candidates were acting in a serum 
dependent or serum independent manner to significantly enhance STRO-1 and/or 
CD105 and/or CD271. Finally, the phenotype enhancing candidates were examined 






5.2.2 Identification of small molecules that support cell growth  
5.2.2.1 Optimisation of cell density for high-throughput screening 
200 small molecules were prepared in 1 mM stock solutions (in DMSO) prior to 
screening. Prior to the screen, cell density optimisation was performed to determine 
the appropriate cell density (Fig. 5.5) for which 6 small molecules were chosen. hES-
MPs were seeded on 96-well plate at various densities (n = 3) and incubated for 24 
hours in hES-MP media, after which cells were washed twice with PBS and media 
containing the small molecules (100 µM) was added. Treating the cells with the 
highest concentration of drugs allowed a more accurate assessment of cell density for 
the subsequent screen. The two controls were untreated cells with no drugs in 
DMEM containing 10% FCS (supplemented with 4ng/ml bFGF) and vehicle controls 
containing the same media but also containing the same concentration of solvent 
used for dissolving the  drugs at 100µM (0.1% DMSO).  
 
Figure 5.5. Plate montage of a 96-well plate stained with DAPI, STRO-1 and CD105. Four 
cell densities were examined for six small molecules (100 μM, n = 3). A vehicle control 
(0.1%, DMSO bottom row) and an untreated control (10 % FCS) were included. Areas of 




hES-MPs were cultured with the small molecules for 7 days with media changes 
every 2 days with media containing the small molecule. A cell counting script was 
performed on the plate, which showed that 3.8 × 10
3
 cells per well was the optimum 
seeding density. At this density, cells had not reached confluence as with the higher 




The first screen was performed with 200 small molecules (Fig. 5.2). After 7 days 
incubation with hES-MP media containing 3 concentrations of the small molecules 
(1 µM, 10 µM and 100 µM), cells were fixed with 4% formaldehyde, stained with 
DAPI, immunostained with STRO-1 and the plates scanned using a high-throughput 
microscope. For each well of the 384-well plate, square 9 quadrants were selected as 
a chosen sampling area to apply to each well. Images of the areas were taken in the 
DAPI (λEx/λEm 340/488 nm) and FITC (λEx/λEm 495/519 nm) channels (Fig. 5.6). 
 
Figure 5.6. Area of a single well of a 384-well plate. 9 areas were selected and scanned. 
Each quadrant was imaged in each channel to obtained nuclear counts and quantification of 
fluorescence (up to a maximum of 4 channels). 
 
Each image was processed using ACAPELLA using prewritten scripts that were 
optimised by varying the parameters for cell counts and fluorescence detection. Each 




analysed and the raw output was processed. Statistical analyses with Instate was used 
to identify candidates that were statistically significant compared to untreated 
controls using the Dunnett‘s test. 
 
5.2.2.3 Identification of small molecule candidates that could enhance 
hES-MP growth 
The results of the first small molecule screen at 1 µM are shown in figure 5.7. At this 
concentration only one small molecule, curcumin (black bars), showed significant 
growth above the DMSO controls and in the subsequent validation screen (i.e. 
candidates that were identified as significant in the first screen were rescreened).  
 
 
Figure 5.7. Results of the small molecule screens (1µM) showing candidates that had a 
significant effect on hES-MP growth (blue bars) above the vehicle control (yellow bars) and 
the one validated candidate from a second screen (black bar) (n = 4, error bars given as 
SD). A) 15 candidates with a significant effect on hES-MP growth from the initial screen of 
200 small molecules. B) Structure of curcumin. 
 
Curcumin has been shown to promote osteogenisis and inhibit adipogenisis in MSCs 
through the up-regulation of heme oxygenase (HO)-1 expression (Cremers et al. 




carbon monoxide and free iron. Curcumin has been widely studied regarding its anti-
inflammatory properties (Aggarwal et al. 2010), but not specifically as a promoter of 
growth in MSCs. 
At 10 µM (Fig. 5.8), three candidates, epinephrine, hydroquinone and L-
noradrenaline, showed significantly higher cell growth than vehicle controls (in the 
second validation screen) although curcumin was not identified. A study of rat 
MSCs, showed that both epinephrine and noradrenaline (norepinephrine) increased 
proliferation in MSCs in a dose dependent manner with 10 µM showing a significant 
increase over controls (Kido et al. 2012). Epinephrine and noradrenaline activate the 
β2-adrenergic receptor (β2AR) signalling, which has been shown to mediate 
osteogenisis via the cyclic AMP/PKA pathway (Kellenberger et al. 1998; Huang et 
al. 2009).   
 
Figure 5.8. Results of the small molecule at 10 µM, showing candidates with significantly 
higher growth than vehicle controls. A) 26 significant candidates (blue bars) from the first 
screen compared to the vehicle control (yellow bar) of which 3 were validated in a second 
screen (black bars) (n = 4, error bars given as SD). B) Structures of epinephrine, 
hydroquinone and L-noradrenaline. 
At the highest concentration (100µM), 8 candidates were growth enhancers in both 
screens (Fig. 5.9). Adenine, D-glucosamine-HCL, synephrine, pyridine-2,5-
dicarboxylic acid, choline chloride, mesalamine, Caffeine and DL-Homocysteine. D-




MSCs by promoting the extracellular matrix proteins collagen II and aggrecan and 
by down regulate the matrix enzyme metalloproteinase 13 (Derfoul et al. 2007). 
Mesalamine is used in the treatment of chronic ulcerative colitis. In these patients, 
mesalamine has been shown to inhibit Wnt/β-catenin signalling through reduced 
PI3K/Akt-mediated β-catenin activation, in addition to down regulation of the 
downstream elements of signalling such as cMyc, GPR49 and MMP7 (Brown et al. 
2010). Other studies have shown increased PPARγ activity in response to 
mesalamine treatment (Rousseaux et al. 2005). Increased PPARγ expression reduces 
β-catenin by cytosolic retention (Fujisawa et al. 2008) and proteasomal targeting (Liu 
et al. 2006). By contrast to the findings of this screen with MSCs, in epithelial cells 
β-catenin signal inhibition has been proposed to prevent endothelial stem cell 
activation and proliferation. 
 
 
Figure 5.9.100 µM screen showing candidates with significantly higher growth than vehicle 
controls. A) 20 significant candidates (blue bars) from the first screen compared to the 
vehicle control (yellow bar).Black bars represent validated candidates  from the second 
screen (n = 4, error bars given as SD) B) Structures of Adenine, mesalamine, caffeine, DL-




5.2.2.4 Validation of screening assay 
Examination of small molecules that could promote growth and their validation 
suggest that the platform is robust. In particular, the validation of two candidates 
epinephrine and L-noradrenalin corresponded to other published work (Kido et al. 
2012). However, the 1µM, 10µM and 100µM screens did not contain overlapping 
molecules. Perhaps the screening conditions where too favourable for growth to 
begin with (10% FCS supplemented with 4ng/ml bFGF), optimisation of the 
screening procedure in low serum conditions may have more readily identified 
candidates that substantially increased growth above basal conditions thereby 
identifying candidates capable of substituting for growth factors. The lack of overlap 
at the different concentrations would suggest that the significance observed at each 
concentration was a consequence of the size of the screen itself (200) which will 
inevitably produce statistical significance by chance. The lack of overlap could also 
be a result of the concentration gap being too wide with a 10 fold difference between 
each concentration, a narrower range could therefore potentially reveal a dose 
response. 
 
5.2.3. Identification of small molecules that enhance MSC phenotype  
Small molecules that enhanced stem cell phenotype, in particular compounds that 
enhanced MSC marker expression were re-screened (along with the growth 
candidates). In the initial screen images taken of each well for all small molecule 
concentrations were individually examined and assessed for STRO-1 expression and 
morphological differences. Candidates that resulted in changes of cell morphology 
and had enhanced STRO-1 expression were selected for the second screen (Appendix 
4.2, Table 4.2.1–3). In the second screen, the marker CD105 (antibody λEx/λEm 
555/565 nm) was added to provide an additional layer of scrutiny. Small molecules 
that significantly enhanced STRO-1 (antibody λEm/λEx 495/519 nm) expression are 
shown in figure 5.10.  
 There was a degree of overlap between candidates from the STRO-1 screen and the 




markers at 1µM. Cumin (c1173), spermine (F436) and niacin significantly enhanced 
both markers at 10µM. Hermethonium Bromide (c1186), oleic acid (FF168), retinyl 
acetate (FF169), megestrol acetate (c1222), diltiazem HCL (c1179), pentoxifylline 
(c1201) and famotidine (c1182) significantly enhance both markers at 100µM. 
Figure 5.10. Results of a screen showing small molecule candidates with significantly 
enhanced STRO-1 expression over vehicle control (DMSO yellow bars) at 1 µM, 10 µM and 
100 µ (n = 4, error bars given as SD). 
 
Interestingly, some small molecules clearly enhanced one marker but not another, for 
example C1163 (tocopherol) showed the largest enhancement of CD105 at 10 µM 
concentration (Fig. 5.11) but did not appear to significantly enhance STRO-1. Only 
one drug appeared to enhance a marker at more than one concentration. Telmisartan 





Figure 5.11. Screen showing small molecules that significantly increased CD105 expression 
compared with the vehicle control ( DMSO, yellow bars) (n = 4, error bars given as SD) 
 
5.2.3.1 Small molecule STRO-1, CD105 and CD271 enhancers in 
undefined (10% FCS containing) media 
In a new screen, the identified candidates were tested using serum containing media 
and also using a defined media formulation (see table 2.1 materials and methods). It 
was reasoned that testing the small molecules in the absence of serum could 
potentially identify small molecules that were serum independent or were serum 
restricted in their effect. 
In this focused screen, a third MSC marker, CD271 (λEm/λEm 650/668 nm), was also 
evaluated. In addition, the small molecules were examined at 6 concentrations (0.3–




increased in a dose dependent manner. This would also reduce the 10 fold gaps 
between the different drug concentrations. 
Figure 5.12 shows the effect of the small molecule estriol on hES-MPs marker 
expression. Clearly, estriol has a significant effect on the three MSC markers 
examined with the most pronounced effect on the marker STRO-1 at 100µM. Estriol, 
a ligand of the estrogen receptor alpha (ER-α), is produced at high levels and is part 
of the modulation of the immune system during pregnancy resulting in a suppression 
of proteins responsible for inflammation e.g. IL-1, IL-2 and IFN-γ (Robinson & 
Klein 2012). This anti-inflammatory immune suppression has also been 
demonstrated in mice with experimental autoimmune encephalomyelitis (EAE) 
(mouse model of multiple sclerosis (MS)), where estriol treatment resulted in 
amelioration of the EAE in treated mice. In male mice, splenocytes treated with 
myelin oligodendrocyte glycoprotein-35-55 peptide (which induces EAE) and estriol 
showed significant reductions in the pro-inflammatory cytokines IFN-γ, TNF-α, 
interleukin-2 (IL-2), and IL-6 (IL-6), and a significant increase in the anti-
inflammatory cytokine IL-5 (Palaszynski et al. 2004). 
Other studies have shown estriol prevents the progression of multiple sclerosis 
through its anti-inflammatory effects, whereas the other estrogen receptor hormone 
estradiol did not have this effect but still improved long-term outcomes (Tiwari-
Woodruff & Voskuhl 2009). The effect of estrogen receptor signalling on MSCs has 
shown that they can act as potent inducers of neural differentiation. Estradiol was 
shown to decrease the neural stem cell marker nestin and increase the expression of 
the oligodendrocyte marker A2B5, particularly in MSCs derived from female 
patients (estriol was not tested) (Tiftikcioglu et al. 2012). The anti-inflammatory 
properties of estriol are well established and now used as part of the treatment for 
MS. MSCs are able to modulate the immune system and produce many of the anti-
inflammatory effects observed with estriol treatment and have been applied as a cell 
therapy for many auto-immune diseases (see section 1.2). It has also been shown that 
the STRO-1 positive fraction of MSCs is responsible for the property of immune-




enhances STRO-1 expression in hES-MPs, the interesting question therefore is does 
estriol affect the immune modulatory properties of MSCs? 
 
 
Figure 5.12. The effect of estriol on MSC markers STRO-1, CD105 and CD271 at 6 
concentrations. A) The STRO-1, CD105 and CD271 graphs showing increased fluorescence 
intensity with increased concentration of estriol. The effect of the small molecule is more 
pronounced with the STRO-1 marker being significantly higher at both 30 µM and 100 µM 
concentration. CD105 and CD271 are significantly higher at 100µM (n = 4, error bars given 
as SD). Scale bar 50µM. B) Fluorescence image of cells taken of a well in the STRO-
1(green), CD271 (red) and DAPI (blue) channels at 100 µM treatment. It can be clearly seen 
in the merged images that some of the hES-MPs show extremely bright STRO-1 
fluorescence (green) in the region surrounding the nucleus. Significant denotes comparison 
with the control at a given drug concentration. C) Structure of estriol. 
 
Telmisartan also significantly increased MSC marker expression in hES-MPs (Fig. 
5.13). Telmisartan, which is used as a treatment for hypertension, has been shown to 
inhibit the angiotensin type 1 receptor (AGTR1). This receptor is involved in the 




vasoconstriction and increased blood pressure. However, telmisartan has also been 
shown to have anti-inflammatory and anti-oxidative properties in experimentally 
induced myocarditis, an autoimmune disease of the heart. Telmisartan treatment 
significantly reduced mRNA levels of the pro-inflammatory cytokines IL-1, IL-6, 
TNF-α and IFN-γ. Serum levels of the anti-inflammatory IL-10 were also 
significantly elevated (Sukumaran et al. 2010). Other studies showed that the anti-
inflammatory response of telmisartan was mediated by peroxisome proliferator-
activated receptor gamma (PPAR-γ) in mouse model of Parkinson‘s disease 
(Garrido-Gil et al. 2012).  
 
Figure 5.13. The effect of telmisartan on hES-MPs at 6 concentrations. A) STRO-1, CD271 
and CD105 marker expression showing the most pronounced effect at the two highest 
concentrations, 30 and 100 µM (n = 4, error bars given as SD). Significant denotes 
comparison with the control at a given drug concentration. B) Image of STRO-1(green), 






Activation of PPAR-γ by telmisartan has also been shown to attenuate T-lymphocyte 
inflammation in the adipose tissue of insulin resistant obese mice (Foryst-Ludwig et 
al. 2010).  PPAR-γ is a regulator of ostegenic and adipogenic differentiation but how 
telmisartan affects this process in MSCs is unknown. However, the use of other 
AGTR1 blockers has been shown to enhance differentiation of MSCs towards the 
cardiac lineage (Numasawa et al. 2011).  
 
 
Figure 5.14. The effect of spermine on hES-MPs at 6 concentrations. A) The effect on 
STRO-1, CD271 and CD105 marker expression shows a significant increase at 1 µM on 
STRO-1 and the toxic effects of spermine above 10 µM (n = 4, error bars given as SD). 
Significant denotes comparison with the control at a given drug concentration. B) Florescent 
Image of spermine treated hES-MPs at 1 µM stained with DAPI (blue), STRO-1 (green) and 




Spermine (Fig. 5.14) is associated with compaction of DNA and initiation of protein 
synthesis in mitochondria and is essential for cell growth (Pegg & McCann 1982). 
Spermine has been shown to regulate inflammation and protect mice against lethal 
sepsis by down regulation of inflammatory factors such as IL-6, monocyte chemo-
attractant protein-1 (MCP-1), macrophage inflammatory protein-2 (MIP-2), and 
TNF-α (Zhu et al. 2009). 
Recently, spermine has been shown to enhance osteogenisis of ADMSCs by β-
catenin activation.  The application of spermine (5 µM) promoted early osteogenic 
markers, such as Runx-2, followed by increased β-catenin expression and activation, 
which lead to the induction of Osterix expression, a mature osteogenic marker 
(Guidotti et al. 2013). This study was performed using 3D culture, so the effect of 
this small molecule on these genes in a traditional 2D culture is yet to be determined. 
Figure 5.14 shows significantly increased expression of all three markers, peaking at 
1 µM spermine with concentrations of above 10 µM being toxic.  
 
5.2.3.2 Small molecule STRO-1, CD105 and CD271 enhancers in defined 
media 
To identify small molecules in a serum independent environment, the small 
molecules were screened concurrently in a serum free media. This identified two 
small molecule candidates, atenolol and niacin, as potential MSC enrichment 
candidates. The effect of atenolol is shown in figure 5.15A, with both STRO-1 and 
CD271 increasing significantly in a dose dependent manner with the highest levels of 
expression obtained at 100 µM. Atenolol is a beta adrenergic receptor blocker (β-
blocker) (in contrast to epinephrine and noradrenalin which are agonists) and is a 
prescribed treatment for hypertension.  
Some of the small molecules chosen in the library are considered nutrients (e.g. 






Figure 5.15. The effect of atenolol on hES-MPs at 6 concentrations in serum free conditions. 
A) The effect on STRO-1, CD271 and CD105 marker expression shows a significant 
increase at the 100 µM on STRO-1 and CD271 but not CD105 (n = 4, error bars given as 
SD). Significant denotes comparison with the control at a given drug concentration. B) 
Florescent Image of atenolol treated hES-MPs at 100 µM stained with DAPI (blue), STRO-
1(green) and CD271 (red). Scale bar 50µM C) Structure of Atenolol. 
 
In this respect, niacin has been shown to suppress inflammatory cytokines in adipose 
tissue (fractalkine, RANTES, and MCP-1) as well as up-regulate anti-inflammatory 
cytokines (adiponectin) (Digby et al. 2010). Niacin, which is used to treat 
atherosclerosis, activates the orphan G-protein couple receptor GPR109A. It has 
been demonstrated that activation of this receptor in immune cells is essential for the 
anti-inflammatory effect in mice with atherosclerosis (Lukasova et al. 2011). Figure 
5.16 shows the effect of niacin on the three MSC markers under no serum conditions. 
Interestingly, the significant increase seems to only occur with the STRO-1 marker 
and not with CD271 and CD105. At 3 µM, there is a 2.5-fold increase in STRO-1 






Figure 5.16. Normalised results of the third small molecule screen in serum free media with 
hES-MPs showing the effect of niacin at 6 concentrations. A) The effect on STRO-1, CD271 
and CD105 marker expression shows a significant increase at 100 µM on STRO-1 and 
CD271 but not CD105 (n = 4, error bars given as SD). Significant denotes comparison with 
the control at a given drug concentration. B) Image of atenolol treated hES-MPs at 3 µM 
stained with DAPI (blue), STRO-1(green) and CD271 (red). Scale bar 50µM. C) Structure of 
niacin. 
 
5.2.3.3 STRO-1, CD105 and CD271 expression with a known 
differentiation factor 
As a comparison, results for retinoic acid, which is a neural differentiation factor of 
hESCs (Murashov et al. 2005), is shown in figure 5.17. Retinoic acid operates by 
activating retinoic acid receptors (RARs), which regulate hundreds of genes 






Figure 5.17. Results of the third small molecule screen in serum containing media with hES-
MPs showing the effect of retinoic acid at 6 concentrations. A) The effect on the CD271 
marker expression shows a significant increase at 100 µM but not STRO-1 or CD105 (n = 4, 
error bars given as SD). Significant denotes comparison with the control at the same drug 
concentration. B) Florescent image of retinoic acid treated hES-MPs at 100 µM stained with 
DAPI (blue), STRO-1(green) and CD271 (red). Intense CD271 staining can be observed at 
the boundaries of the cells. Scale bar 50µM. C) Structure of retinoic acid. 
 
MSCs have also been shown to differentiate into neurons (Tropel et al. 2006) but 
whether retinoic acid is used in this process was not disclosed. Recently, retinoic acid 
has been shown to pre-induce MSCs towards the neuronal lineage (Gong et al. 2013). 
The up-regulation of CD271 in MSCs treated with retinoic acid has not been 
reported. The up-regulation of CD271 also known as low affinity nerve growth 
factor; the non-significant effect on STRO-1 and the down regulation of CD105 
would suggest that that retinoic acid is acting as a differentiation factor. CD271 is 
also a marker for neural stem cells and a pure population of NSCs has been isolated 
using GFAP and CD271 alone (Van Strien et al. 2014). This suggests that CD271 is 




study would indicate that retinoic acid is inducing the cells towards the neural 
lineage.  
 
5.2.4 Small molecules as potential enhancers of immune-modulation 
The majority of small molecule candidates that have been identified in this screening 
process to promote STRO-1 and CD271 (and to a lesser extent CD105), have been 
associated with the reduction of inflammation. As stated in section 1.2.2, there are 
hundreds of clinical trials underway that apply MCSs as a therapy in the modulation 
of the immune system for a number of autoimmune diseases. The anti-inflammatory 
effects of these compounds, e.g. reduction of IL2, IL2, IL-6, MCP-1, RENTES, 
TNF-α, INF-γ, MIP-2, fractalkine and induction of the anti-inflammatory cytokines 
IL-5, IL-10 and adiponectin, have all been characterised as part of the immune 
modulatory properties of MSCs (Singer et al. 2011). The interesting question is what 
effect, if any, do these anti-inflammatory compounds have body‘s anti-inflammatory 
machinery, in this case of MSCs? Does the activation of anti-inflammatory pathways 
recruit or suppress the natural anti-inflammatory properties of MSCs? To test this 
hypothesis, a literature search was performed to identify markers, specifically surface 
markers, associated with the immunomodulation state in MSCs. 
Prior to application of MSCs for therapy, MSCs are stimulated with pro-
inflammatory cytokines IFN-γ and/or TNF-α (Caplan et al. 2011; Polchert et al. 
2008). IFN-γ forms part of the adaptive and innate immune response. It is primarily 
secreted by natural killer cells and natural killer T cells, and is an activator of 
macrophages and inducer of MHC-II molecules for foreign cell recognition. 
Overexpression of IFN-γ is associated with many autoimmune diseases. In MSCs, 
IFN-γ treatment activates indoleamine 2,3 dioxygenase (IDO), the master regulator 
of immune-modulation in human MSCs (Croitoru-Lamoury et al. 2011). TNF-α is a 
pro-inflammatory regulator of immune cells produced by activated macrophages. 
Both IFN-γ and TNF-α differentially regulate immune-modulation in MSCs (English 
et al. 2007). Stimulation by IFN-γ not only causes the up regulation of IDO but also 




primary properties of MSC immune-modulation is the ability to inhibit T cell 
proliferation. When MSCs are treated with IFN-γ, MSCs up regulate a number of 
surface proteins critical for the suppression of T-cell proliferation. B7-1 (also known 
as programmed death ligand 1) is an inhibitory surface protein that has been shown 
through siRNA knockdown studies to be essential in T-cell suppression (Sheng et al. 
2008). Other surface proteins, which are up regulated by IFN-γ and critical for T-cell 
suppression, include intercellular adhesion molecule-1 (ICAM-1). The up-regulation 
of these surface proteins by INF-γ and inflammatory cytokines (TNF-α or IL-1) 
allow the MSCs to directly attach to the T-cells and induce cell death. This is 
achieved through the production of nitric oxide by inducible nitric oxide synthase 
(another key component of MSC immune modulation) (Ren et al. 2010). Other 
surface markers, such as HLA-DR and HLA-ABC (MHC class I and II molecules 
used for cell recognition), are up regulated by IFN-γ but are not necessarily essential 
for the immune function of MSCs, however, these markers offer a potential means of 
identifying ‗activated‘ MSCs.  
 
5.2.4.1 Flow cytometry analysis of MSCs after treatment with IFN-γ, 
TNF-α or small molecules in serum containing and serum free media. 
Prior to the application of MSCs in graft versus host disease, MSCs are treated with 
IFN-γ to activate them into their immune-modulatory state (Polchart et al. 2008). The 
activation occurs through the up-regulation of IDO (Croitoru-Lamoury et al. 2011) 
by stimulation with TNF-α and IFN-γ. The immune-suppression of MSCs directly 
correlates with TNF-α and IFN-γ induction of IDO (Francios et al. 2012). The 
identification of small molecules with known anti-inflammatory properties raised the 
possibility that these compounds may be affecting the immune-modulatory properties 
of MSCs. If the small molecule candidates affect the immune-modulatory properties 
of MSCs, they may also affect surface proteins critical for or associated with 
immunomodulation such as ICAM-1, HLA-DR, and B7-1. 
In order to evaluate the immune-modulatory effects of the candidate small 




niacin at their most effective concentrations (see section 5.2.3). As controls, 
ADMSCs were also treated with IFN-γ and TNF-α. After 4 days of treatment, which 
had been shown to be the optimal treatment time of MSCs for the expression of IFN-
γ associated markers (Chan et al. 2008), cells were trypsinised and immuno-stained 
for ICAM-1, HLA-DR, HLA-ABC, B7-1, B7-2, and STRO-1. ICAM-1 has 
previously been shown to be up-regulated upon IFN-γ. HLA-DR and HLA-ABC are 
normally not expressed in MSCs but are expressed at high levels after IFN-γ 
treatment. The surface protein B7-1 has been shown to be critical for immune-
modulation and to be up-regulated by IFN-γ stimulation. Its related homologue B7-2 
was included for comparison and STRO-1 was included to verify the results of the 
screening. Stained cells were analysed by flow cytometry. It should be noted that 
atenolol and niacin were tested in serum free media. The concentrations for IFN-γ 
(20 ng/mL) and TNF-α (10 ng/mL) were obtained from the literature (English et al. 
2007).  
In this preliminary screen, atenolol, telmisartan and niacin showed no change in the 
expression of MSC immune markers. However, estriol at 100 µM, and spermine at 1 
µM and 3 µM, showed a decrease in ICAM-1 expression. Treatment of ADMSCs 
with IFN-γ up-regulated HLA-ABC, HLA-DR and ICAM-1. TNF-α resulted in the 
up-regulation of HLA-ABC and ICAM-1 (Fig. 5.18).  
For the cells treated with estriol at 100 µM, flow cytometry analysis of markers 
STRO-1 and ICAM-1 showed a minor shift to the STRO-1+ and ICAM-1+ quadrant 
(Fig. 5.19). The ADMSCs treated with spermine showed a reduction in the STRO-1-
and ICAM-1+ quadrant (Fig. 5.19). 
The expression of STRO-1 and ICAM-1 in treated and untreated cells is compared in 
figure 5.20. In this preliminary screen, treatment with estriol at 100 µM and spermine 
at 3µM reduces the proportion of ICAM-1+ cells and increases the proportion of 
STRO-1+ cells (Fig. 5.20A, B and C). The flow data correlates to what was seen in 
the small molecule screens in relation to increased expression of STRO-1.Treatment 
of ADMSCs with IFN-γ increased the STRO-1+ and ICAM-1+ fraction (Fig. 5.20A 
and B, purple histogram). Comparison with the untreated control suggests that there 





Figure 5.18. Flow cytometry analysis of ADMSCs after 4 days of treatment with 
estriol at 50 and 100 µM, and spermine at 1 and 3µM. IFN-γ and TNF-α were used 
at 10 and 20 ng/mL, respectively. The six immune-associated surface markers HLA-
ABC, HLA-DR, STRO-1, B7-1, B7-2 and ICAM-1were compared with the untreated, 
IFN-γ and TNF-α controls. 
As can be seen in figure 5.19, the ICAM-1+ fraction reacts to IFN-γ stimulation by 
substantially up-regulating this surface protein. By contrast, a high proportion of the 
STRO-1+ and ICAM-1- cells do not appear to respond to IFN-γ stimulation.  
Additional experiments are required to confirm the down-regulation of ICAM-1 
receptor in spermine treated cells. ICAM-1 binds two integrins belonging to the β2 
superfamily LFA-1 (αLβ2), and is critical in leucocyte migration and activation of T-
cells (Zuckerman et al. 1998). It has a critical role in the immune-modulatory 
properties of MSCs (Ren et al. 2010).  ICAM-1 is constitutively expressed in wide 







Figure 5.19. STRO-1 and ICAM-1 marker analysis for IFN-γ, untreated, estriol (100µM) and 
spermine treated (3µM) ADMSCs. 
 
Suppression of ICAM-1 expression has been demonstrated in TNF-α activated 
human bronchial epithelial cells using the anti-inflammatory compound eupatilin. 
Here, eupatilin supressed ICAM-1 by inhibiting the phosphorylation of Akt resulting 
in the down-regulation of nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) (a regulator of the immune response) (Jung et al. 2012). 
Similarly, lactoferrin (also an anti-inflammatory compound) suppressed TNF-α 
induced ICAM-1 expression in human umbilical vascular endothelial cells 
(HUVECs) by preventing NF-KB binding to a NF-KB site of the ICAM-1 promoter 
(Kim et al. 2012). These preliminary results indicate that spermine reduces the 
expression of ICAM-1. If confirmed, it would be interesting to see if spermine is able 






Figure 5.20. Analysis of STRO-1 and ICAM-1 expression. A) Percentage each marker 
combination in each of the 5 treatment groups. B) Breakdown of the proportions into 
individual bar graphs. C) Proportion of ADMSCs positive for STRO-1 and ICAM-1.  
 
5.3 CONCLUSIONS 
A ‗knowledge based‘ approach was used to examine the known MSC and ESC 
pathways involved in the maintenance and differentiation of these cells. This 
approach used 200 FDA/EU approved small molecules.  
This focused small molecule library identified 5 compounds, of which 4 were known 
anti-inflammatory agents, which enhanced the expression of MSC markers STRO-1, 
CD105 and CD271. The known anti-inflammatory immune-modulatory properties of 
MSCs led to the investigation of the effect of these small molecules on signature 
immune-modulatory surface proteins. In a preliminary screen, two small molecules, 
spermine and estriol, were found to up-regulate STRO-1 expression and down-
regulate the cell surface protein ICAM-1. Since the small molecule library included 
small molecules with a wide variety of activity, the disproportionate identification of 
anti-inflammatory compounds that effect the phenotype of MSCs (which also have 
anti-inflammatory activity) raises the interesting question of what effect does an anti-




of MSCs. If MSCs have their activities suppressed or activated in the presence of 





















The work of this thesis achieved a number of advances in mesenchymal stem cell 
culture, it identified two defined polymer substrates PA338 and PU157 that could 
promote growth and maintain the MSC phenotype and differentiation capacity in 
long term culture. The process used to identify these candidates was through multiple 
screens, scale up and long term passage examining progressively more phenotypic 
markers through the screening and scale-up process. This means that additional value 
will be obtained from examination of their surface structure and physical properties. 
Examination of the stiffness/elasticity and how cells interact with the surface at the 
micro to the nanoscale level using scanning electron microscopy may identify 
polymer properties and motifs that can be compared with other studies. Examination 
of integrin expression profiles with an integrin antibody panel covering all human 
integrin combinations could potentially identify alteration/up-regulation of specific 
integrins.  
These polymers extend the list of biomaterials for MSC culture and potentially other 
cell types as the extracellular matrix components these polymers substitute for, such 
as collagen/gelatin are widely used in cell culture.  The alteration of surface rigidity 
through a photo-cleavable cross-linked has  shown surface rigidity to heavily 
determine the multipotency of MSCs. Tissue culture plastic is currently used in the 
isolation of MSCs, the stiffness of which (elastic modulus ~3GPa) is several order of 
magnitude higher than substrates shown to predispose cells to the osteogenic lineage 
(Yang et al. 2014). The use of these polymers in the isolation of MSCs may enhance 
their multipotency by avoiding the changes induced by extremely stiff substrates 
such as tissue culture plastic but additional material characterisation is required.  
In addition, PA338 and PU157 could be applied to 3D culture systems where MSCs 
are use as either seeded scaffolds or as scaffolds that recruit MSCs and other cells or 





The advent of 3D printing adds the prospect of using these polymers as a component 
for localizing MSCs in conjunction with other polymers recruiting other cells (such 
as endothelial). High resolution 3D printing to produce complex 3D scaffolds is a 
potential future path for polymer microarray technology.  
This work also identified a ‗smart‘ thermo-modulatable hydrogel HGL1 that allowed 
MSCs to be passaged by modest temperature reduction in the absence of harsh 
enzymatic trypsin passaging. This added an additional dimension to polymer 
microarray technology. The identification of a smart hydrogel that can trigger 
cellular release could be modified further as micro-carriers potentially allowing large 
scale MSC production with temperature controlled cellular release. The superior 
retention of MSC markers over the gelatin control makes this substrate potentially 
superior for the isolation of MSCs and retention of phenotype in long term culture. 
The fact that this is also a hydrogel and its retention of the MSC phenotype opens it 
up to MSC encapsulation studies.  
Monomer analysis of the polymers that promoted growth in chapter 3 revealed PEG 
to be particularly poor monomer for MSC binding and growth. Many of the 
important studies that have examined MSC behaviour while encapsulated (Benoit et 
al. 2008) or on surfaces (Yang et al. 2014) have used PEG based hydrogels. 
Applying HGL1 as the major hydrogel component may improve future studies 
involving hydrogel encapsulation or hydrogel property modification where MSCs are 
used.  Encapsulation with perfusion bioreactor technology or even a vascular 
network is possible with such a hydrogel as was used with encapsulated hepatocytes 
with patterned vascular networks (using human umbilical cord vascular endothelial 
cells) for perfusable engineered tissues (Miller et al. 2012). 
The power of the microarrays at identifying polymers in the presence of serum 
should certainly be applied to defined media systems now available for MSC culture. 
This would result in culture conditions where all the components would be known 
removing the confounding element of unknown protein components to experimental 
analysis. This is particularly true for cell substrate interaction analysis as the key 
extracellular components for cell binding are contained within the FCS component. 




interaction in the absence of integrin binding proteins. This would remove potential 
interactions due to the binding of the proteins to the polymers and the cells binding to 
the proteins. From the work in chapter 3 and 4 it is impossible to determine whether 
the cells favour a polymer because the chemistry of the polymer binds particular 
proteins to that polymer and that this proteins are required for the growth and 
maintenance of the MSC phenotype or if the MSCs are interacting with the chemistry 
of the surface directly. 
Ultimately, the achievement of chapters 3 and 4 was to have taken the goal of MSC 
culture in the absence of biological components a step further. As we move forward 
with tissue engineering and regenerative medicine, the need for platforms that can 
identify defined substrates that allow for the expansion and isolation of different 
stem cell populations will be an essential tool realising the full potential of 
regenerative medicine. Importantly, the polymer microarray platform allows the 
phenotype of the stem cell to be analysed. Advances in the understanding of the stem 
cell phenotypes will facilitate their isolation using this system even where 
components such as preferred functional group, surface rigidity/elasticity, and nano-
topography remain unknown they can be elucidated through the high-throughput 
approach. 
In addition, this work also used a ‗knowledge based‘ small molecule library and a 
high-throughput high content imaging system for screening to identify 5 small 
molecules that enhanced the MSC marker phenotype. In further preliminary work, 
two small molecules estriol and spermine with known anti-inflammatory properties 
down regulated the essential MSC immune-modulation surface protein ICAM-1. In 
future work, the down regulation observed in this initial study should be confirmed. 
Other studies have reported small molecules (also with anti-inflammatory properties) 
that down regulated ICAM-1 after its up-regulation with TNF-α treatment. This 
should also be tested with these two small molecules. The unexpected identification 
of small molecules with anti-inflammatory properties being identified as MSC 
marker enhancers raised the interesting question. What is the effect of anti-
inflammatory signals on the MSCs state and importantly MSCs immune modulatory 




reveal the different aspects of the immune properties of this cell type have immediate 
wide ranging implications. How the activated MSCs cytokine profile alters in the 
presence of anti-inflammatory drugs can be easily tested using Elisa assays for pro 
and anti-inflammatory cytokines with MSCs compared to cells treated with and 
without activation factors.  
The current screening process was however unable to identify candidates that were 
able to substitute for growth factors such as bFGF, TGF-β and PDGF-ββ. A potential 
major flaw in the screening process was the overly favourable conditions in the 
background of the small molecule screening. The drugs were screened in the 
presence of DMEM with 10%FCS supplemented with 4ng/ml of bFGF. The process 
which identified the small molecules was very rigorous, because of this one 
possibility would be to optimise the conditions of MSC growth in the absence of 
bFGF and under optimised low serum conditions in which the readout gives a clear 
signal in the absence of the key growth factors bFGF, TGF-β and PDGF-ββ.  
Addition of the small molecules in low serum in the absence of any growth factors 
should give a more consistant readout. Identified candidates could then be analysed 
individually and in combination with other identified small molecules (it is known 
that the growth factors act synergistically (Ng et al. 2008)). Such identified 
candidates would require testing in serum free conditions such as that described by 
Jung et al but in the absence of one or more of the growth factors. The ultimate 
formulation would have to be tested in long term culture MSC culture and undergo 
differentiation analysis and cell characterisation. This approach may prove to be 
more successful than the one employed in this study, it is also possible however that 
the candidates were not in fact able to substitute for growth factors alone or in 
combination with other small molecules but this has not been exhaustively tested.  
In all, this work represents a significant advance in the development of new culture 
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Appendix 1.1A Charged monomers in the ―PA‖ library Monomers that are likely to be 
positively charged at physiological pH.  
 











Appendix 2.1. Representative flow cytometry traces for hES-MPs stained with 10 MSC markers at ‘passage 0’ (p0) prior to long term culture, and after 5 
passages (p5) on gelatin (GEL), tissue culture plastic (TCP), PU157, PU108 and PA338. The red trace represents the stained cells and the black shaded 





Appendix 2.2. Representative flow cytometry traces for ADMSCs stained with 10 MSC markers at ‘passage 0’ (p0) prior to long term culture, and after 5 
passages (p5) on gelatin (GEL), tissue culture plastic (TCP), PU157, PU108 and PA338. The red trace represents the stained cells and the black shaded 





Appendix 2.3. Representative flow cytometry traces for ADMSCs stained with 10 MSC markers at ‘passage 0’ (p0) prior to long term culture, and after 10 
passages (p10) on gelatin (GEL), tissue culture plastic (TCP), PU157, PU108 and PA338. The red trace represents the stained cells and the black shaded 




Appendix 3: Gene expression 
Genes expressed selectively in MSC (n = 3) compared with fibroblasts, osteoblasts, 
chondrocytes and adipocytes (n = 3). The criterion of selection was a more than 
twofold higher expression in MSC than in any of the other cells.  
Fold average  and Gene name 
Over 100-fold CHI3L1, FLG, KRT19 
30–100-fold DGKG, F2RL1, HB2B, KRT18, KRTAP1-1, LOC401097, SLC14A1 
15–30-fold CDCP1, CFI, CNTNAP3, FRMD5, GATA6, HNT, KRTAP1-5, 
KRTAP2–2, KRTHA4,LOC285758, LOC389734, LYPDC1, RARRES1, RGS4, 
SOX11, TRPC4 
10–15-fold CD33L3, DCBLD2, ENG, ESM1, IFI30, IL6, LOC152742, LOXL2, 
LXN, PAK3, RAB27B,RAC2, TGM2, ZNF423 
5–10-fold ADAMTS1, ARHGAP22, BDNF, BRCC2, C13orf31, CCL26, CCND1, 
CCNE2, CPA4, EGFL3, ETV1, FAM40B, HECW2, HGF, HMGA2, IER3, ITGA2, 
KCTD16, KIAA0746, KIAA1913, KLF12, KRTAP2-1, LAMA3, LOC157693, 
LOC399947, LRB2BP, MET, NALP1, NETO2, NTN4, PASK, PDE5A, PLCXD2, 
PODXL, PRDM16, SAMD3, SLC16A4, SLC4A4, SLC9A7, SMURF2, TFPI2, 
TMEM166 
2–5-fold ABHD2, ABI3BP, ADAMTS5, ADD3, ADORA1, ARL7, ATP6V1G3, 
BRIP1, C1GALTI, C5orf13, C6orf105, CAMK2D, CAPZA1, CDC25A, CDH6, 
CPNE8, DKFZp313A2432, DKFZp761P0423, EDEM1, ETV5, FAM36A, 
FAM44A, FCHSD2, FHL2, FN1, FLJ35409, FOXP1, GDF15, GLIPR1, HTR7, 
HRB2, IGFBP3, KIAA1189, KIAA1946, KIF18A, LAMA1, LOX, MALAT1, 
MAP4K4, MCFD2, MCOLN3, MSCP2, NEK7, NHS, NUPL1,OCIAD2, PAPPA2, 
PHLDB2, PKIA, PLAC3, PSCDBP, RAMP, SH3RF1, SIM2, SKI, SLC25A37, 
SLC26A4, SLC30A7, SLC4A4, SMC2L1, SMYD3, SNK25, SSH1, 





Appendix 4.1 Small molecule library 
 CODE  SMALL MOLECULE 
  





4-AMINOANTIPYRINE, REAGENT GRADE, AMINOPHENAZONE,  US 
WITHDRAWN  
c1165 AMINOSALICYLIC ACID 




c1170 BROMHEXINE HYDROCHLORIDE 
c1171 CARBAMOYLCHOLINE CHLORIDE 
c1172 CHLORPROPAMIDE 
c1173 CURCUMIN 
c1174 CYPROHEPTADINE HYDROCHLORIDE 
c1175 DECAMETHONIUM BROMIDE 
c1176 DEQUALINIUM CHLORIDE HYDRATE 
c1177 DIAZOXIDE 
c1178 DICLOFENAC (NA SALT) 







c1186 HEXAMETHONIUM BROMIDE 
c1187 HISTAMINE DIHYDROCHLORIDE 
c1188 HYDRALAZINE 
c1189 HYDROCHLOROTHIAZIDE 






c1196 MOXISYLYTE HYDROCHORIDE 
c1197 NILUTAMIDE 
c1198 NIZATIDINE 
c1199 OUABAIN OCTAHYDRATE 





c1202 PHENYLEPHRINE HYDROCHLORIDE 
c1203 PILOCARPINE HCL 
c1204 PIPERINE 
c1205 PRIMAQUINE BISPHOSPHATE 
c1206 PRIMIDONE 





c1213 TANNIC ACID 
c1214 TETRAHYDROZOLINE HYDROCHLORIDE 
c1215 TOLAZAMIDE 
c1216 TOLFENAMIC ACID 
c1217 VALPROIC ACID NA SALT 
c1218 VERAPAMIL HYDROCHLORIDE 
c1219 YOHIMBINE HYDROCHLORIDE 
c1220 AMINO-3-HYDROXYBUTYRIC ACID 
c1221 ESTRIOL 
c1222 MEGESTROL ACETATE 
c1223 BERBERINE CHLORIDE 
c1224 ACARBOSE 
c1225 SIBUTRAMINE HCL 
c1226 CHLOROQUINE DIPHOSPHATE SALT 
c1227 ENALAPRIL MALEATE 
c1228 CINNARIZINE 
c1229 S-(+)-CHLORPHENIRAMINE MALEATE SALT 
c1230 OLMESARTAN MEDOXOMIL 
c1231 TETRAETHYLTHIURAM DISULFIDE 
c1232 OMEPRAZOLE 
c1233 RETINOIC ACID (CONTROL) 
c1234 BIFONAZOLE 
c1235 CANRENONE 
c1236 CHLORHEXIDINE ACETATE 
c1237 CLOPIDOGREL SULFATE 
c1238 ANIRACETAM 




c1243 BIS(2,2,2-TRIFLUOROETHYL) ETHER 
c1244 PHENFORMIN HCL 
c1245 TAMOXIFEN CITRATE 
c1246 TELMISARTAN 
c1247 THALIDOMIDE 
c1249 AMANTADINE HYDROCHLORIDE 
c1250 AMILORIDE HYDROCHLORIDE 
c1251 TESTOSTERONE 
c1252 METOPROLOL (+)-TARTRATE SALT 






c1256 QUINACRINE DIHCL 
c1257 PROTAMINE SULFATE SALT FROM SALMON 
c1258 FLUORO-ALPHA-METHYL-4-BIPHENYLACETIC ACID 
c1259 VALSARTAN 
c1260 CLORSULON 
c1261 METFORMIN - HCL 
c1262 ROFECOXIB  
c1263 ISOTRETINOIN 
c1264 PERINDOPRIL ERBUMINE 
c1265 TADALAFIL 
c1266 AMINO-6-(TRIFLUOROMETHOXY) BENZOTHIAZOLE 
c1267 M-HYDROXYPHENYL ACETATE 
c1270 NICOTINE DITARTRATE 











F428 HEPARIN NA 
F429 L-NORADRENALINE 









F440 TRIMEBUTINE MALEATE 
F441 TRIPROLIDINE HYDROCHLORIDE 





F448 DESIPRAMINE HYDROCHLORIDE 
F449 CODEINE 
f450 TRANS-2-PHENYLCYCLOPROPYLAMINE HYDROCHLORIDE   
f451 PINDOLOL 
f452 L-THYROXINE 
F453 TROPICAMIDE  
F454 NEOMYCIN SOLUTION 
F455 PHOSPHOMYCIN DISODIUM 








FF168 OLEIC ACID 
FF169 RETINYL ACETATE 
FF170 TETRACYCLINE HCL 
FF171 TRIFLUOPERAZINE DIHYDROCHLORIDE 
FF172 LEVONORGESTREL 
FF173 DL-HOMOCYSTEINE ?(EXPENSIVE)  
A111 D-THREONINE 
A139 D-SERINE 
A200 AMINOCAPROIC ACID 
Aminobutyric 
acid GAMMA-AMINOBUTYRIC ACID 
Aminothiazole AMINOTHIAZOLE 
Asprin ACETYL SALICYLIC ACID (ASPRIN) 
B68 UREA 
c145 BENZOIC ACID 
c17 ADENINE 
c240 HYDROQUINONE. 




HCl D-GLUCOSAMINE HYDROCHLORIDE 
Ethyl paraben ETHYL PARABEN (ETHYL 4-HYDROXYBENZOATE) 
F228 TACRINE HYDROCHLORIDE 
Fampridine FAMPRIDINE (4-PYRINAMINE) 




Mesna MESNA (2-MERCAPTOETHANESULFONIC ACID) 
Methimazole METHIMAZOLE 
Niacin NIACIN (NICOTINIC ACID) 
Prasterone PRASTERONE (TRANS-DEHYDROXYANDROSTERONE) 
Quin QUININE SEMISULFATE.H2O 
Sulfanilamide SULFANILAMIDE 
Thiamine THIAMINE MONOPHOSPHORIC ACID CHLORIDE 
Vitamine C ASCORBIC ACID 




Acetylcysteine ACETYLCYSTEINE (H2O) 
Mannitol D-MANNITOL 
c1292 PYRIDINE-2,5-DICARBOXYLIC ACID 





Appendix 4.2. Selected candidates from first screen 
Table 4.2.1 – Drugs showing a statistically significant improvement over vehicle control for 
growth (DAPI) or marker expression (% STRO-1) and/or morphology at a concentration of 1 
μM. 
Small Molecule (1μM) n Mean 
Nuclei 
Count 
STDEV P % Stro1 
positive 
cells 
STDEV P Morphology 
C1182  
Famotidine 




76.3 4.2  Fibroblast 
C1168 
Naphthol 




74.5 10.4  Fibroblast 
C1192 
Indomethacin 




75.8 1.3  Fibroblast 
C1173 
Curcumin 




76.2 3.4  Fibroblast 
C1162 
Allopurinol 




76.6 7.7  Fibroblast 
C1178 
Diclofenac (Na Salt) 




79.1 3.9  Fibroblast 
C1183 
Gemfibrozil 




74 4.1  Fibroblast 
C1190 
Hydroxyzine Pamoate 












76.3 4.5  Fibroblast 
C1167 
Atenolol 




72.1 6.2  Fibroblast 
C1189 4 1712 189.6 P<0.01 
w.r.t. 












72 5.5  Fibroblast 
C1179 
Diltiazem HCl 




76.7 4.2  Fibroblast 
C1209 
Quercetin 




69.9 1.9  Fibroblast 
C1184 
Gliclazide 




72.5 4.5  Fibroblast 
C1264 
Perindopril Erbumine 




















Hyaluronic acid Na Salt 











4 1166.8 152.3  64.1 7.6  Fibroblast 
C1277 
Quinazolinamine 





4 907.8 455.2  66.5 1.6  Large 
elongated 
cells 




















4 1234.3 119.1  64.1 4.9  Fibroblast 
FF168 
Oleic Acid 








DMEM 4 1653.3 66.7  77 8.4  Fibroblast 
0.001%DMSO 4 1187.8 335.5  68.1 4.7  Fibroblast 
          
          
     
      
Table 4.2.2 – Drugs showing a statistically significant improvement over vehicle control for 
growth (DAPI) or marker expression (% STRO-1) and/or morphology at a concentration of 10 
μM.  
Small Molecule (10μM) n Mean 
Nuclei 
Count 
STDEV P % Stro1 
positive 
cells 
STDEV P Morphology 
C1195 
Levodopa 




68.6 1.8  Fibroblast 




70.5 2.7  Fibroblast 
F447 
Epinephrine 



















4 1778.5 64.1 P<0.01 
w.r.t. 
DMEM 
72.5 4.5  Fibroblast 
C1207 
Putrescine DiHCl 
4 1601.5 265.5 P<0.01 
w.r.t. 
DMEM 




4 1567.3 94.7 P<0.01 
w.r.t. 
DMEM 
69.3 3.4  Fibroblast 
A-ketoester 
Alpha-ketoester 




71.4 2.7  Fibroblast 
A200 
Aminocaproic acid 
4 1556.8 86.4 P<0.01 
w.r.t. 
DMEM 
65.7 4.1  Fibroblast 
C240 
Hydroquinone 








4 1529.8 151.2 P<0.01 
w.r.t. 
DMEM 
72.9 5  Fibroblast 
F438 
Sulpiride 




68.3 3.6  Fibroblast 




68.8 2.9  Fibroblast 
F429 
L-Noradrenaline 




67.7 4.6  Fibroblast 
C1285 
Cromolyn 




72.5 2.5  Fibroblast 
F437 
Sulfisoxazole 




65.4 10.5  Fibroblast 












68.9 3.6  Fibroblast 
Piracetam 4 1453 177.3 P<0.01 
w.r.t. 
DMEM 
73.5 2  Fibroblast 
C1264 
Perindopril Erbumine 




71.1 6.4  Fibroblast 
FF173 
DL-Homocysteine 
4 1430.3 189.6 P<0.05 
w.r.t. 
DMEM 
68.3 2.1  Fibroblast 
D-Glucosamine HCl 4 1410 28.9 P<0.05 
w.r.t. 
DMEM 
72.7 3.8  Fibroblast 
Aminobutyric Acid 4 1407.3 221.6 P<0.05 
w.r.t. 
DMEM 
67.8 4.8  Fibroblast 
C1222 
Megestrol Acetate 













63.2 5.2  Fibroblast 
ZnCl2 
Zn++ (Zinc Chloride) 
4 1373.5 230.6 P<0.05 
w.r.t. 
DMEM 



































4 233 215.5  62.8 7.1  Large 
elongated 
cells 
DMEM 4 1002 182.7  70.5 5.5  Fibroblast 
0.01%DMSO 4 1036.3 77.8  68.6 3  Fibroblast 
          
          
          
Table 4.2.3 – Drugs showing a statistically significant improvement over vehicle control for 
growth (DAPI) or marker expression (% STRO-1) and/or morphology at a concentration of 


























































































































4 1198.5 370.9  68.3 4.4 Large 
elongated 
cells 
DMEM 4 1271.5 222.5  71 3 Fibroblas
t 














Appendix 4.3 Optimisation of flow data for ADMSCs treated with 20ng/mL of IFN-γ and 
10ng/mL of TNF-α for 4 days. 
 
 
 
 
